Document:

<PAGE>

                                                                   EXHIBIT 10.34

                          SECURITIES PURCHASE AGREEMENT

                         dated as of September 24, 2004,

                                  by and among

                                  MYOGEN, INC.

                                       and

               ENTITIES LISTED ON APPENDIX A (each a "Purchaser").

<PAGE>

                                Table of Contents

<TABLE>
<CAPTION>
                                                                                  Page
                                                                                  ----
<S>                                                                               <C>
SECTION 1.   PURCHASE AND SALE OF SECURITIES....................................    1

SECTION 2.   THE CLOSING........................................................    1

     2.1.    The Closing........................................................    1

     2.2.    Conditions to Closing..............................................    1

SECTION 3.   REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY...........    3

     3.1.    No Material Misstatement...........................................    3

     3.2.    Incorporated Documents.............................................    3

     3.3.    Financial Statements...............................................    4

     3.4.    No Material Adverse Change.........................................    4

     3.5.    Books and Records; Internal Controls...............................    4

     3.6.    Independent Accountants............................................    5

     3.7.    Organization; Good Standing........................................    5

     3.8.    Legal Proceedings..................................................    5

     3.9.    Brokers or Finders.................................................    5

     3.10.   Licenses and Permits...............................................    5

     3.11.   Intellectual Property..............................................    6

     3.12.   Real and Personal Property.........................................    6

     3.13.   Material Contracts.................................................    6

     3.14.   No Violation or Default............................................    7

     3.15.   No Conflicts.......................................................    7

     3.16.   No Consents........................................................    7

     3.17.   Due Authorization and Delivery.....................................    7
</TABLE>

                                       -i-
<PAGE>

<TABLE>
<S>                                                                                <C>
     3.18.   The Securities and the Warrant Shares..............................    8

     3.19.   Capitalization.....................................................    8

     3.20.   Lock-Ups...........................................................    9

     3.21.   Employees..........................................................    9

     3.22.   Related Party Transactions.........................................    9

     3.23.   Market Stabilization...............................................    9

     3.24.   Taxes..............................................................    9

     3.25.   Compliance; Listing................................................    9

     3.26.   Insurance..........................................................   10

     3.27.   Environmental Laws.................................................   10

     3.28.   Investment Company.................................................   10

     3.29.   Solicitation; Other Issuances of Securities........................   10

     3.30.   No Restrictions on Subsidiaries....................................   11

     3.31.   No Registration Rights.............................................   11

     3.32.   Forward-Looking Statements.........................................   11

     3.33.   Statistical and Market Data........................................   11

     3.34.   Compliance in Clinical Trials......................................   11

     3.35.   SEC Filing.........................................................   12

SECTION 4.   REPRESENTATIONS, WARRANTIES AND COVENANTS OF EACH PURCHASER........   12

     4.1.    Organization.......................................................   12

     4.2.    Authorization, Enforcement, and Validity...........................   12

     4.3.    Consents and Approvals; No Violation...............................   12

     4.4.    Investment Experience..............................................   13

     4.5.    Investment Intent and Limitation on Dispositions...................   13
</TABLE>

                                      -ii-
<PAGE>

<TABLE>
<S>                                                                                <C>
     4.6.    Information and Risk...............................................   13

     4.7.    Disclosures to the Company.........................................   13

     4.8.    Nature of Purchasers...............................................   14

     4.9.    Ownership..........................................................   14

     4.10.   Brokers or Finders.................................................   14

     4.11.   Acknowledgement....................................................   14

     4.12.   No Short Sales.....................................................   14

SECTION 5.   SURVIVAL OF REPRESENTATIONS AND WARRANTIES.........................   14

SECTION 6.   REGISTRATION OF THE SHARES; COMPLIANCE WITH THE SECURITIES ACT.....   15

     6.1.    Registration Procedures and Expenses...............................   15

     6.2.    Restrictions on Transferability....................................   18

     6.3.    Termination of Conditions and Obligations..........................   19

SECTION 7.   LEGENDS............................................................   19

SECTION 8.   INDEMNIFICATION....................................................   20

SECTION 9.   NOTICES............................................................   22

SECTION 10.  MISCELLANEOUS......................................................   23

     10.1.   Amendments.........................................................   23

     10.2.   Headings...........................................................   23

     10.3.   Severability.......................................................   24

     10.4.   Governing Law and Forum............................................   24

     10.5.   Counterparts.......................................................   24

     10.6.   Entire Agreement...................................................   24

     10.7.   Independent Nature of Purchasers' Obligations and Rights...........   24

     10.8.   Expenses...........................................................   24
</TABLE>

                                      -iii-
<PAGE>

Appendix A    Schedule of Purchasers
Appendix B    Form of Warrant
Appendix C    Form of Lock-Up Agreement

                                      -iv-
<PAGE>

                          SECURITIES PURCHASE AGREEMENT

            THIS SECURITIES PURCHASE AGREEMENT (this "Agreement") is made as of
the 24th day of September 2004 by and among Myogen, Inc. (the "Company"), a
Delaware corporation, with its principal offices at 7575 West 103rd Avenue,
Suite 102, Westminster, CO 80021, and the entities listed on Appendix A (each, a
"Purchaser").

            IN CONSIDERATION of the mutual covenants contained in this
Agreement, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and the Purchasers
hereby agree as follows:

Section 1. Purchase and Sale of Securities.

            Subject to the terms and conditions of this Agreement, on the
Closing Date (as defined herein), each Purchaser agrees to purchase severally
and not jointly and the Company agrees to issue and sell to such Purchaser
severally and not jointly (i) that number of whole shares of the Company's
common stock, $0.001 par value, (the "Common Stock") set forth opposite such
Purchaser's name on Appendix A (the "Shares") and (ii) warrants in the form
attached hereto as Appendix B (the "Warrants", together with the Shares, the
"Securities") to purchase shares of Common Stock as set forth opposite such
Purchaser's name on Appendix A, at a purchase price that is equal to $6.525 per
Security, of which $0.025 is allocated as consideration for the Warrants.

Section 2. The Closing.

      2.1.  The Closing.

            (a)   The purchase and sale of the Securities upon the terms and
conditions hereof will take place at a closing (the "Closing") to be held at the
offices of Cooley Godward LLP, 380 Interlocken Crescent, Suite 900, Broomfield,
CO 80021 on the date hereof at such time as shall be agreed upon by the Company
and the Purchasers (the "Closing Date").

            (b)   The Company shall provide wire transfer instructions for the
payment of the Purchase Price (as defined below) prior to the Closing.

            (c)   At the Closing, the Company and each Purchaser shall satisfy
all of the conditions set forth in Sections 2.2(b) and (a), respectively.

      2.2.  Conditions to Closing.

            (a)   The Company's obligation to complete the purchase and sale of
the Securities and deliver such stock certificate(s) and Warrants to each
Purchaser is subject to:

            (i)   receipt by the Company of immediately available funds in the
      full amount of the purchase price for the Securities being purchased
      hereunder as set forth opposite

<PAGE>

      such Purchaser's name on Appendix A (the "Purchase Price"), in accordance
      with the wire transfer instructions delivered by the Company pursuant to
      Section 2.1(b); and

            (ii)  the accuracy in all material respects of the representations
      and warranties made by such Purchaser in Section 4 below as of the Closing
      Date and the fulfillment in all material respects of those undertakings of
      such Purchaser in this Agreement to be fulfilled on or prior to the
      Closing Date.

            (b)   Each Purchaser's obligation to complete the purchase and sale
of the Securities is subject to:

            (i)   the accuracy in all material respects of the representations
      and warranties made by the Company in Section 3 below as of the Closing
      Date and the fulfillment in all material respects of those undertakings of
      the Company in this Agreement to be fulfilled on or prior to the Closing
      Date;

            (ii)  confirmation that the notification to list the Shares and the
      shares of Common Stock underlying the Warrants (the "Warrant Shares") on
      the Nasdaq National Market has been filed;

            (iii) delivery by the Company to such Purchaser (as defined herein)
      of an opinion, dated as of the Closing Date, from Cooley Godward LLP,
      counsel to the Company, in a form reasonably acceptable to the Purchasers;

            (iv)  delivery by the Company to such Purchaser of an opinion, dated
      as of the Closing Date, from Fulbright & Jaworski, intellectual property
      counsel to the Company, in a form reasonably acceptable to the Purchasers;

            (v)   delivery by the Company to such Purchaser of an opinion, dated
      as of the Closing Date, from Hyman Phelps LLP, regulatory counsel to the
      Company, in a form reasonably acceptable to the Purchasers;

            (vi)  delivery by the Company to such Purchaser of an opinion, dated
      as of the Closing Date, from Meyer-Koring v. Danwitz Privat, counsel to
      Myogen GmbH, a wholly owned subsidiary of the Company (the "Subsidiary"),
      in a form reasonably acceptable to Purchasers;

            (vii) delivery by PricewaterhouseCoopers LLP to the Placement Agents
      of a letter, in form and substance satisfactory to the Placement Agents,
      confirming that PricewaterhouseCoopers LLP are an independent registered
      public accounting firm within the meaning of the Securities Act (as
      defined herein) and the Exchange Act (as defined herein) and the
      applicable rules and regulations thereunder, containing statements and
      information of the type ordinarily included in an accountant's "comfort
      letters" to placement agents, delivered according to Statement of Auditing
      Standards No. 72 (or any successor bulletins), with respect to the audited
      and unaudited financial statements and certain financial information
      contained in the Memorandum and the SEC Documents (each as defined below);

                                      -2-
<PAGE>

            (viii) the Company's delivery to its transfer agent of irrevocable
      instructions to issue to such Purchaser or in such nominee name(s) as
      designated by such Purchaser in writing such number of Shares set forth
      opposite such Purchaser's name on Appendix A or, if requested by the
      Purchaser, one or more certificates representing such Shares;

            (ix)  except with respect to JPMorgan Partners (SBIC), LLC and
      JPMorgan Securities Inc., the "lock-up" agreements, each substantially in
      the form of Appendix B hereto, between the Placement Agents and officers,
      directors and shareholders owning 5% or more of Common Stock of the
      Company relating to sales and certain other dispositions of shares of
      Common Stock or certain other securities, delivered to the Placement
      Agents on or before the date hereof, being in full force and effect on the
      date hereof; and

            (x)   the aggregate Purchase Price to be paid by the Purchasers for
      the Securities at the Closing shall be greater than or equal to
      $59,999,985.00.

Section 3. Representations, Warranties and Covenants of the Company.

            Except as set forth on the corresponding sections of the Company's
disclosure schedule delivered herewith (the "Schedule of Exceptions"), as
otherwise described in the SEC Documents, or as specifically contemplated by
this Agreement, the Company hereby represents and warrants to, and covenants
with, each Purchaser as of the Closing Date (or such other date specified below)
as follows:

      3.1.  No Material Misstatement. The Private Placement Memorandum dated
September 20, 2004, relating to the offering of the Securities, including all
exhibits, documents incorporated by reference and annexes thereto, as the same
may be amended or supplemented, (the "Memorandum"), did not, as of its date,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein not misleading.

      3.2.  Incorporated Documents.

            (a)   The documents incorporated by reference in the Memorandum, at
the time they became effective or were filed with the Securities and Exchange
Commission (the "Commission"), as the case may be, complied in all material
respects with the requirements of the Securities Act of 1933, as amended (the
"Securities Act") or the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), as applicable, and the rules and regulations of the Commission
thereunder, and none of such documents, at the time filed with the Commission,
contained an untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading.

            (b)   Since October 29, 2003, the Company has filed all documents
required to be filed by it prior to the date hereof with the Commission pursuant
to the reporting requirements of the Exchange Act (the "SEC Documents").

                                      -3-
<PAGE>

      3.3.  Financial Statements.

            (a)   The summary financial data included in the Memorandum present
fairly the information shown therein as at the respective dates and for the
respective periods specified and have been presented on a basis consistent with
the consolidated financial statements set forth in the SEC Documents.

            (b)   As of their respective dates, the financial statements of the
Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and published rules and
regulations of the Commission with respect thereto. Such financial statements
have been prepared in accordance with generally accepted accounting principles,
consistently applied, during the periods involved (except as may be otherwise
indicated in such financial statements or the notes thereto) and fairly present
in all material respects the financial position of the Company and its
Subsidiary as of the dates thereof and the results of its operations and cash
flows for the periods then ended (subject, in the case of unaudited statements,
to normal year-end audit adjustments).

      3.4.  No Material Adverse Change. Since the date of the most recent
financial statements of the Company included in the Memorandum, (i) there has
not been any change in the capital stock or long-term debt of the Company or its
Subsidiary, or any dividend or distribution of any kind declared, set aside for
payment, paid or made by the Company on any class of capital stock, or any
material adverse change, or any development involving a prospective material
adverse change, in or affecting the business, properties, management, financial
position, stockholders' equity, results of operations or prospects of the
Company and its Subsidiary taken as a whole; and (ii) neither the Company nor
its Subsidiary has sustained any material loss or interference with its business
from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor disturbance or dispute or any action, order or
decree of any court or arbitrator or governmental or regulatory authority,
except in each case in (i) and (ii) as otherwise disclosed in the Memorandum.

      3.5.  Books and Records; Internal Controls. The books, records and
accounts of the Company and its Subsidiary accurately and fairly reflect, in
reasonable detail, the transactions in, and dispositions of, the assets of, and
the results of operations of, the Company and its Subsidiary. The chief
executive officer and the chief financial officer of the Company have made all
certifications required by the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley
Act") and any related rules and regulations promulgated by the Commission, and
the statements contained in any such certification are complete and correct; the
Company maintains "disclosure controls and procedures" (as defined in Rule
13a-15e and Rule 15d-15e under the Exchange Act); such disclosure controls and
procedures are designed to ensure that material information relating to the
Company, including its Subsidiary, is made known to the Company's Chief
Executive Officer and its Chief Financial Officer by others within those
entities; the Company's auditors and the Audit Committee of the Board of
Directors have been advised of: (1) any significant deficiencies in the design
or operation of internal controls which could adversely affect the Company's
ability to record, process, summarize and report financial data; and (2) any
fraud, whether or not material, that involves management or other employees who
have a role in the Company's internal controls; any material weaknesses in
internal controls have been identified for the Company's auditors; and since the
date of the most recent evaluation of such disclosure controls and

                                      -4-
<PAGE>

procedures, there have been no significant changes in internal controls or in
other factors that could significantly affect internal controls, including any
corrective actions with regard to significant deficiencies and weaknesses; the
Company is otherwise in compliance in all material respects with all applicable
effective provisions of the Sarbanes-Oxley Act.

      3.6.  Independent Accountants. PricewaterhouseCoopers LLP, whose reports
are included as a part of the Memorandum, are and, during the periods covered by
their reports, were an independent public accounting firm as required by the
Securities Act, and the rules and regulations of the Commission thereunder.

      3.7.  Organization; Good Standing. The Company and its Subsidiary have
been duly organized and are validly existing and in good standing under the laws
of their respective jurisdictions of organization, are duly qualified to do
business and are in good standing in each jurisdiction in which their respective
ownership or lease of property or the conduct of their respective businesses
requires such qualification, and have all power and authority necessary to own
or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or have such power or
authority would not, individually or in the aggregate, have a material adverse
effect on the business, properties, financial position, or results of operations
of the Company and its Subsidiary taken as a whole (a "Material Adverse
Effect"). Myogen GmbH is the only subsidiary of the Company.

      3.8.  Legal Proceedings. Except as set forth in the SEC Documents, there
are no legal, governmental or regulatory investigations, actions, suits or
proceedings pending to which the Company or its Subsidiary is or may be a party
or to which any property of the Company or its Subsidiary is or may be the
subject that, individually or in the aggregate, if determined adversely to the
Company or its Subsidiary, could reasonably be expected to have a Material
Adverse Effect or materially and adversely affect the ability of the Company to
perform its obligations under this Agreement; no such investigations, actions,
suits or proceedings are to the knowledge of the Company threatened or
contemplated by any governmental or regulatory authority or threatened by
others; and (i) there are no current or pending legal, governmental or
regulatory actions, suits or proceedings that are required under the Exchange
Act to be described in the SEC Documents that are not so described and (ii)
there are no statutes, regulations or contracts or other documents that are
required under the Securities Act to be filed as exhibits to the SEC Documents
or described in the SEC Documents that are not so filed or described.

      3.9.  Brokers or Finders. No broker, investment banker, financial advisor
or other individual, corporation, general or limited partnership, limited
liability company, firm, joint venture, association, enterprise, joint
securities company, trust, unincorporated organization or other entity (each a
"Person"), other than CIBC World Markets Corp. and Lazard Freres & Co. LLC (the
"Placement Agents"), the fees and expenses of which will be paid by the Company,
is entitled to any broker's, finder's, financial advisor's or other similar fee
or commission in connection with the transactions contemplated by this Agreement
based upon arrangements made by or on behalf of the Company.

      3.10. Licenses and Permits. The Company and its Subsidiary possess all
licenses, certificates, permits and other authorizations issued by, and have
made all declarations and filings with, the appropriate federal, state, local or
foreign governmental or regulatory authorities or any

                                      -5-
<PAGE>

other person or entity that are necessary for the ownership or lease of their
respective properties or the conduct of their respective businesses as described
in the Memorandum, except where the failure to possess or make the same would
not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect; and except as described in the Memorandum, neither the Company
nor its Subsidiary has received notice of any revocation or modification of any
such license, certificate, permit or authorization.

      3.11. Intellectual Property. To best of its knowledge after due inquiry,
the Company and its Subsidiary own or possess adequate rights to use all
material patents, patent applications, trademarks, service marks, trade names,
trademark registrations, service mark registrations, copyrights, licenses and
know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems, processes or procedures)
(collectively, the "Intellectual Property") necessary for the conduct of their
respective businesses; and the conduct of their respective businesses will not,
to the knowledge of the Company, conflict in any material respect with any such
rights of others, and the Company and its Subsidiary have not received any
notice of any claim of infringement or conflict with any such rights of others.
Neither the Company nor its Subsidiary has received any notice of infringement
of or conflict with, and neither the Company nor its Subsidiary has actual
knowledge of any infringement of or conflict with, asserted rights of others
with respect to its Intellectual Property which could reasonably be expected to
result in a Material Adverse Effect; the discoveries, inventions, products or
processes of the Company and its Subsidiary referred to in the Memorandum do
not, to the knowledge of the Company or its Subsidiary, infringe or conflict
with any right or patent of any third party, or any discovery, invention,
product or process which is the subject of a patent application filed by any
third party. Further, except as described in the Memorandum or the SEC Documents
or exhibits thereto, or as would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect, neither the Company nor its
Subsidiary is obligated to pay a royalty, grant a license or provide other
consideration to any third party in connection with its patents, patent rights,
licenses, inventions, trademarks, service marks, trade names, copyrights and
know-how; and no third party, including any academic or governmental
organization, possesses rights to the Intellectual Property which, if exercised,
could enable such third party to develop products competitive with the business
of the Company or its Subsidiary as currently being conducted.

      3.12. Real and Personal Property. The Company and its Subsidiary have good
and marketable title in fee simple to, or have valid rights to lease or
otherwise use, all items of real and personal property that are material to the
respective businesses of the Company and its Subsidiary, in each case free and
clear of all liens, encumbrances, claims and defects and imperfections of title
except those that (i) do not materially interfere with the use made and proposed
to be made of such property by the Company and its Subsidiary or (ii) would not
reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect.

      3.13. Material Contracts. All material documents, contracts or other
agreements required to be filed as exhibits to the SEC Documents pursuant to
Item 601(b)(10) of Securities and Exchange Commission Regulation S-K are
described in the SEC Documents or are included in the exhibits to the SEC
Documents. Each description of such contracts, documents or other agreements in
the SEC Documents is not inconsistent with the terms of the underlying contract,
document or other agreement and, except as set forth in the SEC Documents, is in
full force and effect and is valid and enforceable by and against the Company or
its Subsidiary, as the case may

                                      -6-
<PAGE>

be, in accordance with its terms. Neither the Company or its Subsidiary nor, to
the Company's knowledge, any other party thereto is in breach of or default
under any such agreement, which breach or default would reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect. The
Company has not received any written notice regarding the termination of any
such agreements.

      3.14. No Violation or Default. Neither the Company nor its Subsidiary is
(i) in violation of its charter or by-laws or similar organizational documents;
(ii) to the knowledge of the Company, in default, and, no event has occurred
that, with notice or lapse of time or both, would constitute such a default, in
the due performance or observance of any term, covenant or condition contained
in any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company or its Subsidiary is a party or by which the
Company or its Subsidiary is bound or to which any of the property or assets of
the Company or its Subsidiary is subject; or (iii) to the knowledge of the
Company, in violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (ii) and (iii) above, for any such default or
violation that would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect.

      3.15. No Conflicts. The execution, delivery and performance by the Company
of this Agreement, the issuance and sale of the Securities, the issuance of the
Warrant Shares and the consummation of the transactions contemplated by this
Agreement will not (i) conflict with or result in a breach or violation of any
of the terms or provisions of, or constitute a default under, or result in the
creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company or its Subsidiary pursuant to, any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the
Company or its Subsidiary is a party or by which the Company or its Subsidiary
is bound or to which any of the property or assets of the Company or its
Subsidiary is subject, (ii) result in any violation of the provisions of the
charter or by-laws or similar organizational documents of the Company or its
Subsidiary or (iii) result in the violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or governmental
or regulatory authority binding upon the Company, except, in the case of clauses
(i) and (iii) above, for any such default or violation that would not reasonably
be expected, individually or in the aggregate, to have a Material Adverse
Effect.

      3.16. No Consents. No consent, approval, authorization, order,
registration or qualification of or with any court or arbitrator or governmental
or regulatory authority is required for the execution, delivery and performance
by the Company of this Agreement, the issuance and sale of the Securities, the
issuance of the Warrant Shares and the consummation of the transactions
contemplated by this Agreement, except for the registration of the Shares and
Warrant Shares under the Securities Act pursuant to Section 6 hereof, such
consents, approvals, authorizations, orders and registrations or qualifications
as may be required under applicable state securities laws in connection with the
purchase and distribution of the Securities by the Purchasers, the filing of a
Form D pursuant to Securities and Exchange Commission Regulation D, and any
required filings or notifications regarding the issuance or listing of
additional shares with the Nasdaq National Market.

      3.17. Due Authorization and Delivery. All necessary corporate action has
been duly and validly taken by the Company to authorize the execution, delivery
and performance of this

                                      -7-
<PAGE>

Agreement, the Warrants, the issuance and sale of the Securities and the
reservation for issuance, and issuance, of the Warrant Shares by the Company.
Each of this Agreement and the Warrants has been duly and validly authorized,
executed and delivered by the Company and, each of this Agreement and the
Warrants constitute and will constitute legal, valid and binding obligations of
the Company enforceable against the Company in accordance with its terms, except
as the enforceability thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting the enforcement of
creditors' rights generally and by general equitable principles and except as
rights to indemnity may be limited by state or federal securities laws or public
policy underlying such laws.

      3.18. The Securities and the Warrant Shares. The Securities to be issued
and sold by the Company hereunder and the Warrant Shares have been duly
authorized by the Company. The Shares, when issued and delivered and paid for as
provided herein, will be duly and validly issued and will be fully paid and
nonassessable. The Warrant Shares have been duly authorized and reserved for
issuance and, upon exercise of the Warrants in accordance with their terms, the
Warrant Shares will be duly and validly issued and will be fully paid and
nonassessable. The Securities are not inconsistent with the descriptions thereof
in the Memorandum; and the issuance of the Securities and the Warrant Shares are
not subject to any preemptive or similar rights.

      3.19. Capitalization. The Company has an authorized capitalization as set
forth in the SEC Documents; all the outstanding shares of capital stock of the
Company have been duly and validly authorized and issued and are fully paid and
non-assessable and are not subject to any pre-emptive or similar rights; except
as described in or expressly contemplated by the Memorandum or the SEC
Documents, as of June 30, 2004 there were no outstanding rights (including,
without limitation, pre-emptive rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any shares of capital stock or
other equity interest in the Company or its Subsidiary, or any contract,
commitment, agreement, understanding or arrangement of any kind obligating the
Company to issue any capital stock of the Company or its Subsidiary, any such
convertible or exchangeable securities or any such rights, warrants or options;
since June 30, 2004 there has been no material change in the capital stock of
the Company except for subsequent issuances, if any, pursuant to this Agreement
or pursuant to reservations, agreements or employee benefit plans, including
employee stock or option incentive plans, referred to in the Memorandum or
pursuant to the exercise of convertible securities or options referred to in the
Memorandum; the capital stock of the Company as of June 30, 2004 is not
inconsistent with the description thereof contained in the Memorandum; and all
the outstanding shares of capital stock or other equity interests of the
Subsidiary of the Company have been duly and validly authorized and issued, are
fully paid and non-assessable (except for directors' qualifying shares and
except as otherwise described in the Memorandum) and are owned directly or
indirectly by the Company, free and clear of any lien, charge, encumbrance,
security interest, restriction on voting or transfer or any other claim of any
third party. The issuance and sale of the Shares will not obligate the Company
to issue shares of Common Stock or other securities to any person and will not
result in a right of any current holder of Company securities to adjust the
exercise, conversion, exchange or reset price under such securities. No further
approval or authorization of any stockholder, the Board of Directors of the
Company or others is required for the issuance and sale of the Shares which has
not already been obtained. Subject to the filing of the notification with the
Nasdaq National Market as contemplated in Section 3.25(b), the issuance and sale
of the Shares

                                      -8-
<PAGE>

under this Agreement does not contravene the rules and regulations of the Nasdaq
National Market, and, in furtherance of the foregoing sentence, no approval of
the stockholders of the Company thereunder is required for the Company to issue
and deliver to the Purchasers the maximum number of Shares contemplated by this
Agreement.

      3.20. Lock-Ups. During the period beginning on the Closing Date and ending
ninety (90) days following the effective date of the Registration Statement (as
defined in Section 6.1(a)(i) below), the Company will not, without the prior
written consent of the Placement Agents, sell, contract to sell or otherwise
dispose of or issue any securities of the Company, except pursuant to previously
issued options or warrants, any agreements providing for anti-dilution or other
stock purchase or share issuance rights in existence on the date hereof, any
employee benefit or similar plan of the Company in existence on the date hereof
or duly adopted hereafter, or any technology license agreement, strategic
alliance or joint venture in existence on the date hereof or which the Company
may enter into hereafter.

      3.21. Employees. Neither the Company nor its Subsidiary is involved in any
labor dispute nor, to the knowledge of the Company, is any such dispute
threatened, which dispute would result in a Material Adverse Effect to the
Company and its Subsidiary taken as a whole. The Company is not aware of any
existing or imminent labor disturbance by the employees of any of its principal
suppliers or contractors which would result in a Material Adverse Effect to the
Company and its Subsidiary taken as a whole.

      3.22. Related Party Transactions. Except as described in the SEC
Documents, no transaction has occurred between or among the Company or its
Subsidiary and any of its officers or directors, shareholders or any affiliate
or affiliates of any such officer or director or shareholder that is not
described in the Memorandum.

      3.23. Market Stabilization. The Company has not taken, nor will it take,
directly or indirectly, any action designed to stabilize or manipulate of the
price of the Common Stock or any security of the Company to facilitate the sale
or resale of any of the Shares.

      3.24. Taxes. The Company and its Subsidiary have paid all federal, state,
local and foreign taxes and filed all tax returns required to be paid or filed
through the date hereof except to the extent that such taxes are being contested
in good faith and any reserves required under GAAP have been made; and except as
otherwise disclosed in the Memorandum, there is, to the knowledge of the
Company, no tax deficiency that has been asserted against the Company or its
Subsidiary or any of their respective properties or assets.

      3.25. Compliance; Listing.

            (a)   The Company is in compliance with the requirements of the
Nasdaq National Market for continued listing of the Common Stock thereon and has
not received any notification that, and has no knowledge that, the Nasdaq
National Market is contemplating terminating such listing nor, to the Company's
knowledge, is there any basis therefor. The transactions contemplated by this
Agreement will not contravene the rules and regulations of the Nasdaq National
Market. The Company will use commercially reasonable efforts to continue the
listing and trading of its Common Stock on the Nasdaq National Market and to
comply in all material

                                      -9-
<PAGE>

respects with the Company's reporting, filing and other obligations under the
rules of the Nasdaq National Market.

            (b)   The Shares and the Warrant Shares have been duly authorized
for listing on the Nasdaq National Market.

      3.26. Insurance. The Company and its Subsidiary have insurance covering
their respective material properties, operations, personnel and businesses,
including business interruption insurance, which insurance is in such amounts
and insures against such losses and risks as would customarily be obtained by
other companies similarly situated and in a similar business; and neither the
Company nor its Subsidiary has (i) received notice from any insurer or agent of
such insurer that capital improvements or other expenditures are required or
necessary to be made in order to continue such insurance or (ii) any reasonable
belief that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business.

      3.27. Environmental Laws. The Company and its Subsidiary (i) are in
compliance with any and all applicable federal, state, local and foreign laws,
rules, regulations, decisions and orders relating to the protection of human
health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (collectively, "Environmental Laws"); (ii) have
received and are in compliance with all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) have not received notice of any actual or potential
liability for the investigation or remediation of any disposal or release of
hazardous or toxic substances or wastes, pollutants or contaminants, except in
any such case for any such failure to comply, or failure to receive required
permits, licenses or approvals, or liability as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect.

      3.28. Investment Company. The Company is not and, after giving effect to
the offering and sale of the Securities and the application of the proceeds
thereof as described in the Memorandum, will not be an "investment company" or
an entity "controlled" by an "investment company" within the meaning of the
Investment Company Act of 1940, as amended, and the rules and regulations of the
Commission thereunder (collectively, "Investment Company Act").

      3.29. Solicitation; Other Issuances of Securities. Neither the Company nor
its Subsidiary or any affiliates, nor any Person acting on its or their behalf,
(i) has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D under the Securities Act) in connection with
the offer or sale of the Securities, (ii) has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security,
under any circumstances that would require registration of the Securities under
the Securities Act or (iii) has issued any shares of Common Stock or shares of
any series of preferred stock or other securities or instruments convertible
into, exchangeable for or otherwise entitling the holder thereof to acquire
shares of Common Stock which would be integrated with the sale of the Securities
to such Purchaser for purposes of the Securities Act or of any applicable
stockholder approval provisions, including, without limitation, under the rules
and regulations of any exchange or automated quotation system on which any of
the securities of the Company are listed or designated, nor will the Company or
its Subsidiary or affiliates take any action or steps that would

                                      -10-
<PAGE>

require registration of any of the Securities under the Securities Act or cause
the offering of the Securities to be integrated with other offerings. Assuming
the accuracy of the representations and warranties of Purchasers, the offer and
sale of the Securities by the Company to the Purchasers pursuant to this
Agreement will be exempt from the registration requirements of the Securities
Act.

      3.30. No Restrictions on Subsidiaries. The Subsidiary of the Company is
not currently prohibited, directly or indirectly, under any agreement or other
instrument to which it is a party or is subject, from paying any dividends to
the Company, from making any other distribution on the Subsidiary's capital
stock, from repaying to the Company any loans or advances to the Subsidiary from
the Company or from transferring any of such Subsidiary's properties or assets
to the Company.

      3.31. No Registration Rights. No person has the right, which right has not
been waived, to require the Company or its Subsidiary to register any securities
for sale under the Securities Act by reason of the filing of the Registration
Statement with the Commission or the issuance and sale of the Securities.

      3.32. Forward-Looking Statements. No forward-looking statement (within the
meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Memorandum has been made or reaffirmed without what the
Company believes to be a reasonable basis or has been disclosed other than in
good faith.

      3.33. Statistical and Market Data. Nothing has come to the attention of
the Company that has caused the Company to believe that the statistical and
market-related data included in the Memorandum is not based on or derived from
sources that are reliable and accurate in all material respects.

      3.34. Compliance in Clinical Trials. The clinical trials conducted by or
on behalf of the Company that are described in the Memorandum, or the results of
which are referred to in the Memorandum, if any, are the only clinical trials
currently being conducted by or on behalf of the Company. Nothing has come to
the attention of the Company that has caused the Company to believe that such
studies and tests were and, if still pending, are being, conducted not in
accordance with experimental protocols, procedures and controls pursuant to
accepted professional scientific standards; the descriptions of the results of
such studies, tests and trials contained in the Memorandum, if any, are not
inconsistent with such results in any material respects. Except as described in
the Memorandum, no results of any other studies or tests have come to the
attention of the Company that have caused the Company to believe that such
results call into question the results described in the Memorandum of the
clinical trials. The Company has not received any notices or correspondence from
the FDA or any other governmental agency requiring the termination, suspension
or modification of any clinical trials currently conducted by, or on behalf of,
the Company or in which the Company has participated that are described in the
Memorandum, if any, or the results of which are referred to in the Memorandum.
Nothing has come to the attention of the Company that has caused the Company to
believe that the clinical trials previously conducted by or on behalf of the
Company while conducted by or on behalf of the Company, were not conducted in
accordance with experimental protocols, procedures and controls pursuant

                                      -11-
<PAGE>

to accepted professional scientific standards; the descriptions of the results
of such studies, tests and trials contained in the Memorandum, if any, are not
inconsistent with such results.

      3.35. SEC Filing. The Company shall use its commercially reasonable
efforts to file with the SEC a current report on Form 8-K under the Exchange Act
describing the transactions contemplated hereby and attaching as exhibits
thereto all material documents relating to the transactions contemplated hereby.

Section 4. Representations, Warranties and Covenants of Each Purchaser.

            Each Purchaser for itself and no other Purchaser hereby represents
and warrants to, and covenants with, the Company as of the Closing Date (or such
other date specified below) as follows:

      4.1.  Organization. Such Purchaser is an entity duly organized and validly
existing in good standing (to the extent such concepts are applicable) under the
laws of its jurisdiction of organization. Such Purchaser has all requisite
corporate power and authority and all necessary governmental approvals to carry
on its business as now being conducted, except as would not result in a Material
Adverse Effect on such Purchaser's ability to consummate the transactions
contemplated by this Agreement.

      4.2.  Authorization, Enforcement, and Validity. Such Purchaser has the
requisite power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. Such Purchaser has taken all necessary action
to authorize the execution, delivery and performance of this Agreement. Upon the
execution and delivery of this Agreement, this Agreement shall constitute a
valid and binding obligation of the Purchaser enforceable in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors' and
contracting parties' rights generally and except as enforceability may be
subject to general principles of equity.

      4.3.  Consents and Approvals; No Violation. The execution, delivery and
performance of this Agreement by such Purchaser and the consummation by such
Purchaser of the transactions contemplated hereby will not (i) result in a
violation of such Purchaser's organizational documents; (ii) conflict with, or
constitute a default or give to others any rights of termination, amendment,
acceleration or cancellation of, any material agreement, indenture or instrument
to which such Purchaser is a party (except for such conflicts, defaults,
terminations, amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, result in a Material Adverse Effect on
such Purchaser's ability to consummate the transactions contemplated by this
Agreement); or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree applicable to such Purchaser or any of its subsidiaries,
except for such violations as would not, individually or in the aggregate,
result in a Material Adverse Effect on such Purchaser's ability to consummate
the transactions contemplated by this Agreement. Such Purchaser is not required
to obtain any consent, authorization or order of, or make any filing or
registration with, any court or governmental agency or any regulatory or
self-regulatory agency in order for it to execute, deliver or perform any of its
obligations under or contemplated by this Agreement, except where the failure to
obtain such consents, authorization or orders or to make such filings or
registrations would not, individually or in the aggregate, result in a Material
Ad-

                                      -12-
<PAGE>

verse Effect on such Purchaser's ability to consummate the transactions
contemplated by this Agreement.

      4.4.  Investment Experience. Such Purchaser is an accredited investor
within the meaning of Rule 501 of Regulation D promulgated under the Securities
Act, is knowledgeable, sophisticated and experienced in making, and is qualified
to make, decisions with respect to investments in shares representing an
investment decision like that involved in the purchase of the Securities.

      4.5.  Investment Intent and Limitation on Dispositions. Such Purchaser is
acquiring Securities for its own account for investment only and has no
intention of selling or distributing any of such Securities or any arrangement
or understanding with any other Persons regarding the sale or distribution of
such Securities except in accordance with the provisions of Section 6 and except
as would not result in a violation of the Securities Act. Such Purchaser will
not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose
of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge
of) any of the Securities except in accordance with the provisions of Section 6
or pursuant to and in accordance with the Securities Act.

      4.6.  Information and Risk.

            (a)   Such Purchaser has received and reviewed the Memorandum and
has requested, received, reviewed and considered all other information relevant
in making an informed decision to purchase the Securities. Such Purchaser has
had an opportunity to discuss the Company's business, management and financial
affairs with its management and also had an opportunity to ask questions of
officers of the Company that were answered to such Purchaser's satisfaction.

            (b)   Such Purchaser recognizes that an investment in the Securities
involves a high degree of risk, including a risk of total loss of such
Purchaser's investment. Such Purchaser is able to bear the economic risk of
holding the Securities for an indefinite period, and has knowledge and
experience in the financial and business matters such that it is capable of
evaluating the risks of the investment in the Securities.

            (c)   Such Purchaser has, in connection with such Purchaser's
decision to purchase Securities, not relied upon any representations or other
information (whether oral or written) other than as set forth in the
representations and warranties of the Company contained herein, the Memorandum,
the SEC Documents and the other information described in Section 4.6(a), and
such Purchaser has, with respect to all matters relating to this Agreement and
the offer and sale of the Securities, relied solely upon the advice of such
Purchaser's own counsel and has not relied upon or consulted any counsel to the
Placement Agents or counsel to the Company.

      4.7.  Disclosures to the Company. Such Purchaser understands that the
Company is relying on the statements contained herein to establish an exemption
from registration under federal and state securities laws. Such Purchaser will
promptly notify the Company of any changes in the information set forth in the
Registration Statement regarding such Purchaser.

                                      -13-
<PAGE>

      4.8.  Nature of Purchasers. To the knowledge of such Purchaser, such
Purchaser: (i) is not an affiliate (as such term is defined pursuant to Rule
12b-2 promulgated under the Exchange Act) of any other Purchaser, (ii) is not
constituted as a partnership, association, joint venture or any other type of
joint entity with any other Purchaser, and (iii) is not acting as part of a
group (as such term is defined under Section 13(d) of the Exchange Act) with any
other Purchaser. If at any time after the Closing Date such Purchaser becomes an
affiliate (as defined herein) of any other Purchaser, such Purchaser will
provide prompt written notice to the Company.

      4.9.  Ownership. Such Purchaser (including any Person controlling,
controlled by, or under common control with such Purchaser, as the term
"control" is defined pursuant to the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and its implementing regulations (the "HSR Act")) does
not, and upon the consummation of the transactions contemplated by this
Agreement will not, hold voting securities of the Company exceeding an aggregate
fair market value as of the Closing Date of fifty million dollars ($50,000,000),
calculated pursuant to the HSR Act.

      4.10. Brokers or Finders. No broker, investment banker, financial advisor
or other Person is entitled to any broker's, finder's, financial advisor's or
other similar fee or commission in connection with the transactions contemplated
hereby based upon arrangements made by or on behalf of such Purchaser.

      4.11. Acknowledgement. Such Purchaser acknowledges and agrees that the
Company does not make and has not made any representations or warranties with
respect to the transactions contemplated by this Agreement other than those
specifically set forth in Section 3.

      4.12. No Short Sales. Between the time such Purchaser learned about the
Offering and the public announcement of the Offering, such Purchaser has not
engaged in any short sales or similar transactions with respect to the Common
stock, nor has such Purchaser, directly or indirectly, caused any Person to
engage in any short sales or similar transactions with respect to the Common
Stock.

Section 5. Survival of Representations and Warranties.

            Notwithstanding any investigation made by any party to this
Agreement or by the Placement Agents, all representations and warranties as to
each respective Closing made by the Company and the Purchasers herein shall
survive for a period of one (1) year following the Closing Date.

                                      -14-
<PAGE>

Section 6. Registration of the Shares; Compliance with the Securities Act.

      6.1.  Registration Procedures and Expenses.

            (a)   Except for such times as the Company may be required to
suspend the use of a prospectus forming a part of the Registration Statement (as
defined below), the Company will, subject to receipt of necessary information
from the Purchasers:

            (i)   as soon as practicable, but in no event later than forty-five
      (45) days following the Closing Date (the "Filing Deadline"), use best
      efforts to prepare and file with the Commission a registration statement
      on Form S-3 (the "Registration Statement") covering the resale of the
      Shares and the Warrant Shares (each of the Shares and Warrant Shares,
      together with any shares of capital stock issued or issuable, from time to
      time, upon any reclassification, share combination, share subdivision,
      stock split, share dividend or similar transaction or event or otherwise
      as a distribution on, in exchange for or with respect to any of the
      foregoing, in each case held at the relevant time by a Purchaser, the
      "Registrable Securities") by each Purchaser;

            (ii)  use best efforts to cause the Registration Statement, as
      amended, to become effective under the Securities Act as soon as
      practicable but in any event no later than one hundred five (105) days
      after the Closing Date (the "Effectiveness Deadline");

            (iii) prepare and file with the Commission such amendments and
      supplements to the Registration Statement and the prospectus used in
      connection therewith (A) as may be necessary to keep the Registration
      Statement continuously effective and in compliance with applicable laws
      until the earlier of (i) the second anniversary of the Closing Date, (ii)
      such time as all Registrable Securities purchased by the Purchasers have
      been sold pursuant to the Registration Statement, or (iii) the date on
      which each Purchaser may sell all of the Registrable Securities under Rule
      144 of the Securities Act during any 90 day period without volume
      limitations and (B) as may be reasonably requested by a Purchaser in order
      to incorporate information concerning such Purchaser or such Purchaser's
      intended method of distribution;

            (iv)  so long as the Registration Statement is effective covering
      the resale of Registrable Securities owned by the Purchasers, furnish to
      each Purchaser with respect to the Registrable Securities registered under
      the Registration Statement (and to each underwriter, if any, of such
      Registrable Securities) such reasonable number of copies of prospectuses
      and such other documents as such Purchaser may reasonably request in order
      to facilitate the public sale or other disposition of all or any of the
      Registrable Securities by such Purchaser, subject, as applicable, to
      confidentiality restrictions reasonably acceptable to the Company;

            (v)   use commercially reasonable efforts to file documents required
      of the Company for normal Blue Sky clearance in states specified in
      writing by the Purchasers; provided, however, that the Company shall not
      be required to qualify to do business or consent to service of process
      generally in any jurisdiction in which the Company is not now so qualified
      or has not so consented;

                                      -15-
<PAGE>

            (vi)  bear all expenses in connection with the procedures in
      paragraphs (a) through (c) of this Section 6.1 and the registration of the
      Registrable Securities pursuant to the Registration Statement, other than
      fees and expenses, if any, of counsel or other advisers to the Purchasers
      or underwriting discounts, brokerage fees and commissions incurred by the
      Purchasers, if any in connection with an underwritten offering of the
      Registrable Securities;

            (vii) use all commercially reasonable efforts to prevent the
      issuance of any stop order or other order suspending the effectiveness of
      such Registration Statement and, if such an order is issued, to obtain the
      withdrawal thereof at the earliest possible time and to notify each
      Purchaser of the issuance of such order and the resolution thereof;

            (viii) furnish to each Purchaser, on the date that such Registration
      Statement becomes effective, (x) a letter, dated such date, of outside
      counsel representing the Company (and reasonably acceptable to such
      Purchaser) addressed to such Purchaser, confirming the effectiveness of
      such Registration Statement and, to the knowledge of such counsel, the
      absence of any stop order, and (y) in the case of an underwriting, (e) an
      opinion addressed to such Purchaser, dated such date, of such outside
      counsel, in such form and substance as is required to be given to the
      underwriters, and (B) a letter addressed to such Purchaser, dated such
      date, from the Company's independent certified public accountants, in such
      form and substance as is required to be given by the Company's independent
      certified public accountants to such underwriters;

            (ix)  provide to each Purchaser and its representatives, if
      requested, the opportunity to conduct a reasonable inquiry of the
      Company's financial and other records during normal business hours and
      make available its officers, directors and employees for questions
      regarding information which such Purchaser may reasonably request in order
      to fulfill any due diligence obligation on its part; and

            (x)   permit counsel for the Purchasers to review the Registration
      Statement and all amendments and supplements thereto, and any comments
      made by the staff of the Commission and the Company's responses thereto,
      within a reasonable period of time prior to the filing thereof with the
      Commission (or, in the case of comments made by the staff of the
      Commission, within a reasonable period of time following the receipt
      thereof by the Company);

provided that, in the case of clauses (ix) and (x) above, the Company shall not
be required to provide, and shall not provide, any Purchaser with material,
non-public information unless such Purchaser agrees to receive such information
and enters into a written confidentiality agreement with the Company in a form
reasonably acceptable to the Company.

            (b)   The Company shall be permitted to suspend for one or more
periods (provided that the aggregate length of such suspension shall not exceed
sixty business days in any 365 day period) the actions required under Sections
6.1(a)(i) through (iii) to the extent that the Board of Directors of the Company
concludes in good faith and based on the advise of counsel that the disclosure
of information in the prospectus relating to any strategic transaction or any
other event, the disclosure of which would have a Material Adverse Effect, is
necessary.

                                      -16-
<PAGE>

            (c)   With a view to making available to the Purchasers the benefits
of Rule 144 (or its successor rule) and any other rule or regulation of the
Commission that may at any time permit the Purchaser to sell Registrable
Securities to the public without registration, the Company covenants and agrees
to: (i) make and keep public information available, as those terms are
understood and defined in Rule 144, until the earlier of (A) six months after
such date as all of the Purchasers' Registrable Securities may be resold
pursuant to Rule 144(k) or any other rule of similar effect or (B) such date as
all of the Purchasers' Registrable Securities shall have been resold; (ii) file
with the Commission in a timely manner all reports and other documents required
of the Company under the Exchange Act; and (iii) furnish to the Purchaser upon
request, as long as the Purchaser owns any Registrable Securities, (A) a written
statement by the Company that it has complied with the reporting requirements of
the Exchange Act, (B) a copy of the Company's most recent Annual Report on Form
10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be
reasonably requested in order to avail the Purchaser of any rule or regulation
of the Commission that permits the selling of any such Registrable Securities
without registration.

            (d)   In the event that: (i) the Registration Statement is not filed
on or prior to the Filing Deadline in violation of this Agreement (if the
Company files the Registration Statement without affording counsel for the
Purchasers the opportunity to review and comment on the same as required by
Section 6.1(a)(x), the Company shall not be deemed to have satisfied this clause
(i)); provided, however, that if a Purchaser fails to provide the Company with
any information that is required to be provided in the Registration Statement
with respect to such Purchaser as set forth herein, then the Filing Deadline
shall be extended until two business days following the date of receipt by the
Company of such required information, or (ii) the Company fails to file with the
SEC a request for acceleration in accordance with Rule 461 promulgated under the
Securities Act, within five business days following the date that the Company is
notified (orally or in writing, whichever is earlier) by the SEC that the
Registration Statement will not be "reviewed," or not subject to further review,
or (iii) prior to the date when the Registration Statement is first declared
effective by the SEC, the Company fails to file a pre-effective amendment and
otherwise respond in writing to comments made by the SEC in respect of the
Registration Statement within ten business days after the receipt of comments by
or notice from the SEC that such amendment is required in order for the
Registration Statement to be declared effective, or (iv) the Registration
Statement filed hereunder is not declared effective by the SEC on or before the
applicable Effectiveness Deadline, or (v) after the Registration Statement is
first declared effective by the SEC, it ceases for any reason to remain
continuously effective as to all Registrable Securities for which it is required
to be effective or the Purchasers are not permitted to utilize the prospectus
therein to resell such Registrable Securities, other than, in each case, within
the time period(s) permitted by Section 6.1(b)) (any such failure or breach
being referred to as an "Event," and for purposes of clause (i) or (iv) the date
on which such Event occurs, or for purposes of clause (ii) the date on which
such five business day period is exceeded, or for purposes of clauses (iii) the
date which such ten business day period is exceeded, or for purposes of clause
(v) the date on which the Registration Statement is not effective or such
prospectus is not available for use being referred to as "Event Date"), then in
addition to any other rights the Purchasers may have hereunder or under
applicable law: on each monthly anniversary of each such Event Date (if the
applicable Event shall not have been cured by such date) until the applicable
Event is cured, and the next business date after the date on which the Event is
cured, the

                                      -17-
<PAGE>

Company shall pay to each Purchaser an amount in cash, as liquidated damages and
not as a penalty, equal to 1% of the aggregate Purchase Price paid by such
Purchaser in cash pursuant to this Agreement for any Registrable Securities then
held by such Purchaser that are covered by the Registration Statement or
prospectus contained therein to which the Event relates, which amount, in the
case of the payment to be made after the date on which the Event is cured, shall
be calculated pro rata based on the number days elapsed since the date of the
Event or the date of the last payment, as applicable. If the Company fails to
pay any liquidated damages pursuant to this Section in full within seven
business days after the date payable, the Company will pay interest thereon at a
rate of 12% per annum (or such lesser maximum amount that is permitted to be
paid by applicable law) to the Purchasers, accruing daily from the date such
liquidated damages are due until such amounts, plus all such interest thereon,
are paid in full.

            (e)   The Purchasers shall have no right to take any action to
restrain, enjoin or otherwise delay any registration pursuant to Section 6.1
hereof as a result of any controversy that may arise with respect to the
interpretation or implementation of this Agreement.

            (f)   As a condition to the inclusion of its Registrable Securities
under the Registration Statement, each Purchaser shall furnish to the Company
such information regarding such Purchaser and the distribution proposed by such
Purchaser as the Company may reasonably request in writing, including completing
a Registration Statement Questionnaire in the form provided by the Company, or
as shall be required in connection with any registration referred to in this
Section 6.1.

      6.2.  Restrictions on Transferability.

            (a)   Each Purchaser agrees that it will not effect any disposition
of the Securities or the Warrant Shares that would constitute a sale within the
meaning of the Securities Act or pursuant to any applicable state securities or
Blue Sky laws of any state, except (i) as to the Registrable Securities, as
contemplated in the Registration Statement referred to in Section 6.1 above,
(ii) as to the Registrable Securities pursuant to the requirements of Rule 144
(in which case such Purchaser will provide the Company with reasonable evidence
of such Purchaser's compliance therewith) or (iii) pursuant to a written opinion
of legal counsel reasonably satisfactory to the Company and addressed to the
Company to the effect that registration is not required in connection with the
proposed transfer; provided, however, that no opinion of legal counsel shall be
required for a transfer to an affiliate of the Purchaser; whereupon the holder
of such securities shall be entitled to transfer such securities. Each
certificate evidencing the securities transferred as above provided shall bear
the appropriate restrictive legends as may be required by Section 7.

            (b)   Each Purchaser acknowledges that there may occasionally be
times when the Company must suspend the use of the prospectus forming a part of
the Registration Statement until such time as an amendment or supplement to the
Registration Statement has been filed by the Company and declared effective, or
until such time as the Company has filed an appropriate report with the
Commission pursuant to the Exchange Act. Each Purchaser hereby covenants that
such Purchaser will not sell any Registrable Securities pursuant to said
prospectus during the period commencing at the time at which the Company gives
the Purchasers written notice of the suspension of the use of said prospectus
and ending at the time the Company gives

                                      -18-
<PAGE>

the Purchasers written notice that the Purchasers may thereafter effect sales
pursuant to said prospectus. The Company agrees to file such amendment,
supplement or report as soon as practicable following such notice of suspension.

            (c)   Neither the Securities nor the Warrant Shares shall be
transferable except upon the conditions specified in this Section 6, and in the
case of the Warrants, in the Warrant, which are intended to ensure compliance
with the provisions of the Securities Act. Each Purchaser will cause any
proposed transferee of the Securities or Warrant Shares held by such Purchaser
to agree to take and hold such Securities or Warrant Shares subject to the
provisions and upon the conditions specified in this Section 6 if and to the
extent that such Securities or Warrant Shares continue to be restricted
securities in the hands of the transferee.

            (d)   Each Purchaser acknowledges and agrees that the Registrable
Securities sold pursuant to the Registration Statement are not transferable on
the books of the Company unless the stock certificate submitted to the transfer
agent evidencing such Registrable Securities is accompanied by a certificate
reasonably satisfactory to the Company to the effect that (i) the Registrable
Securities have been sold in accordance with such Registration Statement and
(ii) the requirement of delivering a current prospectus has been satisfied.

            (e)   Each Purchaser agrees not to take any action with respect to
any distribution deemed to be made pursuant to such Registration Statement which
would constitute a violation of Regulation M under the Exchange Act or any other
applicable rule, regulation or law.

      6.3.  Termination of Conditions and Obligations.

            (a)   The conditions precedent imposed by Section 6.2 above
regarding the transferability of the Shares or Warrant Shares shall cease and
terminate as to any particular number of the Shares or Warrant Shares upon the
date on which the Purchaser may sell within any 90 day period without volume
limitations all such Securities or Warrant Shares then held by the Purchaser
without registration by reason of Rule 144 or any other rule of similar effect.

Section 7. Legends.

            (a)   Such Purchaser understands and agrees that each certificate or
other document evidencing any of the Securities or Warrant Shares shall be
endorsed with the legend in the form set forth below, and such Purchaser
covenants that such Purchaser will not transfer the shares or the Warrants, as
the case may be, represented by any such certificate without complying with the
restrictions on transfer described in the legend endorsed on such certificate
(unless there is in effect a registration statement under the Securities Act
covering such proposed transfer, such securities have been sold under Rule 144
promulgated under the Securities Act ("Rule 144") or as otherwise permitted by
the provisions of Section 6.2 above) and understands that the Company will
refuse to register a transfer of any Securities or Warrant Shares unless the
conditions specified in the following legend are satisfied:

      "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS.
      EXCEPT AS SPECIFIED IN THIS

                                      -19-
<PAGE>

      LEGEND, SUCH SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
      HYPOTHECATED, OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION
      STATEMENT IN EFFECT WITH RESPECT THERETO UNDER SUCH ACT UNLESS SOLD
      PURSUANT TO RULE 144 OF SUCH ACT OR UNLESS SUCH SALE, PLEDGE,
      HYPOTHECATION OR TRANSFER IS OTHERWISE EXEMPT FROM REGISTRATION AND ANY
      APPLICABLE STATE SECURITIES LAWS. THE COMPANY MAY REQUEST A WRITTEN
      OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT
      THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH SALE OR OTHER
      TRANSFER."

            (b)   Such certificates shall not contain any legend (i) while a
Registration Statement (as defined below) covering the resale of such
Registrable Securities is effective under the Securities Act, (ii) following any
sale of such Registrable Securities pursuant to an effective Registration
Statement or Rule 144, or (iii) if such Registrable Securities are eligible for
sale under Rule 144(k). Following the effective date of the Registration
Statement or at such earlier time as a legend is no longer required for certain
Securities or Warrant Shares, the Company will, no later than three trading days
following the delivery by a Purchaser to the Company or the Company's transfer
agent of a legended certificate representing such securities, deliver or cause
to be delivered to such Purchaser a certificate representing such securities
that is free from all restrictive and other legends.

            (c)   Such Purchaser covenants that such Purchaser will not transfer
the Registrable Securities represented by any such certificate without complying
with any applicable requirements under the Securities Act to deliver the final
prospectus included in the effective Registration Statement to any offeree of
such Registrable Securities.

Section 8. Indemnification.

            (a)   For purposes of this Section 8:

            (i)   the term "Purchaser" shall include the Purchaser and any
      affiliate (as such term is defined pursuant to Rule 12b-2 promulgated
      under the Exchange Act) of such Purchaser;

            (ii)  the term "Prospectus" shall mean the prospectus and any
      amendment or supplement thereto in the form first filed with the
      Commission pursuant to Rule 424(b) promulgated under the Securities Act
      or, if no Rule 424(b) filing is required, filed as part of the
      Registration Statement at the time of effectiveness, as supplemented or
      amended from time to time; and

            (iii) the term "Registration Statement" shall include any final
      prospectus, exhibit, supplement or amendment included in or relating to
      the Registration Statement.

            (b)   The Company agrees to indemnify and hold harmless each of the
Purchasers and each Person, if any, who controls any Purchaser within the
meaning of the Securities Act,

                                      -20-
<PAGE>

against any losses, claims, damages, liabilities or expenses, joint or several,
to which such Purchasers or such controlling Person may become subject, under
the Securities Act, the Exchange Act, or any other federal or state statutory
law or regulation, or at common law or otherwise (including in settlement of any
litigation, if such settlement is effected with the written consent of the
Company), insofar as such losses, claims, damages, liabilities or expenses (or
actions in respect thereof as contemplated below) arise out of or are based upon
any untrue statement or alleged untrue statement of any material fact contained
in the Registration Statement or Prospectus, or arise out of or are based upon
the omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances in which they were made, not misleading, or arise out of or are
based in whole or in part on any inaccuracy in the representations and
warranties of the Company contained in this Agreement, or any failure of the
Company to perform its obligations hereunder, and will reimburse each Purchaser
and each such controlling Person for any legal and other expenses reasonably
incurred as such expenses are reasonably incurred by such Purchaser or such
controlling Person in connection with investigating, defending, settling,
compromising or paying any such loss, claim, damage, liability, expense or
action; provided, however, that the Company will not be liable in any such case
to the extent that any such loss, claim, damage, liability or expense arises out
of or is based upon (i) an untrue statement or alleged untrue statement or
omission or alleged omission made in the Registration Statement or Prospectus in
reliance upon and in conformity with written information furnished to the
Company by or on behalf of the Purchaser expressly for use therein, (ii) the
failure of such Purchaser to comply with the covenants and agreements contained
in Section 6 above respecting sale of the Securities and the Warrant Shares,
(iii) the inaccuracy of any representations made by such Purchaser herein or
(iv) any statement or omission in any Prospectus that is corrected in any
subsequent Prospectus that was delivered to the Purchaser a reasonable time
prior to the pertinent sale or sales by the Purchaser, and provided that the
Purchaser has been notified by the Company that such earlier Prospectus should
no longer be delivered by the Purchaser.

            (c)   Each Purchaser will severally, and not jointly, indemnify and
hold harmless the Company, each of its directors, each of its officers who
signed the Registration Statement and each Person, if any, who controls the
Company within the meaning of the Securities Act, against any losses, claims,
damages, liabilities or expenses to which the Company, each of its directors,
each of its officers who signed the Registration Statement or controlling Person
may become subject, under the Securities Act, the Exchange Act, or any other
federal or state statutory law or regulation, or at common law or otherwise
(including in settlement of any litigation, if such settlement is effected with
the written consent of such Purchaser) insofar as such losses, claims, damages,
liabilities or expenses (or actions in respect thereof as contemplated below)
arise out of or are based upon (i) any failure by such Purchaser to comply with
the covenants and agreements contained in Section 6 above respecting the sale of
the Securities and the Warrant Shares, (ii) the inaccuracy of any representation
made by such Purchaser herein or (iii) any untrue or alleged untrue statement of
any material fact contained in the Registration Statement or the Prospectus, or
the omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances in which they were made, not misleading, in each case to the
extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement
or Prospectus in reliance upon and in conformity with written information

                                      -21-
<PAGE>

furnished to the Company by or on behalf of such Purchaser expressly for use
therein, and will reimburse the Company, each of its directors, each of its
officers who signed the Registration Statement or controlling Person for any
legal and other expense reasonably incurred, as such expenses are reasonably
incurred by the Company, each of its directors, each of its officers who signed
the Registration Statement or controlling Person in connection with
investigating, defending, settling, compromising or paying any such loss, claim,
damage, liability, expense or action; provided, however, that the aggregate
liability of any Purchaser hereunder shall not exceed the greater of the
Purchase Price paid by such Purchaser to the Company on the Closing Date or the
net amount received by Purchaser for such Purchaser's shares pursuant to any
sale thereof. No Purchaser shall be liable for the indemnification obligations
of any other Purchaser.

            (d)   Promptly after receipt by an indemnified party under this
Section 8 of notice of the threat or commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this Section 8, promptly notify the indemnifying party
in writing thereof, but the omission so to notify the indemnifying party will
not relieve it from any liability which it may have to any indemnified party
hereunder or otherwise to the extent it is not prejudiced as a result of such
failure. In case any such action is brought against any indemnified party and
such indemnified party seeks or intends to seek indemnity from an indemnifying
party, the indemnifying party will be entitled to participate in, and, to the
extent that it may wish, jointly with all other indemnifying parties similarly
notified, to assume the defense thereof with counsel reasonably satisfactory to
such indemnified party; provided, however, if the defendants in any such action
include both the indemnified party and the indemnifying party and the
indemnified party shall have reasonably concluded that there may be a conflict
between the positions of the indemnifying party and the indemnified party in
conducting the defense of any such action or that there may be legal defenses
available to it and/or other indemnified parties which are different from or
additional to those available to the indemnifying party, the indemnified party
or parties shall have the right to select separate counsel to assume such legal
defenses and to otherwise participate in the defense of such action on behalf of
such indemnified party or parties. Upon receipt of notice from the indemnifying
party to such indemnified party of its election to assume the defense of such
action and approval by the indemnified party of counsel, the indemnifying party
will not be liable to such indemnified party under this Section 8 for any legal
or other expenses subsequently incurred by such indemnified party in connection
with the defense thereof unless (i) the indemnified party shall have employed
such counsel in connection with the assumption of legal defenses in accordance
with the proviso to the preceding sentence (it being understood, however, that
the indemnifying party shall not be liable for the expenses of more than one
separate counsel, reasonably satisfactory to the indemnifying party,
representing the indemnified parties who are parties to such action) or (ii) the
indemnified party shall not have employed counsel reasonably satisfactory to the
indemnified party to represent the indemnified party within a reasonable time
after notice of commencement of action, in each of which cases the reasonable
fees and expenses of counsel shall be at the expense of the indemnifying party.

Section 9. Notices.

            (a)   All notices, requests, consents and other communications
hereunder shall be in writing, shall be mailed by first-class registered or
certified airmail, confirmed facsimile or

                                      -22-
<PAGE>

nationally recognized overnight express courier postage prepaid, and shall be as
addressed as follows:

            if to the Company, to:

                    Myogen, Inc.
                    7575 West 103rd Avenue
                    Suite 102
                    Westminster, CO 80021
                    Attention: Joseph L. Turner
                    Telecopy No.: (303) 410-6667

            with a copy to:

                    Cooley Godward LLP
                    380 Interlocken Crescent
                    Suite 900
                    Broomfield, CO 80021
                    Attention: Brent D. Fassett, Esq.
                    Telecopy No.: (720) 566-4099

and if to any Purchaser, at its address as set forth in Appendix A hereto, or at
such other address or addresses as may have been previously furnished to the
Company in writing in accordance with this Section 9.

            (b)   Such notices or other communications shall be deemed delivered
upon receipt, in the case of overnight delivery, personal delivery, facsimile
transmission (as evidenced by the confirmation thereof), or mail, or five days
after being placed in the mail, in the case of delivery by mail.

Section 10. Miscellaneous.

      10.1. Amendments. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a
particular instance and either retroactively or prospectively) only with the
written consent of the Company and each Purchaser to be charged with
enforcement. Any amendment or waiver effected in accordance with this Section
10.1 shall be binding upon each holder of any securities purchased under this
Agreement at the time outstanding (including securities into which such
securities are convertible), each future holder of all such securities, and the
Company.

      10.2. Headings. The headings of the various sections of this Agreement are
for convenience of reference only and shall not be deemed to be part of this
Agreement.

                                      -23-
<PAGE>

      10.3. Severability. In the event that any provision in this Agreement is
held to be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein shall
not in any way be affected or impaired thereby.

      10.4. Governing Law and Forum. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to
agreements made and to be fully performed therein. The parties hereto agree to
submit to the exclusive jurisdiction of the federal and state courts of the
State of New York with respect to the interpretation of this Agreement or for
the purposes of any action arising out of or related to this Agreement.

      10.5. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, and all of which
together shall constitute one and the same instrument. In the event that any
signature is delivered via facsimile transmission, such signature shall create a
valid and binding obligation of the party executing (or on whose behalf such
signature is executed) the same with the same force and effect as if such
facsimile signature page were an original hereof.

      10.6. Entire Agreement. This Agreement contains the entire understanding
of the parties with respect to the matters covered herein, supersede all prior
agreements and understandings with respect to such matters and executed by and
among the Company and any of the Purchasers, and, except as specifically set
forth herein or therein, neither the Company nor the Purchasers make any
representation, warranty, covenant or undertaking with respect to such matters.

      10.7. Independent Nature of Purchasers' Obligations and Rights. The
obligations of each Purchaser under this Agreement are several and not joint
with the obligations of any other Purchaser, and no Purchaser shall be
responsible in any way for the performance of the obligations of any other
Purchaser under this Agreement. Nothing contained herein and no action taken by
any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert or as
a group, or are deemed affiliates (as such term is defined under the Exchange
Act) with respect to such obligations or the transactions contemplated by this
Agreement. Each Purchaser shall be entitled to independently protect and enforce
its rights, including without limitation the rights arising out of this
Agreement, and it shall not be necessary for any other Purchaser to be joined as
an additional party in any proceeding for such purpose.

      10.8. Expenses. Each party hereto shall pay all costs and expenses
incurred by it in connection with the execution and delivery of this Agreement,
and all the transactions contemplated thereby, including fees of legal counsel.

                  [Remainder of Page Intentionally Left Blank]

                                      -24-
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed and delivered by their duly authorized representatives as of the day
and year first above written.

                                   MYOGEN, INC.

                                   By: /s/ J. William Freytag
                                       ----------------------------------------
                                       Name: J. William Freytag
                                       Title: President & Chief Executive
                                              Officer

                                   PURCHASER:

                                   Baker Biotech Fund I, L.P.
                                   By: Baker Biotech Capital, L.P., (general
                                       partner)
                                   By: Baker Biotech Capital (GP), LLC, (general
                                       partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

                                   Baker/Tisch Investments, L.P.
                                   By: Baker Biotech Capital, L.P., (general
                                       partner)
                                   By: Baker Biotech Capital (GP), LLC,
                                       (general partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

<PAGE>

                                   Baker Biotech Fund II, L.P.
                                   By: Baker Biotech Capital, L.P., (general
                                       partner)
                                   By: Baker Biotech Capital (GP), LLC,
                                       (general partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

                                   Baker Bros. Investments, L.P.
                                   By: Baker Bros. Capital, L.P., (general
                                       partner)
                                   By: Baker Bros. Capital (GP), LLC, (general
                                       partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

                                   Baker Biotech Fund II, (Z) L.P.
                                   By: Baker Biotech Capital II, L.P., (general
                                       partner)
                                   By: Baker Biotech Capital II (GP), LLC,
                                       (general partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

<PAGE>

                                   Baker Bros. Investments II, L.P.
                                   By: Baker Bros. Capital, L.P., (general
                                       partner)
                                   By: Baker Bros. Capital (GP), LLC, (general
                                       partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

                                   Baker Biotech Fund III, L.P.
                                   By: Baker Biotech Capital III, L.P.,
                                       (general partner)
                                   By: Baker Biotech Capital III (GP), LLC,
                                       (general partner)

                                   By: /s/ Felix Baker, Ph.D.
                                       ----------------------------------------
                                   Name: Felix Baker, Ph.D.
                                   Title: Managing Member

                                   Atlas Equity I, LTD.

                                   By: /s/ Scott H. Schroeder
                                       ----------------------------------------
                                       Name: Scott H. Schroeder
                                       Title: Authorized Signatory

                                   Address: c/o BAM, LP
                                            181 W. Madison, Suite 3600
                                            Chicago, IL 60625

<PAGE>

                                   Domain Public Equity Partners, L.P.
                                   By: Domain Public Equity Associates, LLC, its
                                       general partner

                                   By: /s/ Lisa A. Kraeutler
                                       ----------------------------------------
                                       Name: Lisa A. Kraeutler
                                       Title: Attorney in Fact

                                   Address: One Palmer Square
                                            Suite 515
                                            Princeton, NJ 08542

                                   H&Q Healthcare Investors

                                   By: /s/ Kim Carroll
                                       ----------------------------------------
                                       Name: Kim Carroll
                                       Title: Treasurer

                                   Address: 30 Rowes Warf - Suite 430
                                            Boston, MA 02110
                                   Telephone: 617-772-8500
                                   Facsimile: 617-772-8577
                                   Date: 9/24/04

                                   H&Q Life Science Investors

                                   By: /s/ Kim Carroll
                                       ----------------------------------------
                                       Name: Kim Carroll
                                       Title: Treasurer

                                   Address: 30 Rowes Warf - Suite 430
                                            Boston, MA 02110
                                   Telephone: 617-772-8500
                                   Facsimile: 617-772-8577
                                   Date: 9/24/04

<PAGE>

                                   Jennison Health Sciences Fund of the Jennison
                                   Sector Funds, Inc.

                                   By: Jennison Associates LLC, as sub-advisor
                                       to Jennison Health Sciences Fund

                                   By: /s/ David Chan
                                       ----------------------------------------
                                       Name: David Chan
                                       Title: Executive Vice President

                                   Address: Gateway Center Three
                                            100 Mulberry Street
                                            Newark, NJ 07102-4077

                                   Narragansett I, L.P.

                                   By: /s/ Joseph L. Dowling III
                                       ----------------------------------------
                                       Name: Joseph L. Dowling III
                                       Title: Managing Member

                                   Address: 540 Madison Ave
                                            38th Floor
                                            New York, NY 10022

                                   Narragansett Offshore, Ltd.

                                   By: /s/ Joseph L. Dowling III
                                       ----------------------------------------
                                       Name: Joseph L. Dowling III
                                       Title: Managing Member

                                   Address: 540 Madison Ave
                                            38th Floor
                                            New York, NY 10022

                                   Oz Mac 13 Ltd.

                                   By: Oz Management, L.L.C., as Investment
                                       Manager

                                   By: /s/ Dan S. Och
                                       ----------------------------------------
                                       Name: Dan S. Och
                                       Title: Senior Managing Member

                                   Address: Oz Mac 13 Ltd.
                                            c/o Oz Management, L.L.C.
                                            9 West 57th Street, 39th Floor
                                            New York, NY 10019

<PAGE>

                                   Oz Master Fund, Ltd.

                                   By: Oz Management, L.L.C., as Investment
                                       Manager

                                   By: /s/ Dan S. Och
                                       ----------------------------------------
                                       Name: Dan S. Och
                                       Title: Senior Managing Member

                                   Address: Oz Master Fund, Ltd.
                                            c/o Oz Management, L.L.C.
                                            9 West 57th Street, 39th Floor
                                            New York, NY 10019

                                   Fleet Maritime, Inc.

                                   By: Oz Management, L.L.C., as Investment
                                       Manager

                                   By: /s/ Dan S. Och
                                       ----------------------------------------
                                       Name: Dan S. Och
                                       Title: Senior Managing Member

                                   Address: Fleet Maritime, Inc.
                                            c/o Oz Management, L.L.C.
                                            9 West 57th Street, 39th Floor
                                            New York, NY 10019

<PAGE>

                                   T. ROWE PRICE ASSOCIATES, INC., in
                                        its capacity as Investment Adviser to
                                        its participating clients listed in
                                        Appendix A

                                   By: /s/ Jay Markowitz
                                       ----------------------------------------
                                       Name: Jay Markowitz
                                       Title: Vice President

                                   Address: T. Rowe Price Associates, Inc.
                                            100 East Pratt Street
                                            Baltimore, MD 21202
                                            Attn: Darrell N. Braman
                                                  Associate Legal Counsel
                                   Facsimile number: (410) 345-6575

                                   UBS O'Connor LLC F/B/O O'Connor
                                   PIPES Corporate Strategies Master Ltd.

                                   By: /s/ Jeff Putman
                                       ----------------------------------------
                                       Name: Jeff Putman
                                       Title: Executive Director

                                   Address: UBS O'Connor
                                            1 N. Wacker Dr.
                                            32nd Flr
                                            Chicago, IL 60606

                                   InterWest Partners VI, LP

                                   By: /s/ W. Stephen Holmes
                                       ----------------------------------------
                                       Name: W. Stephen Holmes
                                       Title: Managing Director

                                   Address: 2710 Sand Hill Road
                                            2nd Floor
                                            Menlo Park, CA 94025

<PAGE>

                                   InterWest Investors VI, LP

                                   By: /s/ W. Stephen Holmes
                                       ----------------------------------------
                                       Name: W. Stephen Holmes
                                       Title: Managing Director

                                   Address: 2710 Sand Hill Road
                                            2nd Floor
                                            Menlo Park, CA 94025

                                   InterWest Partners VIII, LP

                                   By: /s/ W. Stephen Holmes
                                       ----------------------------------------
                                       Name: W. Stephen Holmes
                                       Title: Managing Director

                                   Address: 2710 Sand Hill Road
                                            2nd Floor
                                            Menlo Park, CA 94025

                                   InterWest Investors VIII, LP

                                   By: /s/ W. Stephen Holmes
                                       ----------------------------------------
                                       Name: W. Stephen Holmes
                                       Title: Managing Director

                                   Address: 2710 Sand Hill Road
                                            2nd Floor
                                            Menlo Park, CA 94025

                                   InterWest Investors Q VIII, LP

                                   By: /s/ W. Stephen Holmes
                                       ----------------------------------------
                                       Name: W. Stephen Holmes
                                       Title: Managing Director

                                   Address: 2710 Sand Hill Road
                                            2nd Floor
                                            Menlo Park, CA 94025

<PAGE>

                                   New Enterprise Associates 10, Limited
                                   Partnership

                                   By: NEA Partners 10, Limited Partnership Its
                                       General Partner

                                   By: /s/ Eugene A. Trainor, III
                                       ----------------------------------------
                                       Name: Eugene A. Trainor, III
                                       Title: Administrative General Partner &
                                              Chief Operating Officer

                                   Perseus-Soros BioPharmaceutical Fund, LP

                                   By: /s/ John F. Brown
                                       ----------------------------------------
                                       Name: John F. Brown
                                       Title: Attorney-in-Fact

                                   Sequel Limited Partnership III
                                   by its General Partner Sequel Venture
                                   Partners III, LLC

                                   By: /s/ John T. Greff
                                       ----------------------------------------
                                       Name: John T. Greff
                                       Title: Manager

                                   Address: 4430 Arapahoe Ave.
                                            Suite 220
                                            Boulder, CO 80303

                                   Sequel Entrepreneurs' Fund III, L.P.
                                   by its General Partner Sequel Venture
                                   Partners III, LLC

                                   By: /s/ John T. Greff
                                       ----------------------------------------
                                       Name: John T. Greff
                                       Title: Manager

                                   Address: 4430 Arapahoe Ave.
                                            Suite 220
                                            Boulder, CO 80303

<PAGE>

                                   APPENDIX A

                             SCHEDULE OF PURCHASERS

<TABLE>
<CAPTION>
                                                         AGGREGATE    PURCHASE
                                 AGGREGATE   PURCHASE      NUMBER     PRICE PER      AGGREGATE
      PURCHASER NAME               NUMBER    PRICE PER   OF WARRANT    WARRANT       PURCHASE
       AND ADDRESS               OF SHARES     SHARE       SHARES       SHARE         PRICE
------------------------------------------------------------------------------------------------
<S>                              <C>         <C>         <C>          <C>         <C>
T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, MD 21202

on behalf of:

------------------------------------------------------------------------------------------------
      Nominee Name -               100,000   $    6.50       20,000   $   0.125   $   652,500.00
      Lobstercrew & Co.
------------------------------------------------------------------------------------------------
      Nominee Name -                   500   $    6.50          100   $   0.125   $     3,262.50
      HorizonBeach & Co.
------------------------------------------------------------------------------------------------
      Nominee Name - Mac &          31,600   $    6.50        6,320   $   0.125   $   206,190.00
      Co.
------------------------------------------------------------------------------------------------
      Nominee Name - Squidrig       12,300   $    6.50        2,460   $   0.125   $    80,257.50
      & Co.
------------------------------------------------------------------------------------------------
      Nominee Name - Lamppost       14,800   $    6.50        2,960   $   0.125   $    96,570.00
      & Co.
------------------------------------------------------------------------------------------------
      Nominee Name - Hare &         14,500   $    6.50        2,900   $   0.125   $    94,612.50
      Co.
------------------------------------------------------------------------------------------------
      Nominee Name - BOST            1,800   $    6.50          360   $   0.125   $    11,745.00
      & Co.
------------------------------------------------------------------------------------------------
      Nominee Name - BOST &          3,800   $    6.50          760   $   0.125   $    24,795.00
      Co.
------------------------------------------------------------------------------------------------
      Nominee Name - Bridge &      565,000   $    6.50      113,000   $   0.125   $ 3,686,625.00
      Co.
------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<S>                                <C>       <C>            <C>       <C>         <C>
      Nominee Name - Hare &         21,980   $    6.50        4,396   $   0.125   $   143,419.50
      Co.
------------------------------------------------------------------------------------------------
Domain Public Equity               306,515   $    6.50       61,303   $   0.125   $ 2,000,010.38
Partners, L.P.
One Palmer Square
Suite 515
Princeton, NJ 08542
------------------------------------------------------------------------------------------------
H&Q Healthcare Investors           510,880   $    6.50      102,176   $   0.125   $ 3,333,492.00
30 Rowes Wharf
Boston, MA 02110
------------------------------------------------------------------------------------------------
H&Q Life Science Investors         255,400   $    6.50       51,080   $   0.125   $ 1,666,485.00
30 Rowes Wharf
Boston, MA 02110
------------------------------------------------------------------------------------------------
Atlas Equity I, Ltd.               459,770   $    6.50       91,954   $   0.125   $ 2,999,999.25
c/o BAM, L.P.
181 W. Madison
36th Floor
Chicago, IL 60625
------------------------------------------------------------------------------------------------
New Enterprise Associates 10,      858,235   $    6.50      171,647   $   0.125   $ 5,599,983.38
Limited Partnership
2490 Sand Hill Road
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
InterWest Partners VI, LP          148,595   $    6.50       29,719   $   0.125   $   969,582.38
2710 Sand Hill Road
2nd Floor
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
InterWest Investors VI, LP           4,660   $    6.50          932   $   0.125   $    30,406.50
2710 Sand Hill Road
2nd Floor
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<S>                                <C>       <C>            <C>       <C>         <C>
InterWest Partners VIII, LP        591,390   $    6.50      118,278   $   0.125   $ 3,858,819.75
2710 Sand Hill Road
2nd Floor
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
InterWest Investors VIII, LP         4,720   $    6.50          944   $   0.125   $    30,798.00
2710 Sand Hill Road
2nd Floor
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
InterWest Investors Q VIII, LP      16,920   $    6.50        3,384   $   0.125   $   110,403.00
2710 Sand Hill Road
2nd Floor
Menlo Park, CA 94025
------------------------------------------------------------------------------------------------
UBS O'Connor LLC                    76,630   $    6.50       15,326   $   0.125   $   500,010.75
One N. Wacker Drive
32nd Floor
Chicago, IL 60640
------------------------------------------------------------------------------------------------
Narragansett I, LP.                463,959   $    6.50       92,792   $   0.125   $ 3,027,332.50
540 Madison Avenue
38th Floor
New York, NY 10022
------------------------------------------------------------------------------------------------
Narragansett Offshore, Ltd.        941,976   $    6.50      188,395   $   0.125   $ 6,146,393.38
540 Madison Avenue
38th Floor
New York, NY 10022
------------------------------------------------------------------------------------------------
Sequel Limited Partnership III     745,565   $    6.50      149,113   $   0.125   $ 4,864,811.63
4430 Arapahoe Ave.,
Suite 220
Boulder, CO 80303
------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<S>                                <C>       <C>             <C>      <C>         <C>
Sequel Entrepreneurs' Fund          20,720   $    6.50        4,144   $   0.125   $   135,198.00
III, L.P.
4430 Arapahoe Ave.,
Suite 220
Boulder, CO 80303
------------------------------------------------------------------------------------------------
Baker Bros. Investments, L.P.       35,800   $    6.50        7,160   $   0.125   $   233,595.00
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Baker Bros. Investments II,         34,850   $    6.50        6,970   $   0.125   $   227,396.25
L.P.
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Baker/Tisch Investments, L.P.       42,800   $    6.50        8,560   $   0.125   $   279,270.00
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P.         357,400   $    6.50       71,480   $   0.125   $ 2,332,035.00
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Baker Biotech Fund II, L.P.        326,700   $    6.50       65,340   $   0.125   $ 2,131,717.50
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Baker Biotech Fund II, (Z)          45,100   $    6.50        9,020   $   0.125   $   294,277.50
L.P.
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<S>                              <C>         <C>          <C>         <C>         <C>
Baker Biotech Fund III, L.P.       307,350   $    6.50       61,470   $   0.125   $ 2,005,458.75
667 Madison Avenue, 17th Floor
New York, NY 10021
------------------------------------------------------------------------------------------------
Perseus-Soros                      919,540   $    6.50      183,908   $   0.125   $ 5,999,998.50
Biopharamaceutical Fund, LP
888 Seventh Avenue
29th Floor
New York, NY 10106
------------------------------------------------------------------------------------------------
COMPOUND & CO.                     306,515   $    6.50       61,303   $   0.125   $ 2,000,010.38
c/o Jennison Health Sciences
Fund of the Jennison Sector
Funds, Inc.
Gateway Center Three
100 Mulberry St.
Newark, NJ 07102-4077
------------------------------------------------------------------------------------------------
OZ Mac 13 Ltd.                       6,083   $    6.50        1,217   $   0.125   $    39,691.63
c/o OZ Management, L.L.C.
9 West 57th St.
39th Floor
New York, NY 10019
------------------------------------------------------------------------------------------------
OZ Master Fund, Ltd.               630,693   $    6.50      126,138   $   0.125   $ 4,115,271.75
c/o OZ Management, L.L.C.
9 West 57th St.
39th Floor
New York, NY 10019
------------------------------------------------------------------------------------------------
Fleet Maritime, Inc.                10,354   $    6.50        2,071   $   0.125   $    67,559.88
c/o OZ Management, L.L.C.
9 West 57th St.
39th Floor
New York, NY 10019
------------------------------------------------------------------------------------------------
                        Total:   9,195,400          --    1,839,080          --   $59,999,985.00
------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

                                   APPENDIX B

                                 FORM OF WARRANT

NEITHER THIS WARRANT NOR THE COMMON STOCK OF MYOGEN, INC. FOR WHICH THIS WARRANT
IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE AND ACCORDINGLY, MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED, OR OTHERWISE TRANSFERRED IN
THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT THERETO UNDER THE
ACT UNLESS SOLD PURSUANT TO RULE 144 OF THE ACT OR UNLESS SUCH SALE, PLEDGE,
HYPOTHECATION OR TRANSFER IS OTHERWISE EXEMPT FROM REGISTRATION AND ANY
APPLICABLE STATE SECURITIES LAWS. THE ISSUER OF THIS WARRANT MAY REQUEST A
WRITTEN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY, TO THE
EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH SALE OR OTHER
TRANSFER.

                                  MYOGEN, INC.

           WARRANT TO PURCHASE                 SHARES OF COMMON STOCK

                        THIS WARRANT MAY NOT BE EXERCISED
                     AFTER 5:00 P.M., NEW YORK CITY TIME, ON
                               SEPTEMBER 29, 2009

THIS CERTIFIES THAT, for value received,                        or registered
assigns (the "Registered Holder") is entitled to, upon the terms and conditions
hereinafter set forth, subscribe for and purchase at the Exercise Price (defined
below) from Myogen, Inc., a Delaware corporation (the "Company"),
                    fully paid and nonassessable shares (the "Warrant Shares")
of Common Stock, par value $0.001 per share (the "Common Stock"), of the
Company, at the initial exercise price of $7.80 per Warrant Share (the "Exercise
Price") at any time during the period beginning six months and one day after the
date hereof and ending on the Expiration Date (as hereinafter defined)(the
"Exercise Period"), by surrendering this Warrant, with the Form of Election to
Purchase duly executed at the principal office of the Company and by paying in
full the Exercise Price, plus transfer taxes, if any. The term "Warrant" as used
herein shall include this Warrant, and any warrant delivered in substitution or
exchange for this Warrant as provided herein. Payment of the Exercise Price
shall be made (i) in United States currency, by certified check or money order
payable to the order of the Company, or (ii) by "cashless exercise" in
accordance with the provisions below, but only when a registration statement
under the Act for the resale of the shares of Warrant Shares is not then in
effect.

            This Warrant has been issued pursuant to a private placement of
Common Stock and warrants.

<PAGE>

            1.    Purchase Agreement and Registration Rights. This Warrant is
issued under and in accordance with the Securities Purchase Agreement dated as
of September 24, 2004, (the "Purchase Agreement") between the Company and the
Registered Holder and is subject to the terms and provisions contained in the
Purchase Agreement. Section 6 of the Purchase Agreement governs the registration
rights of the Warrant Shares.

            2.    Definitions. Unless otherwise defined herein, the capitalized
terms used herein shall have the meanings assigned to such terms in the Purchase
Agreement.

            3.    Cashless Exercise. Notwithstanding any provisions herein to
the contrary, if, at any time during the Exercise Period, (i) the Current Market
Price (as defined below) of one share of Common Stock is greater than the
Exercise Price (at the date of calculation as set forth below) and (ii) a
registration statement under the Act for the resale of the Warrant Shares is not
then in effect, the Registered Holder may exercise this Warrant by a cashless
exercise and shall receive the number of shares of Common Stock equal to an
amount (as determined below) by surrender of this Warrant at the principal
office of the Company together with the properly endorsed Election to Purchase
in which event the Company shall issue to the Registered Holder a number of
shares of Common Stock computed using the following formula:

            X = Y - (A)(Y)
                    ------
                       B

Where       X = the number of shares of Common Stock to be issued to the
                Registered Holder.

            Y = the number of shares of Common Stock purchasable upon exercise
                of all of the Warrant or, if only a portion of the Warrant is
                being exercised, the portion of the Warrant being exercised.

            A = the Exercise Price.

            B = the Current Market Price of one share of Common Stock.

            "Current Market Price" means on any particular date:

            (a)   if the Common Stock is traded on the Nasdaq SmallCap Market or
the Nasdaq National Market, the average of the closing prices of the Common
Stock of the Company on such market over the five (5) trading days ending
immediately prior to the applicable date of valuation;

            (b)   if the Common Stock is traded on any registered national stock
exchange but is not traded on the Nasdaq SmallCap Market or the Nasdaq National
Market, the average of the closing prices of the Common Stock of the Company on
such exchange over the five (5) trading days ending immediately prior to the
applicable date of valuation

                                      B-2
<PAGE>

            (c)   if the Common Stock is traded over-the-counter, but not on the
Nasdaq SmallCap Market, the Nasdaq National Market or a registered national
stock exchange, the average of the closing bid prices over the 30-day period
ending immediately prior to the applicable date of valuation; and

            (d)   if there is no active public market for the Common Stock, the
value thereof, as determined in good faith by the Board of Directors of the
Company, upon due consideration of the proposed determination thereof of the
Registered Holder.

            4.    [RESERVED]

            5.    Issuance of Warrant Shares. As soon as practicable after the
date of exercise of this Warrant the Company shall issue, or cause the transfer
agent for the Common Stock, if any, to issue a certificate or certificates for
the number of full Warrant Shares to which the Registered Holder is entitled,
registered in accordance with the instructions set forth in the Form of Election
to Purchase; provided, however, that such certificate or certificates shall be
delivered within no later than three (3) business days after the Company's
receipt of the Purchaser's surrender of this Warrant, including, without
limitation, a properly completed Form of Election To Purchase. All Warrant
Shares shall be validly authorized and issued, fully paid and nonassessable, and
free from all taxes, liens and charges created by the Company in respect of the
issue thereof. Each person in whose name any such certificate for Warrant Shares
is issued shall for all purposes be deemed to have become the holder of record
of the Warrant Shares represented thereby on the date of exercise of this
Warrant resulting in the issuance of such Warrant Shares, irrespective of the
date of issuance or delivery of such certificate for such Warrant Shares.

            6.    Partial Exercise. If this Warrant is exercised in part only,
the Company shall, upon surrender of this Warrant, execute and deliver, within
10 days of the date of exercise, a new Warrant evidencing the rights of the
Registered Holder, or such other person as shall be designated in the Form of
Election to Purchase, to purchase the balance of the Warrant Shares purchasable
hereunder. In no event shall this Warrant be exercised for a fractional Warrant
Share, and the Company shall distribute no Warrant exercisable for a fractional
Warrant Share. Fractional Warrant shares shall be treated as provided for
herein.

            7.    Available Authorized Shares. The Company shall at all times
reserve and keep available for issuance upon the exercise of this Warrant a
number of its authorized but unissued shares of Common Stock that will be
sufficient to permit the exercise in full of this Warrant.

            8.    Adjustments. Subject to the provisions hereof, the Exercise
Price in effect from time to time shall be subject to adjustment, as follows:

            (a)   In case the Company shall at any time after the date hereof
(i) declare a dividend on the outstanding Common Stock payable in shares of its
capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the
outstanding Common Stock into a

                                      B-3
<PAGE>

smaller number of shares, or (iv) issue any shares of its capital stock by
reclassification of the Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), then, in each case, the Exercise Price, and the number of Warrant
Shares issuable upon exercise of this Warrant in effect at the time of the
record date for such dividend or of the effective date of such subdivision,
combination, or reclassification, shall be proportionately adjusted so that the
Registered Holder after such time shall be entitled to receive the aggregate
number and kind of shares which, if such Warrants had been exercised immediately
prior to such time, the Registered Holder would have owned upon such exercise
and been entitled to receive by virtue of such dividend, subdivision,
combination or reclassification. Such adjustment shall be made successively
whenever any event listed above shall occur.

            (b)   In case the Company shall issue or fix a record date for the
issuance to all holders of Common Stock of rights, options, or warrants to
subscribe for or purchase Common Stock (or securities convertible into or
exchangeable for Common Stock) at a price per share (or having a conversion or
exchange price per share, if a security convertible into or exchangeable for
Common Stock) less than the Current Market Price per share of Common Stock on
such record date, then, in each case, the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to such record date
by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding on such record date plus the number of shares of Common Stock
which the aggregate offering price of the total number of shares of Common Stock
so to be offered (or the aggregate initial conversion or exchange price of the
convertible or exchangeable securities so to be offered) would purchase at such
Current Market Price and the denominator of which shall be the number of shares
of Common Stock outstanding on such record date plus the number of additional
shares of Common Stock so issued or to be offered for subscription or purchase
(or into which the convertible or exchangeable securities so to be offered are
initially convertible or exchangeable). Such adjustment shall become effective
at the close of business on such record date; provided, however, that, to the
extent the shares of Common Stock (or securities convertible into or
exchangeable for shares of Common Stock) are not delivered, the Exercise Price
shall be readjusted after the expiration of such rights, options, or warrants
(but only with respect to the exercise of this Warrant after such expiration),
to the Exercise Price which would then be in effect had the adjustments made
upon the issuance of such rights, options, or warrants been made upon the basis
of delivery of only the number of shares of Common Stock (or securities
convertible into or exchangeable for shares of Common Stock) actually issued and
the Exercise Price shall also be adjusted for any subsequent adjustment or other
change to the number of shares of Common Stock issuable upon exercise, exchange
or conversion of such rights, options, warrants or other securities.
Notwithstanding anything to the contrary contained herein, no adjustment shall
be made to the Exercise Price until any condition to the vesting of such rights,
options or warrants shall be fulfilled or satisfied (and then only with respect
to the portion thereof which shall have vested). In case any subscription price
may be paid in a consideration part or all of which shall be in a form other
than cash, the value of such consideration shall be as determined in good faith
by the board of directors of the Company, whose determination shall be
conclusive absent manifest error. Shares of

                                      B-4
<PAGE>

Common Stock owned by or held for the account of the Company or any
majority-owned subsidiary shall not be deemed outstanding for the purpose of any
such computation. If any event occurs of the type contemplated by the provisions
of this paragraph but not expressly provided for by such provisions (including,
without limitation, the granting of stock appreciation rights, phantom stock
rights or other rights with equity features), then the Board shall make an
appropriate adjustment in the Exercise Price so as to equitably protect the
rights of holders of this Warrant.

            (c)   In case the Company shall distribute to all holders of Common
Stock (including any such distribution made to the stockholders of the Company
in connection with a consolidation or merger in which the Company is the
continuing corporation) evidences of its indebtedness, cash (other than any cash
dividend which, together with any cash dividends paid within the twelve (12)
months prior to the record date for such distribution, does not exceed 5% of the
Current Market Price at the record date for such distribution) or assets (other
than distributions and dividends payable in shares of Common Stock), or rights,
options, or warrants to subscribe for or purchase Common Stock, or securities
convertible into or exchangeable for shares of Common Stock (excluding those
with respect to the issuance of which an adjustment of the Exercise Price is
provided pursuant to the foregoing paragraph), then, in each case, the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately
prior to the record date for the determination of stockholders entitled to
receive such distribution by a fraction, the numerator of which shall be the
Current Market Price per share of Common Stock on such record date, less the
fair market value (as determined in good faith by the board of directors of the
Company, whose determination shall be conclusive absent manifest error) of the
portion of the evidences of indebtedness or assets so to be distributed, or of
such rights, options, or warrants or convertible or exchangeable securities, or
the amount of such cash, applicable to one share, and the denominator of which
shall be such Current Market Price per share of Common Stock. Such adjustment
shall become effective on the date of such distribution.

            No adjustment in the Exercise Price shall be required if such
adjustment is less than $.05; provided, however, that any adjustments which by
reason of this Warrant are not required to be made shall be carried forward and
taken into account in any subsequent adjustment. All calculations under this
Warrant shall be made to the nearest cent or to the nearest one thousandth of a
share, as the case may be.

            In any case in which this Warrant shall require that an adjustment
in the Exercise Price be made effective as of a record date for a specified
event, the Company may elect to defer, until the occurrence of such event,
issuing to the Registered Holder of, if the Registered Holder has exercised this
Warrant after such record date, the shares of Common Stock, if any, issuable
upon such exercise over and above the shares of Common Stock, if any, issuable
upon such exercise on the basis of the Exercise Price in effect prior to such
adjustment; provided, however, that the Company shall deliver to the exercising
Registered Holder a due bill or other appropriate instrument evidencing the
Registered Holder's right to receive such additional shares upon the occurrence
of the event requiring such adjustment.

                                      B-5
<PAGE>

            Upon each adjustment of the Exercise Price as a result of the
calculations made above this Warrant shall thereafter evidence the right to
purchase, at the adjusted Exercise Price, that number of shares (calculated to
the nearest thousandth) obtained by dividing (A) the product obtained by
multiplying the number of shares purchasable upon exercise of this Warrant prior
to adjustment of the number of shares by the Exercise Price in effect prior to
adjustment of the Exercise Price by (B) the Exercise Price in effect after such
adjustment of the Exercise Price.

            In case of any capital reorganization, other than in the cases
referred to above, or the consolidation or merger of the Company with or into
another corporation (other than a merger or consolidation in which the Company
is the continuing corporation and which does not result in any reclassification
of the outstanding shares of Common Stock or the conversion of such outstanding
shares of Common Stock into shares of other stock or other securities or
property), or the sale of the property of the Company as an entirety or
substantially as an entirety (collectively such actions being hereinafter
referred to as "Reorganizations"), the Company shall provide to the Registered
Holder twenty (20) days' (or such shorter period agreed in writing by the
holders of a majority of the shares of Common Stock issuable upon exercise of
this Warrant and all other then outstanding Warrants to Purchase Shares of
Common Stock issued pursuant to the Purchase Agreement) advance written notice
of such Reorganization, and this Warrant shall terminate upon consummation of
such Reorganization unless properly exercised prior to the occurrence of such
Reorganization.

            In case of any reclassification or change of the shares of Common
Stock issuable upon exercise of this Warrant, including, without limitation, in
any reorganization (other than a change in par value or from no par value to a
specified par value, or as a result of a subdivision or combination, but
including any change in the shares into two or more classes or series of
shares), the Registered Holder of this Warrant shall have the right thereafter
to receive upon exercise of this Warrant solely the kind and amount of shares of
stock and other securities, property, cash, or any combination thereof
receivable upon such reclassification or change by a Registered Holder of the
number of shares of Common Stock for which this Warrant might have been
exercised immediately prior to such reclassification or change and the term
"Warrant Shares" shall thereafter include, without limitation, such stock and
other securities. Thereafter, appropriate provision shall be as nearly
equivalent as practicable to the adjustments in this Warrant. The above
provisions of this paragraph shall similarly apply to successive
reclassifications and changes of shares of Common Stock.

            Whenever the Exercise Price is adjusted as provided in this Warrant,
the Company will promptly obtain a certificate of the chief financial officer of
the Company setting forth the Exercise Price as so adjusted and a brief
statement of the facts accounting for such adjustment. Whenever any adjustment
is made pursuant to this Warrant, the Company shall cause notice of such
adjustment to be mailed to the Registered Holder within fifteen (15) days
thereafter, such notice to include in reasonable detail (i) the events
precipitating the adjustment, (ii) the computation of any adjustments, and (iii)
the Exercise Price, the number of

                                      B-6
<PAGE>

shares or the securities or other property purchasable upon exercise of this
Warrant after giving effect to such adjustment.

            In no event shall the Exercise Price be adjusted below the par value
per share of the Common Stock.

            Irrespective of any adjustments pursuant to this Warrant, any
Warrant theretofore or thereafter issued need not be amended or replaced, but
certificates thereafter issued shall bear an appropriate legend or other notice
of any adjustments.

            The Company shall not be required upon the exercise of any Warrant
to issue fractional shares of Common Stock which may result from adjustments in
accordance with this Warrant to the Exercise Price or number of shares of Common
Stock purchasable under each Warrant. If more than one Warrant is exercised at
one time by the same Registered Holder, the number of full shares of Common
Stock which shall be deliverable shall be computed based on the number of shares
deliverable in exchange for the aggregate number of Warrants exercised. With
respect to any fractional Warrant Share called for upon the exercise this
Warrant, the Company shall pay a cash adjustment in respect of such fractional
Warrant Share in an amount equal to the same fraction of the Current Market
Price of a share of Common Stock calculated in accordance with this Warrant.

            If any change to the capitalization of the Company should occur with
respect to which a favorable adjustment to the rights and interests of the
Registered Holder should be made, and such adjustment is not otherwise provided
for in this Warrant, such appropriate adjustment should be made as determined in
good faith by the Board of Directors of the Company.

            9.    Expiration Date. This Warrant may not be exercised after 5:00
P.M., New York City time, on September 29, 2009 (the "Expiration Date") and
shall be void after the Expiration Date.

            10.   No Rights as Stockholder. This Warrant shall not entitle the
Registered Holder to any of the rights of a stockholder of the Company,
including, without limitation, the right to vote, to receive dividends and other
distributions, to receive any notice of, or to attend, meetings of stockholders
or any other proceedings of the Company.

            11.   Mutilation, Loss, Theft or Destruction of Warrant. If this
Warrant shall be mutilated, lost, stolen or destroyed, the Company in its
discretion may execute and deliver, in exchange and substitution for and upon
cancellation of this Warrant, or in lieu of or in substitution for a lost,
stolen or destroyed Warrant and upon receipt of an affidavit of the Registered
Holder or other evidence reasonably satisfactory to the Company of the loss,
theft or destruction of such Warrant and an indemnification of loss by the
Registered Holder in favor of the Company, a new Warrant for the number of
Warrant Shares represented by the Warrant so mutilated, lost, stolen or
destroyed but only upon receipt of evidence of such loss, theft or destruction
of such Warrant Certificate, and of the ownership thereof, and indemnity, if
re-

                                      B-7
<PAGE>

quested, all reasonably satisfactory to the Company. Applicants for such
substitute Warrant shall also comply with such other reasonable regulations and
pay such other reasonable charges incidental thereto as the Company may
prescribe. Any such new Warrant shall constitute an original contractual
obligation of the Company, whether or not the allegedly lost, stolen, mutilated
or destroyed Warrant shall be at any time enforceable by anyone.

            12.   Representations of Registered Holders.

            The Registered Holder agrees not to make any disposition of all or
any part of the Warrant or Common Stock in any event unless and until:

            (d)   The Company shall have received a letter secured by the
Registered Holder from the Securities and Exchange Commission stating that no
action will be recommended to the Commission with respect to the proposed
disposition;

            (e)   There is then in effect a registration statement under the Act
covering such proposed disposition and such disposition is made in accordance
with said registration statement; or

            (f)   The Registered Holder shall have notified the Company of the
proposed disposition and shall have furnished the Company with a statement
briefly describing the circumstances surrounding the proposed disposition, and
if reasonably requested by the Company, the Registered Holder shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the
Company, for the Registered Holder to the effect that such disposition will not
require registration of such Warrant or Common Stock under the Act or any
applicable state securities laws; provided that such statement will not be
required if the disposition is permitted under Rule 144 of the Securities Act.

            The Registered Holder understands and agrees that all certificates
evidencing the Common Stock to be issued to the Registered Holder may bear a
legend in substantially the following form:

            THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
            OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY
            STATE AND ACCORDINGLY, MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
            HYPOTHECATED, OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A
            REGISTRATION STATEMENT IN EFFECT WITH RESPECT THERETO UNDER THE ACT
            UNLESS SOLD PURSUANT TO RULE 144 OF THE ACT OR UNLESS SUCH SALE,
            PLEDGE, HYPOTHECATION OR TRANSFER IS OTHERWISE EXEMPT FROM
            REGISTRATION AND ANY APPLICABLE STATE SECURITIES LAWS. THE ISSUER OF
            THESE SECURITIES MAY REQUEST A WRITTEN OPINION OF COUNSEL,

                                      B-8
<PAGE>

            REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT
            REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH SALE OR OTHER
            TRANSFER.

            13.   Split Up, Combination, Exchange or Transfer of Warrant. Prior
to the latest time at which this Warrant may be exercised, subject to any
applicable laws, rules or regulations restricting transferability, this Warrant,
subject to the provisions hereof, may be split up, combined with or exchanged
for other Warrants representing a like aggregate number of Warrant Shares or may
be transferred in whole or in part. Any holder desiring to split up, combine,
exchange or transfer this Warrant shall make such request in writing delivered
to the Company at its principal office and shall surrender this Warrant to be
split up, combined or exchanged at said office with the Form of Assignment. Upon
any such surrender for split up, combination, exchange or transfer, the Company
shall execute and deliver to the person entitled thereto a new Warrant or
Warrants, as the case may be, as so requested in the Form of Assignment. The
Company may require the holder to pay a sum sufficient to cover any tax or
governmental charge that may be imposed in connection with any split up,
combination, exchange or transfer of this Warrant prior to the issuance of any
new Warrant.

            If this Warrant is surrendered upon its exercise or for split up,
combination, exchange or transfer, or purchased or otherwise acquired by the
Company, shall be canceled and shall not be reissued by the Company; and, except
as otherwise provided herein in case of the exercise of this Warrant for less
than all of the Warrant Shares or in case of a split up, combination, exchange
or transfer, no Warrant shall be issued hereunder in lieu of such canceled
Warrant. Any Warrant so canceled shall be destroyed by the Company.

            By accepting this Warrant, the Registered Holder consents and agrees
with the Company that:

            (g)   transfer of this Warrant shall be registered on the books of
the Company only if surrendered at the principal office of the Company, duly
endorsed or accompanied by a proper instrument of transfer; and

            (h)   prior to due presentment for registration of transfer, the
Company may deem and treat the person in whose name this Warrant is registered
as the absolute owner thereof and of the rights evidenced thereby
(notwithstanding any notations of ownership or writing on the Warrant made by
anyone other than the Company) for all purposes whatsoever, and the Company
shall not be affected by any notice to the contrary.

            14.   Headings. The headings of the various sections of this Warrant
are for convenience of reference only and shall not be deemed to be part of this
Warrant.

            15.   Governing Law. The laws of the State of New York shall govern
this Warrant.

                                      B-9
<PAGE>

            IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed.

                                             MYOGEN, INC.

                                             By: ______________________________

                                      B-10
<PAGE>

                                     FORM OF

                              ELECTION TO PURCHASE

The undersigned hereby irrevocably elects to (check one box only):

      [ ]   purchase ________ shares of Myogen, Inc. (the "Company") common
            stock ("Common Stock") pursuant to the terms of the attached warrant
            (the "Warrant"), and tenders herewith payment of the exercise price
            in full, together with all applicable transfer taxes, if any;

      [ ]   purchase the number of shares of Common Stock by cashless exercise
            pursuant to the terms of the Warrant as shall be issuable upon
            cashless exercise of the portion of the Warrant relating to ________
            shares, and shall tender payment of all applicable transfer taxes,
            if any;

The undersigned represents and warrants to the Company as of the date hereof the
same statements with respect to the shares being acquired upon exercise of this
warrant as are set forth in Section 4 of the Securities Purchase Agreement dated
September 24, 2004, pursuant to which the above-referenced warrant was sold,
regarding the securities purchased thereby.

The undersigned requests that certificates for such shares be issued and
delivered as follows:

ISSUE
TO:__________________________________________
                      (NAME)

_______________________________________________________________________________
                          (ADDRESS, INCLUDING ZIP CODE)

_______________________________________________________________________________
                (SOCIAL SECURITY OR OTHER TAX IDENTIFYING NUMBER)

DELIVER
TO:__________________________________________
                      (NAME)

_______________________________________________________________________________
                          (ADDRESS, INCLUDING ZIP CODE)

<PAGE>

If the attached Warrant is exercised in part only, the undersigned requests that
a new Warrant evidencing the right to purchase the balance of the shares
purchasable under the Warrant be issued and delivered as set forth below.

ISSUE
TO:__________________________________________
                      (NAME)

_______________________________________________________________________________
                          (ADDRESS, INCLUDING ZIP CODE)

_______________________________________________________________________________
                (SOCIAL SECURITY OR OTHER TAX IDENTIFYING NUMBER)

DELIVER
TO:__________________________________________
                      (NAME)

_______________________________________________________________________________
                          (ADDRESS, INCLUDING ZIP CODE)

Dated:___________________

________________________________               _______________________________
(Insert Social Security or                     (Signature of registered holder)
other identifying number
of holder)

                                               _______________________________
                                               (Signature of registered
                                               holder, if co-owned)

 NOTE: Signature must conform in all respects to name of holder as specified on
                            the face of the Warrant.

<PAGE>

                                     FORM OF
                                   ASSIGNMENT

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the
Assignee named below all of the rights of the undersigned represented by the
within Warrant, with respect to the number of Warrant Shares set forth below:

Name of Assignee                 Address                 No. of Warrant Shares

and does hereby irrevocably constitute and appoint ________________ Attorney to
make such transfer on the books of Myogen, Inc. maintained for that purpose,
with full power of substitution in the premises.

Dated:_____________, 200_.

____________________________________________      _____________________________
(Insert Social Security or other identifying      Signature
number of holder)

                                                  _____________________________

<PAGE>

                                   APPENDIX C

                            FORM OF LOCK-UP AGREEMENT

                                                                          , 2004

CIBC WORLD MARKETS CORP.
LAZARD FRERES & CO. LLC
c/o CIBC World Markets Corp.
2420 Sand Hill Road
Suite 300
Menlo Park, CA 94025

                                 Re:   Myogen, Inc. -
                                       PIPE Offering of Common Stock

Ladies and Gentlemen:

            The undersigned [a/an] [                  ] of Myogen, Inc., a
Delaware corporation (the "Company"), understands that CIBC World Markets Corp.
and Lazard Freres & Co. LLC (the "Placement Agents" or "you") have entered into
a Placement Agency Agreement (the "Placement Agency Agreement") with the Company
whereby you will act as its exclusive agents in the private placement of common
stock, $0.001 par value, of the Company (the "Common Stock") and accompanying
warrants to a limited number of sophisticated investors (the "Transaction").

            In recognition of the benefit that the Transaction will confer upon
the undersigned as [a/an] [                 ] of the Company, and for other good
and valuable consideration receipt of which is hereby acknowledged, the
undersigned hereby agrees that, without the prior written consent of both of the
Placement Agents, the undersigned will not, directly or indirectly, from the
date hereof and through the period ending 90 days after the effective date of
the registration statement (the "Registration Statement") required to be filed
with the Securities and Exchange Commission pursuant to the Securities Purchase
Agreement dated September __, 2004 among the Company and the several purchasers
listed on Appendix A attached thereto (the "Securities Purchase Agreement") ,
(1) offer, pledge, announce the intention to sell, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or dispose
of any shares of Common Stock or any securities of the Company which are
substantially similar to the Common Stock, including but not limited to any
securities convertible into or exercisable or exchangeable for, or that
represent the right to receive, Common Stock (including, but not limited to,
Common Stock which may be deemed to be beneficially owned by the undersigned in
accordance with the rules and regulations of the Securities and Exchange
Commission and securities which may be issued upon exercise of a stock option or
warrant) (collectively, the "Company Securities") or (2) enter into any swap,
option, future, forward or other agreement that transfers, in whole or in part,
any of the economic conse-

<PAGE>

quences of ownership of the Company Securities, regardless of whether any of the
transactions described in clause (1) or (2) above is to be settled by delivery
of Company Securities, in cash or otherwise. In addition, the undersigned agrees
that, without the prior written consent of both of the Placement Agents, it will
not, from the date hereof and through the period ending 90 days after the
effective date of the Registration Statement, (1) make any demand for, or
exercise any right with respect to, the registration of any Company Securities
or (2) make any demand for, or exercise any preemptive right relating to the
purchase of any Company Securities. Notwithstanding the foregoing, in the event
that the Company has provided written notice to either Placement Agent that it
will not be acting as a Placement Agent in connection with this Transaction (a
"Non-Participating Party"), then the consent of such Non-Participating Party
shall not be required hereunder.

            The foregoing paragraph shall not apply to (i) transfers of shares
of Common Stock or options to purchase Common Stock made as a bona fide gift or
gifts, provided that the donee or donees thereof agree to be bound by the
restrictions set forth herein prior to such transfer, (ii) transfers of shares
of Common Stock or options to purchase Common Stock made to any trust for the
direct or indirect benefit of the undersigned or the immediate family of the
undersigned, provided that the trustee of the trust agrees to be bound by the
restrictions set forth herein prior to such transfer, and provided further that
any such transfer shall not involve a disposition for value, (iii) transactions
relating to shares of Common Stock or other securities acquired in open market
transactions after the completion of the Transaction and (iv) distributions to
partners, members or shareholders of the undersigned, provided that the
undersigned is a limited partnership, limited liability company or corporation
and the distributees thereof agree in writing to be bound by the restrictions
set forth herein prior to such distribution.

            In furtherance of the foregoing, the Company and any duly appointed
transfer agent for the registration or transfer of the securities described
herein are hereby authorized to decline to make any transfer of securities if
such transfer would constitute a violation or breach of this Lock-Up Agreement.

            The undersigned hereby represents and warrants that the undersigned
has full power and authority to enter into this Lock-Up Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the
undersigned shall be binding upon the successors, assigns, heirs or personal
representatives of the undersigned.

            The undersigned recognizes that the Transaction will be of benefit
to the undersigned and will benefit the Company by, among other things, raising
capital for its operations. The undersigned understands that the several
purchasers listed on Appendix A attached to the Securities Purchase Agreement
are entering into the Securities Purchase Agreement and proceeding with the
Transaction in reliance upon this Lock-Up Agreement.

            THIS LOCK-UP AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE
CONFLICT OF LAWS PRINCIPLES THEREOF.

                                      C-2
<PAGE>

                                             Very truly yours,

                                             __________________________________
                                             Name:
                                             Title:

                                      C-3QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.10  

[*]=CERTAIN
INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS. 

 
 

COLLABORATION AGREEMENT    
    
    by and between    
    
    THERAVANCE, INC.    
    
    and    
    
    GLAXO GROUP LIMITED    

Dated:
November 14, 2002 

 
TABLE OF CONTENTS  

	ARTICLE 1 DEFINITIONS	 	1
	ARTICLE 2 RIGHTS AND OBLIGATIONS	 	9
	 	2.1	 	License Grants from Theravance to GSK	 	9
	 	 	 	2.1.1	 	Development License	 	9
	 	 	2.1.2	 	Commercialization License	 	9
	 	 	2.1.3	 	Manufacturing License	 	9
	 	2.2	 	Sublicensing and Subcontracting	 	9
	 	2.3	 	Trademarks and Housemarks	 	10
	 	 	2.3.1	 	Trademarks	 	10
	 	 	2.3.2	 	Housemarks	 	10
	 	 	2.3.3	 	Ownership of Inventions	 	10
	ARTICLE 3 GOVERNANCE OF DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS	 	10
	 	3.1	 	Joint Steering Committee	 	10
	 	 	3.1.1	 	Purpose	 	10
	 	 	3.1.2	 	Members; Officers	 	10
	 	 	3.1.3	 	Responsibilities	 	11
	 	 	3.1.4	 	Meetings	 	11
	 	 	3.1.5	 	Decision-Making	 	11
	 	3.2	 	Joint Project Committee	 	12
	 	 	3.2.1	 	Purpose	 	12
	 	 	3.2.2	 	Members; Officers	 	12
	 	 	3.2.3	 	Responsibilities	 	12
	 	 	3.2.4	 	Meetings	 	13
	 	 	3.2.5	 	Decision-Making	 	13
	 	3.3	 	Minutes of Committee Meetings	 	13
	 	 	3.3.1	 	Distribution of Minutes	 	13
	 	 	3.3.2	 	Review of Minutes	 	14
	 	 	3.3.3	 	Discussion of Comments	 	14
	 	3.4	 	Expenses	 	14
	 	3.5	 	General Guidelines and Initial Coordination Efforts	 	14
	ARTICLE 4 DEVELOPMENT OF PRODUCTS	 	14
	 	4.1	 	Pooling of Compounds	 	14
	 	4.2	 	Obligations for Development	 	15
	 	 	4.2.1	 	General; GSK	 	15
	 	 	4.2.2	 	GSK's Funding Responsibility	 	15
	 	 	4.2.3	 	Decisions with Respect to Products	 	15
	 	 	4.2.4	 	Development Timelines	 	16
	 	4.3	 	Replacement Compounds	 	16
	 	4.4	 	Transfer of Data	 	16
	 	4.5	 	LABA Activity Inside and Outside of the Collaboration	 	16
	ARTICLE 5 COMMERCIALIZATION	 	17
	 	5.1	 	Global Marketing Plans	 	17
	 	 	5.1.1	 	General	 	17
	 	 	5.1.2	 	Contents of Each Marketing Plan	 	17
	 	5.2	 	Obligations for Commercialization	 	17
	 	5.3	 	Commercialization	 	18
	 	 	5.3.1	 	GSK Responsibility	 	18
	 	 	 	 	 	 	 

i

 

	 	 	5.3.2	 	Semi-Annual Reports	 	18
	 	 	5.3.3	 	Exports to the United States	 	18
	ARTICLE 6 FINANCIAL PROVISIONS	 	18
	 	6.1	 	Signing Payment; Equity Investment; One-Time Fee	 	18
	 	 	6.1.1	 	Signing Payment	 	18
	 	 	6.1.2	 	Stock Purchase	 	18
	 	 	6.1.3	 	One-Time Fee for [*]	 	18
	 	 	6.1.4	 	One-Time Fee for Each Theravance New Compound	 	19
	 	6.2	 	Milestone Payments	 	19
	 	 	6.2.1	 	General	 	19
	 	 	6.2.2	 	GSK to Theravance	 	20
	 	 	6.2.3	 	Theravance to GSK	 	21
	 	 	6.2.4	 	Notification and Payment	 	21
	 	6.3	 	Payment of Royalties on Net Sales	 	21
	 	 	6.3.1	 	Royalty on Single-Agent Collaboration Products and LABA/ICS Combination Products	 	21
	 	 	6.3.2	 	Royalty Adjustment	 	22
	 	 	6.3.3	 	Royalties on Other Collaboration Products Launched After the LABA/ICS Combination Product	 	22
	 	6.4	 	Royalty Responsibilities; Net Sales Reports	 	22
	 	 	6.4.1	 	Payments to Third Parties	 	22
	 	 	6.4.2	 	Net Sales Report	 	22
	 	6.5	 	GAAP	 	23
	 	6.6	 	Currencies	 	23
	 	6.7	 	Manner of Payments	 	23
	 	6.8	 	Interest on Late Payments	 	23
	 	6.9	 	Tax Withholding	 	23
	 	6.10	 	Financial Records; Audits	 	24
	ARTICLE 7 PROMOTIONAL MATERIALS AND SAMPLES	 	24
	 	7.1	 	Promotional Materials	 	24
	 	 	7.1.1	 	Review of Core Promotional Materials	 	24
	 	 	7.1.2	 	Markings of Promotional Materials	 	25
	 	7.2	 	Samples	 	25
	 	7.3	 	Statements Consistent with Labeling	 	25
	 	7.4	 	Implications of Change in Control in Theravance	 	25
	ARTICLE 8 REGULATORY MATTERS	 	25
	 	8.1	 	Governmental Authorities	 	25
	 	8.2	 	Filings	 	25
	 	8.3	 	Exchange of Drug Safety Information	 	25
	 	8.4	 	Recalls or Other Corrective Action	 	25
	 	8.5	 	Events Affecting Integrity or Reputation	 	26
	ARTICLE 9 ORDERS; SUPPLY AND RETURNS	 	26
	 	9.1	 	Orders and Terms of Sale	 	26
	 	9.2	 	Supply of API Compound and Formulated Collaboration Product for Development	 	26
	 	 	9.2.1	 	Supply of API Compound for Development	 	26
	 	 	9.2.2	 	Supply of Formulated Collaboration Products for Development	 	26
	 	9.3	 	Supply of API Compound for Commercial Requirements	 	27
	 	9.4	 	Supply of Collaboration Products for Commercialization	 	27
	 	9.5	 	Inventories	 	27

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

ii

 

	ARTICLE 10 CONFIDENTIAL INFORMATION	 	27
	 	10.1	 	Confidential Information	 	27
	 	10.2	 	Permitted Disclosure and Use	 	27
	 	10.3	 	Publications	 	28
	 	10.4	 	Public Announcements	 	28
	 	10.5	 	Confidentiality of This Agreement	 	28
	 	10.6	 	Termination of Prior Confidentiality Agreements	 	28
	 	10.7	 	Survival	 	28
	ARTICLE 11 REPRESENTATIONS AND WARRANTIES; COVENANTS	 	29
	 	11.1	 	Mutual Representations and Warranties	 	29
	 	11.2	 	Additional GSK Representations and Warranties	 	30
	 	11.3	 	Additional Theravance Representations and Warranties	 	30
	 	11.4	 	Covenants	 	30
	 	11.5	 	Disclaimer of Warranty	 	31
	ARTICLE 12 INDEMNIFICATION	 	31
	 	12.1	 	Indemnification by GSK	 	31
	 	12.2	 	Indemnification by Theravance	 	31
	 	12.3	 	Procedure for Indemnification	 	31
	 	 	12.3.1	 	Notice	 	31
	 	 	12.3.2	 	Defense of Claim	 	31
	 	12.4	 	Assumption of Defense	 	32
	 	12.5	 	Insurance	 	32
	ARTICLE 13 PATENTS	 	33
	 	13.1	 	Prosecution and Maintenance of Patents	 	33
	 	 	13.1.1	 	Prosecution and Maintenance of Theravance Patents	 	33
	 	 	13.1.2	 	Prosecution and Maintenance of Patents Covering Joint Inventions	 	33
	 	 	13.1.3	 	Prosecution and Maintenance of GSK Patents	 	35
	 	 	13.1.4	 	GSK Step-In Rights	 	35
	 	 	13.1.5	 	Theravance Step-In Rights	 	35
	 	 	13.1.6	 	Execution of Documents by Agents	 	35
	 	 	13.1.7	 	Patent Term Extensions	 	35
	 	13.2	 	Patent Infringement	 	36
	 	 	13.2.1	 	Infringement Claims	 	36
	 	 	13.2.2	 	Infringement of Theravance Patents	 	36
	 	 	13.2.3	 	Infringement of GSK Patents	 	36
	 	13.3	 	Notice of Certification	 	36
	 	 	13.3.1	 	Notice	 	36
	 	 	13.3.2	 	Option	 	36
	 	 	13.3.3	 	Name of Party	 	36
	 	13.4	 	Assistance	 	37
	 	13.5	 	Settlement	 	37
	ARTICLE 14 TERM AND TERMINATION	 	37
	 	14.1	 	Term and Expiration of Term	 	37
	 	14.2	 	Termination for Material Breach	 	37
	 	14.3	 	GSK Right to Terminate Development of a Collaboration Product	 	37
	 	14.4	 	GSK Right to Terminate Commercialization of a Collaboration Product Following First Commercial Sale	 	38
	 	14.5	 	Termination of the Agreement Due to Discontinuation of Development of All Collaboration Products and All Pooled Compounds	 	38
	 	14.6	 	Effects of Termination	 	38
	 	 	14.6.1	 	Effect of Termination for Material Breach	 	38
	 	 	 	 	 	 	 

iii

 

	 	 	14.6.2	 	Effect of Termination by GSK of Certain Terminated Development Collaboration Product(s)	 	39
	 	 	14.6.3	 	Effect of Termination by GSK of a Terminated Commercialized Collaboration Product	 	40
	 	 	14.6.4	 	Effect of Termination of the Agreement Due to Discontinuation of Development Prior to First Commercial Sale of All Collaboration Products and All Pooled Compounds	 	41
	 	14.7	 	License Rights	 	42
	 	14.8	 	Milestone Payments	 	42
	 	14.9	 	Subsequent Royalties	 	42
	 	14.10	 	Accrued Rights; Surviving Obligations	 	42
	ARTICLE 15 LIMITATIONS RELATING TO THERAVANCE EQUITY SECURITIES	 	43
	 	15.1	 	Purchases of Equity Securities	 	43
	 	15.2	 	Exceptions for Purchasing Securities of Theravance	 	43
	 	15.3	 	Voting	 	44
	 	15.4	 	Theravance Voting Securities Transfer Restrictions	 	45
	 	15.5	 	Termination of Purchase Restrictions	 	45
	ARTICLE 16 MISCELLANEOUS	 	45
	 	16.1	 	Relationship of the Parties	 	45
	 	16.2	 	Registration and Filing of This Agreement	 	46
	 	16.3	 	Force Majeure	 	46
	 	16.4	 	Governing Law	 	46
	 	16.5	 	Attorneys' Fees and Related Costs	 	46
	 	16.6	 	Assignment	 	46
	 	16.7	 	Notices	 	47
	 	16.8	 	Severability	 	47
	 	16.9	 	Headings	 	47
	 	16.10	 	Waiver	 	47
	 	16.11	 	Entire Agreement	 	48
	 	16.12	 	No License	 	48
	 	16.13	 	Third Party Beneficiaries	 	48
	 	16.14	 	Counterparts	 	48
	 	16.15	 	Single Closing Condition	 	48
	Schedules	 	 	 	 	 	 
	 	1.19	 	Criteria for Theravance New Compounds and Replacement Compounds	 	 
	 	6.1.2	 	Preferred Stock Purchase Agreement	 	 

iv

  

 
 

COLLABORATION AGREEMENT    
    

        This COLLABORATION AGREEMENT ("Agreement") dated November 14, 2002, is made by and between THERAVANCE, INC., a Delaware corporation, and having its
principal office at 901 Gateway Boulevard, South San Francisco, California 94080 ("Theravance"), and GLAXO GROUP LIMITED, a United Kingdom corporation, and having its principal office at Glaxo
Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom ("GSK"). Theravance and GSK may be referred to as a "Party" or together, the "Parties". 

RECITALS  

        WHEREAS, Theravance is currently developing Long-Acting b2 Adrenoceptor Agonists such as but not
limited to TD-3327 and AMI-15471 for the treatment and/or prophylaxis of asthma and other respiratory diseases; 

        WHEREAS,
GSK is also currently developing Long-Acting b2 Adrenoceptor Agonists such as but not limited to
[*], as well as other anti-inflammatory compounds, for the treatment and/or prophylaxis of respiratory disease; 

        WHEREAS,
GSK and Theravance desire to pool certain of their respective development compounds on an exclusive, worldwide basis to commercialize at least one Long-Acting
b2 Adrenoceptor Agonist that can be used as a single agent and/or in combination with a Long-Acting Inhaled Corticosteroid and potentially
other compounds for treatment and/or prophylaxis of respiratory disease; 

        WHEREAS,
GSK and Theravance are willing to undertake research and development activities and investment and to coordinate such activities and investment as provided by this Agreement
with respect to the Collaboration Products; and 

        WHEREAS,
GSK and Theravance believe that a collaboration pursuant to this Agreement for the development and commercialization of Collaboration Products would be desirable and compatible
with their respective business objectives. 

        NOW,
THEREFORE, in consideration of the foregoing premises and the representations, covenants and agreements contained herein, Theravance and GSK, intending to be legally bound, hereby
agree as follows: 

 
 

ARTICLE 1
  DEFINITIONS    
    

        For purposes of this Agreement, the following initially capitalized terms, whether used in the singular or plural, shall have the following meanings: 

        1.1   "AMI-15471"
means the Long-Acting b2 Adrenoceptor Agonist designated as such by Theravance and
all pharmaceutically acceptable salts and solvates thereof. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

1

 

        1.2    "Adverse
Drug Experience" means any of: an "adverse drug experience," a "life-threatening adverse drug experience," a "serious adverse drug experience," or
an "unexpected adverse drug experience," as those terms are defined at either 21 C.F.R.(S)312.32 or 21 C.F.R.(S)314.80. 

        1.3    "Affiliate"
of a Party means any Person, whether de jure or de facto, which directly or indirectly controls, is controlled by, or is under common control with such
Person for so long as such control exists, where "control" means the decision-making authority as to such Person and, further, where such control shall be presumed to exist where a Person owns more
than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power to vote on or direct
the affairs of the entity. 

        1.4    "API
Compound" means bulk quantities of active pharmaceutical ingredient compound prior to the commencement of secondary manufacturing resulting in a Collaboration
Product. 

        1.5    "Breaching
Party" shall have the meaning set forth in Section 14.2. 

        1.6    "Business
Day" means any day on which banking institutions in both New York City, New York, United States and London, England are open for business. 

        1.7    "Calendar
Month" means for each Calendar Year, each of the one-month periods. 

        1.8    "Calendar
Quarter" means for each Calendar Year, each of the three month periods ending March 31, June 30, September 30 and December 31;
provided, however, that the first calendar quarter for the first Calendar Year shall extend from the Effective Date to the end of the first complete calendar quarter thereafter. 

        1.9    "Calendar
Year" means, for the first calendar year, the period commencing on the Effective Date and ending on December 31 of the calendar year during which the
Effective Date occurs, and each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 

        1.10    "Change
in Control" means, with respect to a Party, any transaction or series of related transactions following which continuing stockholders of such Party hold less
than 50% of the outstanding voting securities of either such Party or the entity surviving such transaction. 

        1.11    "Claim"
means all charges, complaints, actions, suits, proceedings, hearings, investigations, claims and demands. 

        1.12    "Collaboration
Product" means any of the Long-Acting â2 Adrenoceptor Agonists identified in Section 4.1 as Pooled Compounds (including
any Theravance New Compounds and Replacement Compounds, as applicable) which may become Developed and Commercialized subject to and in accordance with the terms of this Agreement, which such
Collaboration Product can be used as a single agent and/or in combination with other therapeutically active components, including but not limited to a Long-Acting Inhaled Corticosteroid,
for the treatment and prophylaxis of respiratory diseases. The term "Collaboration Product" shall also include any formulation of [*] or other components necessary to prepare
and deliver a pharmaceutically effective dose of the Pooled Compound and any other therapeutically active component together with any delivery device. 

        1.13    "Commercial
Conflict" means a situation where Theravance determines that GSK's decision related to Development or Commercialization of a Collaboration Product is likely
to result in a [*], and that such decision is not based on the technical profile of the Collaboration Product but primarily on commercial factors whereby GSK is likely to
achieve [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

2

 

        1.14    "Commercial
Failure" means failure of a Collaboration Product for reasons other than Technical Failure, based on the determination that such product will result in a
[*] that is materially worse than the [*] based on GSK's normal and customary procedures for determining. The [*] of a
Collaboration Product will be based on [*] from such product not taking into account the [*]. 

        1.15    "Commercialization"
means any and all activities directed to marketing, promoting, distributing, offering for sale and selling a Collaboration Product, importing a
Collaboration Product (to the extent applicable) and conducting Phase IV Studies. When used as a verb, "Commercialize" means to engage in Commercialization. 

        1.16    "Competing
Product" means a product that is intended for the treatment and/or prophylaxis of respiratory diseases. 

        1.17    "Confidential
Information" means all secret, confidential or proprietary information, data or Know-How (including GSK Know-How and Theravance
Know-How) whether provided in written, oral, graphic, video, computer or other form, provided by one Party (the "Disclosing Party") to the other Party (the "Receiving Party") pursuant to
this Agreement or generated pursuant to this Agreement, including but not limited to, information relating to the Disclosing Party's existing or proposed research, development efforts, patent
applications, business or products, the terms of this Agreement and any other materials that have not been made available by the Disclosing Party to the general public. Confidential Information shall
not include any information or materials that the Receiving Party can document with competent written proof: 

        1.17.1    were
already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by the Disclosing Party; 

        1.17.2    were
generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

        1.17.3    became
generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, and other than through any
act or omission of a Party in breach of such Party's confidentiality obligations under this Agreement; 

        1.17.4    were
disclosed to a Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such
information to others; or 

        1.17.5    were
independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential Information belonging to the other Party. 

        1.18    "Country"
means any generally recognized sovereign entity. 

        1.19    "Criteria"
means the requirements set forth in Schedule 1.19 that the Replacement Compounds and Theravance New Compounds must meet to become a Pooled Compound.
These requirements may be amended after the Effective Date by written agreement of the Parties (such agreement not to be unreasonably withheld by either Party) to take account of any newly established
data or knowledge that has or have arisen since the Effective Date that affect or is likely to affect same. 

        1.20    "Designated
Foreign Filing" shall have the meaning set forth in Section 13.1.2(b). 

        1.21    "Development"
or "Develop" means preclinical and clinical drug development activities, including, among other things: test method development and stability testing,
toxicology, formulation, process development, manufacturing scale-up, development-stage manufacturing, current Good Manufacturing Practices audits, current Good Clinical Practices audits,
current Good Laboratory Practices audits, analytical method validation, manufacturing process validation, cleaning validation, scale-up and post approval changes, quality assurance/quality
control development, statistical analysis and report writing, preclinical and clinical studies, regulatory filing submission and approval, and regulatory affairs related to the foregoing. When used as
a verb, "Develop" means to engage in Development. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

3

 

        1.22    "Development
Expenses" means the cost of all studies or activities performed by or on behalf of GSK or any of its Affiliates pursuant to this Agreement. 

        1.23    "Development
Milestone" shall have the meaning set forth in Section 6.2.1. 

        1.24    "Development
Plan" means the outline plan for each Collaboration Product designed to achieve the Development for such Collaboration Product, including, without
limitation, the nature, number and schedule of Development activities as well as the estimated resources necessary to implement such activities as such may be amended in accordance with the terms of
this Agreement. 

        1.25    "Diligent
Efforts" means the carrying out of obligations in a sustained manner consistent with the efforts a Party devotes to [*], based on
conditions then prevailing and [*], with the objective of [*]. Diligent Efforts requires that: (i) each Party [*] and
monitor such progress on an on-going basis, (ii) each Party [*] for carrying out such obligations, and (iii) each Party [*] designed to
advance progress with respect to such objectives. 

        1.26    "Disclosing
Party" shall have the meaning set forth in Section 1.17. 

        1.27    "Effective
Date" means the first business day following the date on which the last of the conditions contained in Section 16.15 of this Agreement has been
satisfied. 

        1.28    "Exchange
Act" shall have the meaning set forth in Section 15.1.1. 

        1.29    "FDA"
means the United States Food and Drug Administration and any successor agency thereto. 

        1.30    "Field"
means human pharmaceutical use of Long-Acting b2 Adrenoceptor Agonists for the treatment and/or prophylaxis of
respiratory diseases. 

        1.31    "First
Commercial Sale" means the first shipment of commercial quantities of any Collaboration Product sold to a Third Party by a Party or its sublicensees in any
Country after receipt of Marketing Authorization Approval for such Collaboration Product in such Country. Sales for test marketing, sampling and promotional uses, clinical trial purposes or
compassionate or similar uses shall not be considered to constitute a First Commercial Sale. 

        1.32    "Force
Majeure Event" shall have the meaning set forth in Section 16.3. 

        1.33    "Governmental
Authority" means any court, tribunal, arbitrator, agency, legislative body, commission, official or other instrumentality of (i) any government of
any Country, (ii) a federal, state, province, county, city or other political subdivision thereof or (iii) any supranational body, including without limitation the European Agency for
the Evaluation of Medicinal Products. 

        1.34    "GSK
Compound" means a GSK Initially Pooled Compound, any Replacement Compound offered up to the collaboration by GSK or a GSK non-LABA Compound utilised by
GSK for Development purposes in relation to combination product activity under this Agreement currently owned or subsequently discovered by GSK and/or its predecessors in title or
in-licensed from a Third Party by GSK and/or its predecessors in title. 

        1.35    "GSK
Initially Pooled Compound" shall mean the chemical entities individually identified as [*] and all pharmaceutically acceptable
[*] thereof. 

        1.36    "GSK
Invention" means an Invention that is invented by an employee or agent of GSK solely or jointly with a Third Party. 

        1.37    "GSK
Know-How" means all present and future information directly relating to the Collaboration Products, a GSK Compound or the GSK Inventions, including
without limitation all data, records, and regulatory filings relating to Collaboration Products, that is required for Theravance to perform its obligations or exercise it rights under this Agreement,
and which during the Term are in GSK's or any of its Affiliates' possession or control and are or become owned by, or otherwise may be licensed to (provided there is no restriction on GSK thereof),
GSK. GSK Know-How does not include any GSK Patents. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

4

 

        1.38    "GSK
non-LABA Compound" means any other compound contributed to the collaboration by GSK pursuant to Section 4.2.1 for the purpose of developing a
combination product. 

        1.39    "GSK
Patents" means all present and future patents and patent applications including United States provisional applications and any continuations,
continuations-in-part, divisionals, registrations, confirmations, revalidations, reissues, Patent Cooperation Treaty applications, certificates of addition, utility models,
design patents, petty patents as well as all other intellectual property related to the application or patent including extensions or restorations of terms thereof, pediatric use extensions,
supplementary protection certificates or any other such right covering the Pooled Compounds, Collaboration Products, a GSK Compound or the GSK Inventions which are or become owned by GSK or GSK's
Affiliates, or as to which GSK or GSK's Affiliates otherwise are or become licensed, now or in the future, where GSK has the right to grant the sublicense rights granted to Theravance under this
Agreement, which such patent rights cover the making, having made, use, offer for sale, sale or importation of the Collaboration Products. 

        1.40    "Hatch-Waxman
Certification" shall have the meaning set forth in Section 13.3. 

        1.41    "Hostile
Tender Offer" shall have the meaning set forth in Section 15.2.6. 

        1.42    "Indemnified
Party" shall have the meaning set forth in Section 12.3.1. 

        1.43    "Indemnifying
Party" shall have the meaning set forth in Section 12.3.1. 

        1.44    "Invention"
means any discovery (whether patentable or not) invented during the Term as a result of research, Development or manufacturing activities and specifically
related to a Pooled Compound or Collaboration Product hereunder. 

        1.45    "Investigational
Authorization" means, with respect to a Country, the regulatory authorization required to investigate a Collaboration Product in such Country as
granted by the relevant Governmental Authority. 

        1.46    "Joint
Invention" means an Invention that is invented jointly by employees and/or agents of both Theravance and GSK hereunder and the patent rights in such Invention. 

        1.47    "Joint
Project Committee" shall have the meaning set forth in Section 3.2. 

        1.48    "Joint
Steering Committee" shall have the meaning set forth in Section 3.1. 

        1.49    "LABA/ICS
Combination Product" means a product that contains a Pooled Compound and a Long-Acting Inhaled Corticosteroid for the treatment and/or prophylaxis
of respiratory diseases. A LABA/ICS Combination Product shall also be considered a Collaboration Product. 

        1.50    "Laws"
means all laws, statutes, rules, regulations (including, without limitation, current Good Manufacturing Practice Regulations as specified in 21 C.F.R. (S)(S) 210
and 211; Investigational New Drug Application regulations at 21 C.F.R. (S) 312; NDA regulations at 21 C.F.R. (S) 314, relevant provisions of the Federal Food, Drug and Cosmetic Act, and
other laws and regulations enforced by the FDA), ordinances and other pronouncements having the binding effect of law of any Governmental Authority. 

        1.51    "Litigation
Condition" shall have the meaning set forth in Section 12.3.2. 

        1.52    "Long-Acting
b2 Adrenoceptor Agonist" or "LABA" means a chemical entity that
(i) [*] and (ii) has significantly longer activity than [*]. 

        1.53    "Long-Acting
Inhaled Corticosteroid" or "ICS" means a corticosteroid that has duration of action of [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

5

 

        1.54    "Losses"
means any and all damages (including all incidental, consequential, statutory an treble damages), awards, deficiencies, settlement amounts, defaults,
assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including without limitation court costs, interest and reasonable fees of
attorneys, accountants and other experts) incurred by or awarded to Third Parties and required to be paid to Third Parties with respect to a Claim by reason of any judgment, order, decree, stipulation
or injunction, or any settlement entered into in accordance with the provisions of this Agreement, together with all documented out-of-pocket costs and expenses incurred in
complying with any judgments, orders, decrees, stipulations and injunctions that arise from or relate to a Claim of a Third Party. 

        1.55    "Major
Market Country" means each of the United States, Canada, Japan, France, United Kingdom, Italy, Germany and Spain. 

        1.56    "Marketing
Authorization" means, with respect to a Country, the regulatory authorization required to market and sell a Collaboration Product in such Country as granted
by the relevant Governmental Authority. 

        1.57    "Marketing
Authorization Approval" shall mean approval by a Governmental Authority for sale of a Collaboration Product, including any applicable pricing, final labeling
or reimbursement approvals. 

        1.58    "Marketing
Plan" means for each relevant Collaboration Product the global plan prepared by GSK identifying the core strategic, commercial and promotional claims and
objectives for the specific Collaboration Product as reviewed and approved under Section 5.1.1. 

        1.59    "NDA"
means a new drug application or supplemental new drug application or any amendments thereto submitted to the FDA in the United States. 

        1.60    "NDA
Acceptance" shall mean the written notification by the FDA that the NDA has met all the criteria for filing acceptance pursuant to 21 C.F.R.(S)314.101. 

        1.61    "Net
Sales" means the [*] GSK, its Affiliates or their licensees (or such licensees' Affiliates) to a Third Party, less the following to the
extent borne by the seller and not taken into account in determining [*]: (a) [*]; (b) [*], including
[*]; and (c) [*]. Net Sales shall exclude Samples distributed in the usual course of business. 

        1.62    "Net
Sales Report" shall have the meaning set forth in Section 6.4.2. 

        1.63    "Officers"
shall have the meaning set forth in Section 3.1.5(b). 

        1.64    "Other
Combination Product" means any product developed pursuant to this Agreement for the treatment and/or prophylaxis of respiratory disease that contains a
[*]. 

        1.65    "Patent
Infringement Claim" shall have the meaning set forth in Section 13.2.1. 

        1.66    "Patent
Infringement Notice" shall have the meaning set forth in Section 13.2.2. 

        1.67    "Person"
means any natural person, corporation, general partnership, limited partnership, limited liability company, joint venture, proprietorship or other business
organization. 

        1.68    "Phase
I Studies" means that portion of the Development Plan or Development relating to each Collaboration Product which provides for the first introduction into humans
of such Collaboration Product including small scale clinical studies conducted in normal volunteers to obtain information on such Collaboration Product's safety, tolerability, pharmacological
activity, pharmacokinetics, drug metabolism and mechanism of action, as well as early evidence of effectiveness, as more fully defined in 21 C.F.R. (S) 312.21(a). 

        1.69    "Phase
II Studies" means, subject to Section 6.2.2, that portion of the Development Plan or Development relating to each Collaboration Product which provides for
well controlled clinical trials of such Collaboration Product in patients, including clinical studies conducted in patients with the condition, and designed to evaluate clinical efficacy and safety
for such Collaboration Product for one or more indications, as well as to obtain an indication of the dosage regimen required, as more fully defined in 21 C.F.R. (S) 312.21(b). 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

6

 

        1.70    "Phase
III Studies" means that portion of the Development Plan or Development relating to each Collaboration Product which provides for large scale, pivotal, clinical
studies conducted in a sufficient number of patients and whose primary objective is to obtain a definitive evaluation of the therapeutic efficacy and safety of the Collaboration Product in patients
for the particular indication in question that is needed to evaluate the overall risk-benefit profile of the Collaboration Product and to provide adequate basis for obtaining requisite
regulatory approval(s) and product labeling, as more fully defined in 21 C.F.R. (S) 312.21(c). 

        1.71    "Phase
IV Studies" means a study for a Collaboration Product that is initiated after receipt of a Marketing Authorization for a Collaboration Product and is principally
intended to support the marketing and Commercialization of such Collaboration Product, including without limitation investigator initiated trials, clinical experience trials and studies conducted to
fulfill local commitments made as a condition of any Marketing Authorization. 

        1.72    "Pooled
Compounds" means (i) the four Long-Acting Beta-2 Adrenoceptor Agonists provided by GSK as of the Effective Date (identified as
[*]), (ii) the two Long-Acting Beta-2 Adrenoceptor Agonists provided by Theravance as of the Effective Date (identified as TD-3327
and AMI-15471), (iii) the Theravance New Compounds provided by Theravance pursuant to Section 4.1, and any Replacement Compounds provided by Theravance or GSK. 

        1.73    "Product
Supplier" means any manufacturer, packager or processor of a Collaboration Product for development, marketing and sale. 

        1.74    "Promotional
Materials" means the core written, printed, video or graphic advertising, promotional, educational and communication materials (other than Collaboration
Product labeling) for marketing, advertising and promotion of the Collaboration Products. 

        1.75    "Receiving
Party" shall have the meaning set forth in Section 1.17. 

        1.76    "Replacement
Compound" means a Long-Acting b2 Adrenoceptor Agonist that meets the Criteria and is provided
by Theravance or GSK, as applicable, (and "GSK Replacement Compound" and "Theravance Replacement Compound" shall be interpreted accordingly) after the Effective Date to replace a Pooled Compound for
which Development has been discontinued due to Technical Failure. 

        1.77    "ROW"
means Countries other than the Major Market Countries. 

        1.78    "Samples"
means Collaboration Product packaged and distributed as a complimentary trial for use by patients in the Territory. 

        1.79    "SEC"
shall have the meaning set forth in Section 15.1.2. 

        1.80    "Selectively"
means the chemical entity binds human b2 adrenoreceptors (a) [*] as
determined by receptor binding, radioligand displacement or functional in vitro assays, and (b) [*]. 

        1.81    "TD-3327"
means the Long-Acting â2 Adrenoceptor Agonist so designated by Theravance and all pharmaceutically acceptable salts and
solvates thereof contributed to the collaboration by Theravance. 

        1.82    "Taxes"
shall have the meaning set forth in Section 6.9.1. 

        1.83    "Technical
Failure" means the discontinuation of Development of a Collaboration Product for [*] reasons, such as but not limited to, or the
inability to [*], or demonstraton of [*], currently marketed products, or inability to manufacture [*], or inability to produce
[*] with acceptable [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

7

  

        1.84    "Term" means, on a Country-by-Country and Collaboration Product-by-Collaboration Product basis, the period from the
Effective Date until the later of (a) the expiration or termination of the last Valid Claim of a Patent Right covering the Pooled Compound in such Collaboration Product in such Country, and
(b) fifteen (15) years from First Commercial Sale in such Country, unless this Agreement is terminated earlier in accordance with Article 14. 

        1.85    "Terminated
Collaboration Product" shall mean a Terminated Development Collaboration Product or a Terminated Commercialized Collaboration Product. 

        1.86    "Terminated
Commercialized Collaboration Product" shall have the meaning set forth in Section 14.4. 

        1.87    "Terminated
Development Collaboration Product" shall have the meaning set forth in Section 14.3. 

        1.88    "Territory"
means worldwide. 

        1.89    "Theravance
Compound" means TD-3327 and AMI-15471, (together the "Theravance Initially Pooled Compounds"), the two Theravance New Compounds and
any Replacement Compound that is offered up to the collaboration by Theravance. 

        1.90    "Theravance
New Compound" means each of the two chemical entities meeting the Criteria and provided by Theravance to the collaboration as Pooled Compounds after the
Effective Date pursuant to Section 4.1. 

        1.91    "Housemark"
means the name and logo of GSK or Theravance or any of their respective Affiliates as identified by one Party to the other from time to time. 

        1.92    "Theravance
Invention" means an Invention that is invented by an employee or agent of Theravance solely or jointly with a Third Party. 

        1.93    "Theravance
Know-How" means all present and future information directly relating to the Collaboration Products, a Theravance Compound or the Theravance
Inventions that is required for GSK to perform its obligations or exercise its rights under this Agreement, and which during the Term are in Theravance's or any of its Affiliates' possession or
control and are or become owned by, or otherwise may be licensed (provided there are no restrictions on Theravance thereof) by, Theravance. Theravance Know-How does not include any
Theravance Patents. 

        1.94    "Theravance
Patents" means all present and future patents and patent applications including United States provisional applications and any continuations,
continuations-in-part, divisionals, registrations, confirmations, revalidations, reissues, Patent Cooperation Treaty applications, certificates of addition, utility models,
design patents, petty patents as well as all other intellectual property related to the application or patent including extensions or restorations of terms thereof, pediatric use extensions,
supplementary protection certificates or any other such right covering the Pooled Compounds, the Collaboration Products, a Theravance Compound or the Theravance Inventions which are or become owned by
Theravance or Theravance's Affiliates, or as to which Theravance or Theravance's Affiliates are or become licensed, now or in the future, with the right to grant the sublicense rights granted to GSK
under this Agreement, which patent rights cover the making, having made, use, offer for sale, sale or importation of Collaboration Products. 

        1.95    "Third
Party" means a Person who is not a Party or an Affiliate of a Party. 

        1.96    "Third
Party Claim" shall have the meaning set forth in Section 12.3.1. 

        1.97    "United
States" means the United States, its territories and possessions. 

8

 

        1.98    "Valid
Claim" means any claim(s) pending in a patent application or in an unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision
of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not has been admitted to be invalid or unenforceable
through reissue or disclaimer. If in any country there should be two or more such decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal
shall thereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when the decisions are equal in number, and the majority of
decisions shall prevail when the conflicting decisions are unequal in number. 

        1.99    "Withholding
Party" shall have the meaning set forth in Section 6.9.1. 

 
 

ARTICLE 2
  RIGHTS AND OBLIGATIONS    
    

        2.l    License Grants from Theravance to GSK.    

        2.1.1    Development License.    Subject to the terms of this Agreement, including without limitation
Section 2.2, Theravance grants to GSK, and GSK accepts, an exclusive (except as to Theravance and its Affiliates) license in the Field under the Theravance Patents, Theravance
Know-How and Theravance's rights in the Joint Inventions to make, have made, use and Develop Collaboration Products for Commercialization in the Territory. 

        2.1.2    Commercialization License.    Subject to the terms of this Agreement, including without limitation
Section 2.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license in the Field under the Theravance Patents, Theravance Know-How and Theravance's rights in the
Joint Inventions to make, have made use, sell, offer for sale and import Collaboration Products in the Territory. 

        2.1.3    Manufacturing License.    Subject to the terms of this Agreement, including without limitation
Section 2.2, Theravance grants to GSK an exclusive license in the Field under the Theravance Patents, Theravance Know-How and Theravance's rights in the Joint Inventions to make and
have made API Compound or formulated Collaboration Product in the Territory. 

        2.2    Sublicensing and Subcontracting.    GSK may sublicense or subcontract its rights to Develop, Manufacture or
Commercialize the Collaboration Products in whole or in part to one or more of its Affiliates, provided that the rights sublicensed or subcontracted to such Affiliate shall automatically terminate
upon a change of control of such Affiliate in connection with which such Affiliate ceases to be an Affiliate of GSK. GSK may also sublicense or subcontract any of GSK's rights to Develop or
Manufacture the Collaboration Products, in whole or in part, to one or more Third Parties. In the event GSK wishes to sublicense or subcontract any of GSK's rights to Commercialize the Collaboration
Products, in whole or in part, to one or more Third Parties, GSK shall obtain the prior written consent of Theravance, such consent not to be unreasonably withheld, provided always that no such
restriction shall apply in respect of those countries of the Territory wherein GSK is or has been required under applicable local laws to appoint a Third Party as its distributor or marketing partner.
GSK shall secure all appropriate covenants, obligations and rights from any such sublicensee or subcontractor granted by it under this Agreement, including, but not limited to, intellectual property
rights and confidentiality
obligations in any such agreement or other relationship, to ensure that such sublicensee can comply with all of GSK's covenants and obligations to Theravance under this Agreement. GSK's rights to
sublicense, subcontract or otherwise transfer its rights granted under Section 2.1 are limited to those expressly set forth in this Section 2.2. 

9

 

        2.3    Trademarks and Housemarks.    

        2.3.1    Trademarks.    The Collaboration Products shall be Commercialized under trademarks (the "Trademarks") and
trade dress selected by the Joint Project Committee and approved by the Joint Steering Committee. Prior to any such proposed Trademark(s) being submitted to the Joint Project Committee, GSK shall be
responsible for undertaking their preliminary selection. GSK shall exclusively own all Trademarks, and shall be responsible for the procurement, filing and maintenance of trademark registrations for
such Trademarks and all costs and expenses related thereto. GSK shall also exclusively own all trade dress and copyrights associated with the Collaboration Products. Nothing herein shall create any
ownership rights of Theravance in and to the Trademarks or the copyrights and trade dress associated with the Collaboration Products. 

        2.3.2    Housemarks.    Each Party acknowledges the goodwill and reputation that has been associated with the other
Party's Housemarks over the years, and shall use such Housemarks in a manner that maintains and promotes such goodwill and reputation and is consistent with trademark guidelines. Each Party shall take
all reasonable precautions and actions to protect the goodwill and reputation that has inured to the other Party's Housemarks, shall refrain from doing any act that is reasonably likely to impair the
reputation of such Housemarks, and shall cooperate fully to protect such Housemarks. 

        2.3.3    Ownership of Inventions.    Each Party shall promptly disclose to the other Party all Inventions made by it
during the Term; provided that GSK will be allowed a reasonable time to file patent applications covering GSK Inventions prior to disclosing the GSK Invention to Theravance, and Theravance will be
allowed a reasonable time to file patent applications covering Theravance Inventions prior to disclosing the Theravance Invention to GSK. Theravance shall own all Theravance Inventions and GSK shall
own all GSK Inventions. All Joint Inventions shall be owned jointly by Theravance and GSK, and each Party hereby consents to the assignment or license or other disposition by the other Party of its
joint interests in Joint Inventions without the need to seek the consent of the other Party to such assignment or license or other disposition; provided that any such assignment, license or other
disposition shall at all times be subject to the grant of rights and accompanying conditions under Sections 2.1 and 2.2 and Article 14. The determination of inventorship for Inventions shall be
made in accordance with applicable laws relating to inventorship set forth in the patent laws of the United States (Title 35, United States Code). 

 
 

ARTICLE 3
  GOVERNANCE OF DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS    
    

        3.1    Joint Steering Committee.    

        3.1.1    Purpose.    The purposes of the Joint Steering Committee shall be (i) to determine the overall
strategy for this collaboration between the Parties and (ii) to coordinate the Parties' activities hereunder. The Parties intend that their respective organizations will work together and will
use Diligent Efforts to assure success of the collaboration. 

        3.1.2    Members; Officers.    Within thirty (30) days after the Effective Date, the Parties shall establish a
joint steering committee (the "Joint Steering Committee"), which shall consist of four (4) members, two (2) of whom shall be designated by each of GSK and Theravance and shall have
appropriate expertise, with at least one (1) member from each Party being at least at a vice president level or higher. Each of GSK and Theravance may replace any or all of its representatives
on the Joint Steering Committee at any time upon written notice to the other Party. A Party may designate a substitute to temporarily attend and perform the functions of such Party's designee at any
meeting of the Joint Steering Committee. GSK and Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party to 

10

 

attend
meetings of the Joint Steering Committee. The Joint Steering Committee shall be chaired on an annual rotating basis by a representative of either Theravance or GSK, as applicable, on the Joint
Steering Committee, with Theravance providing the first such chairperson. The chairperson shall appoint a secretary of the Joint Steering Committee, who shall be a representative of the other Party
and who shall serve for the same annual term as such chairperson. 

        3.1.3    Responsibilities.    The Joint Steering Committee shall perform the following functions: 

        (a)   Manage
and oversee the Development and Commercialization of the Collaboration Products pursuant to the terms of this Agreement; 

        (b)   Review
and approve the Development Plans and the Marketing Plans for Collaboration Products and any material amendments to the Development Plans and Marketing Plans; 

        (c)   At
each meeting of the Joint Steering Committee, review Net Sales for the year-to-date as available; 

        (d)   Review
and approve the progress of the Joint Project Committee; 

        (e)   Review
and approve the Trademarks selected under Section 2.3; 

        (f)    Review
and approve "go/no-go" decisions and other matters referred to the Joint Steering Committee, including, without limitation, the continued Development
of a particular Collaboration Product or the inclusion of Replacement Compounds; 

        (g)   Life
cycle management of, and intellectual property protection for, the Collaboration Products; 

        (h)   In
accordance with the procedures established in Section 3.1.5, resolve disputes, disagreements and deadlocks unresolved by the Joint Project Committee; and 

        (i)    Have
such other responsibilities as may be assigned to the Joint Steering Committee pursuant to this Agreement or as may be mutually agreed upon by the Parties from time
to time. 

        3.1.4    Meetings.    The Joint Steering Committee shall meet in person at least once during every Calendar Year, and
more frequently (i) as mutually agreed by the Parties or (ii) as required to resolve disputes, disagreements or deadlocks in the Joint Project Committee, on such dates, and at such
places and times, as such Parties shall agree; provided that the Parties shall endeavor to have the first meeting of the Joint Steering Committee within thirty (30) days after the establishment
of the Joint Steering Committee. The Joint Steering Committee shall arrange to meet in person or convene otherwise to assess and approve any Development Plans or Marketing Plans, if any, submitted to
the Joint Steering Committee in each Calendar Year so that such plans will be reviewed and approved within thirty (30) days following submission to the Joint Steering Committee. To the extent
any such Development Plans or Marketing Plans are not approved and need to be reformulated by the Joint Project Committee, such plans shall be reviewed by the Joint Steering Committee as soon as
reasonably practicable after resubmission of same. Meetings of the Joint Steering Committee that are held in person shall alternate between offices of GSK and Theravance, or such other place as the
Parties may agree. In addition to the annual face to face meetings the Joint Steering Committee may also be held by means of telecommunications or, video conferences as deemed appropriate by the
Parties. 

        3.1.5    Decision-Making.    

        (a)   The
Joint Steering Committee may make decisions with respect to any subject matter that is subject to the Joint Steering Committee's decision-making authority and
functions as 

11

 

set
forth in Section 3.1.3. Except as specified in Section 3.1.5(b), all decisions of the Joint Steering Committee shall be made by consensus, with the representatives from each Party
presenting a unified position on behalf of such Party. The Joint Steering Committee shall use Diligent Efforts to resolve the matters within its roles and functions or otherwise referred to it. 

        (b)   With
respect to any issue, if the Joint Steering Committee cannot reach consensus within ten (10) Business Days after the matter has been brought to the Joint
Steering Committee's attention, then such issue shall be referred to the Chief Executive Officer of Theravance and the Chairman of R&D of GSK (collectively, the "Officers") for resolution. The Parties
accept that the use of the Officers for resolution of any unresolved issues will be on an exceptional basis. In the event that the use of the Officers occurs on more than two occasions in any
consecutive twelve (12) month period and such disputes are not related to [*], then GSK will from then on retain the final vote within the Joint Steering Committee for
all issues [*]. If the Officers are unable to reach consensus within thirty (30) days after the matter has been referred to them, the final decision on such disputed
issue will reside with GSK; provided, however, that if the disputed issue involves [*], then the final decision will be made by a mutually acceptable Third Party mediator.
Either Party can initiate such mediation on [*] to the other Party. The Parties will use best efforts to agree on a mediator within such [*]. Such
mediation will occur as promptly as practicable following selection of the mediator and will be held in [*]. The decision of the mediator will be final and binding on the
Parties; provided that either party shall retain all rights to bring an action against the other for damages and other monetary relief related to or arising out of the issue decided by the mediator. 

        3.2    Joint Project Committee.    

        3.2.1    Purpose.    The purposes of the Joint Project Committee shall be to manage the Parties'
day-to-day activities hereunder. 

        3.2.2    Members; Officers.    Within thirty (30) days after the Effective Date, the Parties shall establish a
Project Committee (the "Joint Project Committee"), and GSK and Theravance shall designate an equal number of representatives, up to a maximum total of eight (8) members on such Joint Project
Committee, with a maximum of four (4) from each Party. Each of GSK and Theravance may replace any or all of its representatives on the Joint Project Committee at any time upon written notice to
the other Party. Such representatives shall include individuals who have the relevant experience and
expertise for the next twelve months as included in the Development Plan for the Collaboration Products. A Party may designate a substitute to temporarily attend and perform the functions of such
Party's designee at any meeting of the Joint Project Committee. GSK and Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party
to attend meetings of the Joint Project Committee. The Joint Project Committee shall be chaired by a representative of GSK. The chairperson shall appoint a secretary of the Joint Project Committee,
who shall be a representative of Theravance. 

        3.2.3    Responsibilities.    The Joint Project Committee shall perform the following functions: 

        (a)   Review
the Development Plans as prepared by GSK; 

        (b)   On
an annual rolling basis beginning within six months of the Effective Date, update and amend any initial Development Plan and review the Development Plan for each
Collaboration Product for the following Calendar Year so that it can immediately thereafter submit such proposed Development Plan to the Joint Steering Committee for review and approval; 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

12

 

        (c)   At
each meeting of the Joint Project Committee, review the Development strategy for the Collaboration Products in the Territory; 

        (d)   At
each meeting of the Joint Project Committee, review and recommend to the Joint Steering Committee any material amendments or modifications to the Development Plans; 

        (e)   Coordinate
and monitor regulatory strategy and activities for the Collaboration Products in accordance with Article 8; 

        (f)    Review
and recommend to the Joint Steering Committee "go/no-go" decisions for the Development of Collaboration Products; 

        (g)   Review
the Marketing Plans where appropriate; 

        (h)   Review
and recommend to the Joint Steering Committee any material amendments or modifications to the Marketing Plans; 

        (j)    Discuss
the state of the markets for Collaboration Products and opportunities and issues concerning the Commercialization of the Collaboration Products, including
consideration of marketing and promotional strategy, marketing research plans, labeling, Collaboration Product positioning and Collaboration Product profile issues; 

        (k)   At
each meeting of the Joint Project Committee, review the status of all Studies conducted on Collaboration Products and any results therefrom; 

        (l)    At
each meeting of the Joint Project Committee, review Net Sales for the year-to-date, as available; and 

        (m)  Have
such other responsibilities as may be assigned to the Joint Project Committee pursuant to this Agreement or as may be mutually agreed upon by the Parties through
the Joint Steering Committee from time to time. 

        3.2.4    Meetings.    The Joint Project Committee shall meet at least once during every Calendar Quarter, and more
frequently as GSK and Theravance mutually agree on such dates, and at such places and times, as such Parties shall agree; provided that the Parties shall endeavor to have the first meeting of the
Joint Project Committee as a face to face meeting within thirty (30) days after the establishment of the Joint Project Committee. Meetings of the Joint Project Committee that are held in person
shall alternate between the offices of GSK and Theravance, or such other place as the Parties may agree and such face to face meetings shall occur no less than twice a year. The remaining meetings may
be held by means of telecommunications or video conferences as deemed appropriate. Following Commercialization of a Collaboration Product in the first Major Market, the Joint Project Committee shall
meet twice a year with only one annual face to face meeting required. 

        3.2.5    Decision-Making.    The Joint Project Committee may make decisions with respect to any subject matter that is
subject to the Joint Project Committee's decision-making authority and functions as set forth in Section 3.2.3. All decisions of the Joint Project Committee shall be made by consensus, with the
representatives from each Party presenting a unified position on behalf of such Party. If the Joint Project Committee cannot reach consensus within ten (10) Business Days after it has first met
and attempted to reach such consensus, the matter shall be referred on the eleventh (11th) Business Day to the Joint Steering Committee for resolution. 

        3.3    Minutes of Committee Meetings.    Definitive minutes of all committee meetings shall be finalized no later than
thirty (30) days after the meeting to which the minutes pertain as follows: 

        3.3.1    Distribution of Minutes.    Within ten (10) days after a committee meeting, the secretary of such
committee shall prepare and distribute to all members of such committee draft minutes of 

13

 

the
meeting. Such minutes shall provide a list of any issues yet to be resolved, either within such committee or through the relevant resolution process. 

        3.3.2    Review of Minutes.    The Party members of each committee shall have ten (10) days after receiving
such draft minutes to collect comments thereon and provide them to the secretary of such committee. 

        3.3.3    Discussion of Comments.    Upon the expiration of such second ten (10) day period, the Parties shall
have an additional ten (10) days to discuss each other's comments and finalize the minutes. The secretary and chairperson(s) of such committee shall each sign and date the final minutes. The
signature of such chairperson(s) and secretary upon the final minutes shall indicate each Party's assent to the minutes. 

        3.4    Expenses.    Each Party shall be responsible for all travel and related costs and expenses for its members and
other representatives to attend meetings of, and otherwise participate on, a committee. 

        3.5    General Guidelines and Initial Coordination Efforts.    In all matters related to the collaboration established
by this Agreement, the Parties shall strive to balance as best they can the legitimate interests and concerns of the Parties and to realize the economic potential of Collaboration Products. In all
matters relating to this Agreement, the Parties shall seek to comply with good pharmaceutical and environmental practices. The Parties intend, following the Effective Date, to organize meetings of
internal staff to communicate and explain the provisions of this Agreement to ensure the efficient and timely Development and Commercialization of the Collaboration Products. 

 
 

ARTICLE 4
  DEVELOPMENT OF PRODUCTS    
    

        4.1.    Pooling of Compounds.    Subject to and consistent with the further Development principles outlined herein,
each Party will offer a minimum of four (4) identified LABA compounds to this collaboration, with the intention of commercializing [*] Long-Acting Beta2
Adrenoceptor Agonist as a single agent and/or as a LABA/ICS Combination Product. Upon commencement of the collaboration pursuant to this Agreement, GSK and Theravance will contribute the following
LABA compounds as Pooled Compounds to the collaboration: 

GSK
Compounds [*] and Theravance Compounds [*]. 

For
the avoidance of doubt, it is agreed and hereby acknowledged by both Parties that the compounds [*] are hereby accepted as Pooled Compounds. 

Theravance
will provide two (2) Theravance New Compounds to the collaboration within [*] of the Effective Date in order to meet the requirement that Theravance
contribute a total of four (4) LABA compounds to the Pooled Compounds. Without prejudice to the foregoing, GSK will endeavor to provide Theravance, upon Theravance's request and at
[*], such assistance as may be reasonably required by Theravance to achieve this objective, including providing directly or through GSK's vendors, assistance in
(i) [*], (ii) [*], (iii) [*], (iv) [*], and
(v) [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

14

 

        4.2    Obligations for Development.    

        4.2.1    General; GSK.    Under the direction of the Joint Project Committee, specific Pooled Compounds will be
identified from time to time and, as applicable, selected for Development as a Collaboration Product. The Joint Project Committee will determine the number and extent of Development of the Pooled
Compounds and the criteria to be used for selecting among the eight Pooled Compounds and, subject to the other terms of this Agreement, will endeavor to move [*]
forward in Development. In relation to the foregoing, GSK shall have the overall responsibility for, and use Diligent Efforts in, the performance of all such Development activities which shall
include, where applicable, relevant regulatory filings (as contemplated under Article 8) for any such Collaboration Product moved forward in Development. Further, GSK shall use Diligent Efforts
to advance such Collaboration Product through Development in accordance with the Go/No-Go checkpoints identified in the then current Development Plan for such Collaboration Product. GSK shall also use
Diligent Efforts to contribute [*] to the collaboration for the purpose of developing a combination product and Diligent Efforts to develop an [*] which
may be [*] of the Collaboration Compound and Development activities of such may continue in parallel. 

        4.2.2    GSK Funding Responsibility.    GSK shall bear all costs and expenses associated with the Development of
Collaboration Products for Commercialization including those incurred by Theravance (or to which it has become obligated) after the signature date of this Agreement and which previously have been
discussed with and agreed to by GSK and, so far as the aforementioned Theravance costs are concerned, for the avoidance of doubt, the maximum amount shall not exceed [*]. 

        4.2.3    Decisions with Respect to Products.    

        (a)   GSK
shall have the sole discretion with respect to Development decisions for Collaboration Products subject to and in accordance with Sections 3.1.5, 3.2.5, and 4.3. 

        (b)   Notwithstanding
the foregoing, the Parties acknowledge that Theravance is about to initiate a Phase I Study in two parts, on TD-3327. The initiation of this
study will be approved via the Joint Project Committee in accordance with all other Development activities. Theravance shall be responsible for the routine monitoring of this study and will transfer
remaining clinical development responsibility for TD-3327 to the Joint Project Committee on [*]. 

        (c)   GSK
shall provide the Joint Project Committee with an update report within thirty days of (i) the initiation (i.e., first person dosed) of any Study involving a
Collaboration Product, and (ii) the last person dosed/last visit in any Study relating to a Collaboration Product. GSK will provide the Joint Project Committee with a reasonably detailed "top
line results" report within sixty days following the last person dosed/last visit in any Study involving a Collaboration Product. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

15

 

        4.2.4    Development Timelines.    It is hereby acknowledged that GSK's strategic objective is
[*]. GSK will consult with the Joint Project Committee and will share, modify and further develop all applicable Development Plans and timelines in that forum. It is recognised
that success can be optimised [*]. At a strategic level, GSK is committed to this objective. However, at an operational level it is recognised that [*].
GSK will use Diligent Efforts to secure the necessary resource and will keep the Joint Project Committee informed on the progress of individual studies and activities relating to Collaboration
Products as part of any changes to Development Plans and timelines. The current objective of the Collaboration is to achieve Marketing Authorization Approval in the US and other Major Markets for a
Collaboration Product from one of the eight Pooled Compounds which can be used as a single agent and/or in combination with other therapeutically active components (including but not limited to a Long
Acting Inhaled Corticosteroid) for the treatment and/or prophylaxis of one or more respiratory diseases [*] and Development Plans and timelines will be developed and/or refined
in an effort to achieve this objective. 

        4.3    Replacement Compounds.    If within [*] after the Effective Date, the Development of
Collaboration Products containing [*] of the Pooled Compounds contributed by a Party is [*], it will be the option of the Party who contributed the
discontinued compounds to discover and offer up to the collaboration [*] Replacement Compounds as replacements for the discontinued compounds within [*]
following the discontinuation of the [*] failed compound. For the avoidance of doubt, any such new compound that satisfies the Criteria will automatically be accepted as a
Pooled Compound in place of the relevant Party's discontinued compound, subject to Joint Steering Committee approval pursuant to Section 3.1.3(f). Nothing in the foregoing shall preclude either
Party from having the option of offering up a Replacement Compound for a Pooled Compound at any time during the period referred to in Section 14.5 (subject to the Criteria being met and Joint
Steering Committee approval pursuant to Section 3.1.3(f)). 

        4.4    Transfer of Data.    As soon as practicable but in no event more than thirty (30) days after the
Effective Date, the Parties shall determine what data and materials relating to TD-3327 and AMI-15471 are necessary for GSK's Development obligations pursuant to this
Article 4, including any technology transfer required for API Compound manufacturing activities contemplated by Article 9, and establish a process for transferring copies of such data
and material to GSK (including, to the extent available, in appropriate electronic format) or provide means of access thereto reasonably acceptable to GSK. 

        4.5    LABA Activity Inside and Outside of the Collaboration.    

        4.5.1    The
intent of the Parties in respect of the Pooled Compounds is that such Pooled Compounds remain exclusive to this Collaboration and, subject to Sections
4.5.2 - 4.5.4 and Article 14 below, no activity in respect of such Pooled Compounds shall be permitted outside of this Agreement. 

        4.5.2    Subject
to Article 14 and to Section 4.5.4, if prior to First Commercial Sale of a GSK Initially Pooled Compound or a GSK Replacement Compound,
Development of such compound is discontinued under this Agreement ("GSK Discontinued Compound"), all rights in respect of such GSK Discontinued Compound shall revert in full to GSK and such GSK
Discontinued Compound shall automatically fall outside of this Agreement except that (i) GSK shall thereafter be prohibited from carrying out any further clinical Development work or clinical
activity in respect of such GSK Discontinued Compound inside the Field for at least [*] after the termination of this Agreement, and (ii) for the avoidance of doubt, GSK
shall pay to Theravance a royalty on Net Sales of any such GSK Discontinued Compound in accordance with Section 14.9. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

16

  

        4.5.3    Subject
to Article 14 and Section 4.5.4, if prior to First Commercial Sale of a Theravance Compound, Development of such compound is discontinued under
this Agreement ("Theravance Discontinued Compound"), all rights in respect of such Theravance Discontinued Compound shall revert in full to Theravance and such Theravance Discontinued Compound shall
automatically fall outside of this Agreement except that (i) Theravance thereafter shall be prohibited from carrying out any further clinical Development work or clinical activity in respect of
such Theravance Discontinued Compound inside the Field until after the termination of this Agreement, and (ii) for the avoidance of doubt, Theravance shall pay to GSK a royalty on Net Sales of
any such Theravance Discontinued Compound in accordance with Section 14.9. 

        4.5.4    Notwithstanding
Sections 4.5.2 and 4.5.3, for so long as there is one Collaboration Product being Developed under this Agreement, neither Party shall carry out
clinical Development inside the Field with any Long Acting b2 Adrenoceptor Agonist that is not a Pooled Compound under this Agreement; provided,
however, that this restriction shall not apply to any compound or product (including new product line extensions and/or re-formulation work) where the original compound or product is, as
of the date of signature of this Agreement, already Commercialized. 

 
 

ARTICLE 5
  COMMERCIALIZATION    
    

        5.1    Global Marketing Plans.    

        5.1.1    General.    The Joint Project Committee shall be responsible for reviewing and approving a Global Marketing
Plan for each Collaboration Product ("Marketing Plan"). Each Marketing Plan shall define the goals and objectives for Commercializing the Collaboration Products in the pertinent Calendar Year
consistent with the applicable Development Plan. 

        5.1.2    Contents of Each Marketing Plan.    The Marketing Plan for each Collaboration Product shall be prepared
during the Calendar Year wherein, and where applicable, Phase III Studies for such Collaboration Product have commenced and shall be a rolling, three year plan, updated annually and shall contain at a
minimum and as appropriate to current knowledge: 

        (a)   Results
of market research and strategy, including market size, dynamics, growth, customer segmentation, customer targeting, competitive analysis and global
Collaboration Product positioning; 

        (b)   Annual
sales forecasts for Major Market Countries; 

        (c)   For
each major Market Country (as available): sales plans which will include target number of sales representatives, detail order and target number of details 

        (d)   Core,
global advertising and promotion programs and strategies, including literature, media plans, symposia and speaker programs; and 

        (e)   Core
Phase III/Phase IV Studies to be conducted 

        5.2    Obligations for Commercialization.    GSK shall use Diligent Efforts to Commercialize the Collaboration
Products. 

17

 

        5.3    Commercialization.    

        5.3.1    GSK Responsibility.    GSK shall have the sole right and responsibility for Commercialization of
Collaboration Products for distribution and sale. GSK shall bear all costs and expenses associated with the Commercialization of Collaboration Products for sale or distribution. 

        (a)   GSK
shall have the sole right and responsibility to distribute, sell, record sales and collect payments for Collaboration Products. 

        (b)   GSK
shall have the sole right and responsibility for establishing and modifying the terms and conditions with respect to the sale of Collaboration Products, including,
without limitation, the price or prices at which the Collaboration Products will be sold, any discount applicable to payments or receivables, and similar matters. 

        (c)   GSK
will be responsible for storage, order receipt, order fulfillment, shipping and invoicing of Collaboration Products. 

        5.3.2    Semi-Annual Reports.    GSK shall provide the Joint Project Committee reports
semi-annually. Such reports shall set forth in summary form the results of GSK's Commercialization activities performed during such semi-annual period in the Major Markets. 

        5.3.3    Exports to the United States.    To the extent permitted by Law, the Parties shall use Diligent Efforts to
prevent the Collaboration Products distributed for sale in a particular Country other than the United States from being exported to the United States for sale. 

 
 

ARTICLE 6
  FINANCIAL PROVISIONS    
    

        6.1    Signing Payment; Equity Investment; One-Time Fee.    

        6.1.1    Signing Payment.    In partial consideration for the acquisition of license rights under the Theravance
Patents and the Theravance Know-How by GSK under this Agreement, GSK shall on the Effective Date, pay to Theravance a non-creditable, non-refundable amount of Ten
Million United States Dollars (U.S. $10,000,000). 

        6.1.2    Stock Purchase.    On the Effective Date, GSK will purchase 4,000,000 shares of Theravance Series E
Preferred Stock at a price of U.S.$10.00 per share for total consideration of Forty Million United States Dollars (U.S. $40,000,000). Such purchase will be made pursuant to the Preferred Stock
Purchase Agreement attached hereto as Schedule 6.1.2. 

        6.1.3    One-Time Fee for [*].    Within thirty days following receipt by GSK of
Theravance's written notification of the decision by Theravance to nominate [*] as a "development candidate," and in further partial consideration for the acquisition of
license rights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, GSK shall pay to Theravance a non-creditable, non-refundable
amount of [*]. [*] will be declared a development
candidate when Theravance (a) completes a study demonstrating [*] (as per the Criteria in Schedule 1.19), and (b) [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

18

 

        6.1.4    One-Time Fee for Each Theravance New Compound.    Within thirty days following the acceptance by
the Joint Project Committee or the Joint Steering Committee of each of the [*] Theravance New Compounds to be contributed to the collaboration pursuant to Section 4.1,
and in further partial consideration for the acquisition of license rights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, GSK shall pay to Theravance
a non-creditable, non-refundable amount of [*] for each such Theravance New Compound. 

        6.2    Milestone Payments.    

        6.2.1    General.    In further consideration of the covenants and agreements contained herein, the Parties shall also
pay to each other the payments set forth below for each such Development milestone referred to therein (each, a "Development Milestone"); provided always that each such payment shall be made only one
time for each Collaboration Product regardless of how many times such Development Milestones are achieved for such Collaboration Product, and no payment shall be owed for a Development Milestone which
is not reached (except that, upon achievement of a Development Milestone for a particular Collaboration Product, any previous Development Milestone for that Collaboration Product for which payment was
not made shall be deemed achieved and payment therefore shall be made); provided further that, in the event that more than one Development Milestone is achieved with respect to the same Collaboration
Product at one time, then all applicable payments under Section 6.2 shall be made. For example, [*]. In the event of termination of development of a particular
Collaboration Product and an alternative Collaboration Product replaces such Terminated Collaboration Product then milestone payments for such replacement compound shall not be paid in respect of
milestones already achieved by the Terminated Collaboration Product. For example, [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

19

 

        6.2.2    GSK to Theravance.    GSK shall make the following milestone payments to Theravance upon the achievement of
the indicated Development Milestone for the first Collaboration Product in which the Long-Acting b2 Adrenoceptor Agonist is
[*], and for the first LABA/ICS Combination Product in which the Long-Acting b2 Adrenoceptor Agonist
[*]: 

	Milestone
 
	 	Amount

	[*]*	 	[*]
	[*]**	 	[*]
	[*]**	 	[*]
	[*]	 	[*]
	
Registration	
 	

 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	
Launch	
 	

 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	

Annual Worldwide Net Sales over [*] Collaboration Product	
 	

[*]
	

Annual Worldwide Net Sales over [*] Combination Product	
 	

[*]

	*
	GSK
will make a [*]. The [*] for [*] is defined as [*] and will
[*]. The [*] is defined as [*] and will [*].

	**
	[*]
is defined as [*] where such [*]. [*] is defined as [*]. 

Other
Combination Products that contain a Long-Acting b2 Adrenoceptor Agonist that is a Theravance Compound are not subject to milestone
payments by GSK only if [*]. The Parties intend that if the collaboration is successful [*]
Collaboration Products that contain a Theravance Compound, Theravance be paid the applicable milestones [*]. 

If
GSK, either individually or as a member of the Joint Steering Committee or Joint Project Committee, discontinues the Development of a [*] Collaboration Product that is a
Theravance Compound for reasons other than [*], and such compound is the [*], it will [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

20

 

        6.2.3    Theravance to GSK.    Theravance shall make the following milestone payments to GSK upon the achievement of
the indicated Development Milestone for the first Collaboration Product in which the Long-Acting b2 Adrenoceptor Agonist is a GSK Compound
and for the first LABA/ICS Combination Product in which the Long-Acting b2 Adrenoceptor Agonist is a GSK Compound: 

	Milestone
 
	 	Amount

	Registration	 	 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	
Launch	
 	

 
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

        Other
Combination Products that contain a Long-Acting b2 Adrenoceptor Agonist that is a GSK Compound are not subject to
milestone payments by Theravance only if all milestone payments through launch have otherwise been made to GSK from any Collaboration Product
[*]. The Parties intend that if the collaboration is successful
[*] Collaboration Products that contain a GSK Compound, GSK be paid the applicable milestones [*]. 

        6.2.4    Notification and Payment.    In the event a Party achieves a Development Milestone, such Party shall
promptly, but in no event more than ten (10) days after the achievement of each such Development Milestone, notify the other Party in writing of the achievement of same. For all Development
Milestones achieved, each Party shall promptly, but in no event more than thirty (30) days after notification of the achievement of each such Development Milestone, remit payment to the other
Party for such Development Milestone. 

        6.3    Payment of Royalties on Net Sales.    

        6.3.1    Royalty on Single-Agent Collaboration Products and LABA/ICS Combination Products.    

Within
twenty (20) days after the end of each Calendar Quarter, GSK shall pay Theravance royalty payments based on Net Sales in such Calendar Quarter during the Term as follows: 

        [*]

it
being understood that [*] for purposes of the foregoing royalty calculation. 

The
quarterly royalty payments made under this Section 6.3.1 may be based on estimated Net Sales. Within thirty (30) days after the end of each Calendar Quarter, GSK shall calculate the
actual amount of Net Sales for the previous Calendar Quarter and either credit or debit the difference between such actual and projected amount on the succeeding Calendar Quarter's royalty payment to
Theravance. As soon as practical following the end of each Calendar Month, but in no event later than the 10th business day of the following month, GSK will provide Theravance with an
estimate of Net Sales for such Calendar Month. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

21

 

The
royalties payable under this Section 6.3 shall be paid on a Country-by-Country basis from the date of first commercial sale of each Collaboration Product in a
particular Country for the Term of the Collaboration. 

        6.3.2    Royalty Adjustment.    The [*] royalty payable on the first
[*] of total annual worldwide Net Sales under this Section 6.3 shall be reduced to [*] if all of the following occur:
(i) [*]; (ii) [*]; and (iii) [*]. The [*] royalty payable on
[*] under this Section 6.3 shall be [*] if all of the following occur: (i) [*];
(ii) [*]; and (iii) [*]. Nothing in the foregoing shall affect other royalties owed under this Agreement. 

        6.3.3    Royalties on Other Collaboration Products Launched After the LABA/ICS Combination Product.    For any Other
Collaboration Product launched after the LABA/ICS Combination Product, GSK shall within twenty (20) days after the end of each Calendar Quarter, pay Theravance royalty payments based on Net
Sales in such Calendar Quarter during the Term as follows: 

	Annual Net Sales
	 	Percentage Royalty

	[*]	 	[*]

For
the avoidance of doubt, the Parties agree that the royalty set forth in this Section 6.3.3 shall only be effective if GSK has launched and is selling a LABA/ICS Combination Product that is
subject to the royalties under Section 6.3.1. If GSK is not selling a LABA/ICS Combination Product, then the royalty set forth in Section 6.3.1 shall apply to the first Other Combination
Product launched by GSK, provided such Other Combination Product does not contain a product [*]; if such Other Combination Product contains a product
[*], then the royalty payable to Theravance will be [*], provided that in no case will the royalty payable to Theravance be less than set forth in this
Section 6.3.3. 

        6.4    Royalty Responsibilities; Net Sales Reports.    

        6.4.1    Payments to Third Parties.    

        (a)   If,
as a result of a settlement approved by both Parties or as a result of a final non-appealable judgment, GSK is required to pay any amounts to a Third
Party directly because using or selling a Theravance Compound is found to infringe the rights of such Third Party, GSK shall deduct [*] of any such amount paid to such Third
Party from the royalties otherwise due Theravance for the Collaboration Product containing such Theravance Compound, provided in no event shall such reduction reduce the royalties otherwise payable to
Theravance during any Calendar Year by more than [*]; provided, further, that any excess deduction shall be carried over into subsequent years of this Agreement until the full
deduction is taken. 

        (b)   GSK
shall pay any amounts owed to a Third Party as a result of the use of GSK Patents or GSK Know-How with respect to sales of Collaboration Products and
shall not deduct any of such amounts from the royalties due Theravance. The foregoing is subject to Section 6.3.3. 

        6.4.2    Net Sales Report.    Within thirty (30) days after the end of each Calendar Quarter, GSK shall submit
to Theravance a written report setting forth Net Sales in the Territory on a Country-by-Country and Collaboration Product-by-Collaboration Product basis
during such Calendar Quarter, total royalty payments due Theravance, relevant market share data and any payments made to any Third Party pursuant to Section 6.4.1(a) (each a "Net Sales
Report"). 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

22

 

        6.5    GAAP.    All financial terms and standards defined or used in this Agreement for sales or activities occurring
in the United States shall be governed by and determined in accordance with United States generally accepted accounting principles, consistently applied. Except as otherwise set forth herein, all
financial terms and standards defined or used in this Agreement for sales or activities occurring outside
the United States shall be governed by and determined in accordance with United Kingdom generally accepted accounting principles, consistently applied. 

        6.6    Currencies.    Monetary conversion from the currency of a foreign country in which Collaboration Product is
sold into US Dollars shall be calculated in accordance with either (a) the methodology referred to in GSK's then current Corporate Finance Reporting Policy or (b) as otherwise may be
mutually agreed by the Parties. The following summarizes GSK's current methodology applied in accordance with its current Corporate Finance Reporting System: the cumulative
year-to-date Average Rates are calculated by determining the average of (i) the preceding 31st December Spot Rate plus (ii) the Closing Spot Rates of the relevant
months to date using the exact figures provided by the Reuters 2000 download. (By way of example, the Average Rate for the five months from January, 2002 to May, 2002 would be computed by taking the
sum of the Spot Rates for the preceding 31st December, 2001, plus the month-end Spot Rates for the five months to May, 2002, divided by six). 

        6.7    Manner of Payments.    All sums due to either Party under this Section 6 shall be payable in United
States Dollars by bank wire transfer in immediately available funds to such bank account(s) as each of GSK and Theravance shall designate. GSK shall notify Theravance as to the date and amount of any
such wire transfer to Theravance at least five (5) Business Days prior to such transfer. Theravance shall notify GSK as to the date and amount of any such wire transfer to GSK at least five
(5) Business Days prior to such transfer. 

        6.8    Interest on Late Payments.    If either Theravance or GSK shall fail to make a timely payment pursuant to this
Article 6, any such payment that is not paid on or before the date such payment is due under this Agreement shall bear interest, to the extent permitted by applicable law, at the average
one-month London Inter-Bank Offering Rate (LIBOR) for the United States Dollar as reported from time to time in The Wall Street Journal, effective for the first date on which
payment was delinquent and calculated on the number of days such payment is overdue or, if such rate is not regularly published, as published in such source as the Joint Steering Committee agrees. 

        6.9    Tax Withholding.    

        6.9.1    Any
taxes, levies or other duties ("Taxes") paid or required to be withheld under the appropriate local tax laws by one of the Parties ("Withholding Party") on account
of monies payable to the other Party under this Agreement shall, subject to Sections 6.9.2 and 6.9.3, be deducted from the amount of monies otherwise payable to the other Party under this Agreement.
The Withholding Party shall secure and send to the other Party within a reasonable period of time proof of any such Taxes paid or required to be withheld by Withholding Party for the benefit of the
other Party. 

        6.9.2    If
GSK or any GSK Affiliate is or becomes liable to withhold any taxes from payments made to Theravance under Sections 6.1 and 6.2 of this Agreement, then GSK shall
pay to Theravance an amount equal to the amount GSK or the applicable GSK Affiliate owes to the relevant tax authority provided always that if Theravance is able to obtain credit for any taxes
withheld ("Creditable Taxes") against any liability to tax either in the year in which the receipt is taxable or any preceding years, Theravance shall reimburse to GSK an amount equivalent to the
Creditable Taxes. Theravance shall provide GSK with such reasonable evidence as GSK may reasonably request to determine whether the taxes are creditable against taxes payable by Theravance. 

23

 

        6.9.3    If
GSK or any GSK Affiliate is or becomes liable to withhold any taxes from payments made to Theravance under Section 6.3, then such taxes may be withheld by
GSK or the applicable GSK Affiliate up to a limit of [*] of the relevant payment. GSK shall pay to Theravance an amount equal to the amount GSK owes to the relevant tax
authority in excess of such [*] provided always that if Theravance is able to obtain credit for any taxes withheld ("Creditable Taxes") against any liability to tax either in
the year in which the receipt is taxable or any preceding years, Theravance shall reimburse to GSK an amount equivalent to the Creditable Taxes. Theravance shall provide GSK with such reasonable
evidence as GSK may reasonably request to determine whether the taxes are creditable against taxes payable by Theravance. 

        6.10    Financial Records; Audits.    GSK shall keep, and shall cause its Affiliates and sublicensees to keep, such
accurate and complete records of Net Sales as are necessary to determine the amounts due to Theravance under this Agreement and such records shall be retained by GSK or any of its Affiliates or
sublicensees (in such capacity, the "Recording Party") for at least the three preceding Calendar Years to which the Net Sales relate. During normal business hours and with reasonable advance notice to
the Recording Party, such records shall be made available for inspection, review and audit, at the request and expense of Theravance, by an independent certified public accountant, or the local
equivalent, appointed by Theravance and reasonably acceptable to the Recording Party for the sole purpose of verifying the accuracy of the Recording Party's accounting reports and payments made or to
be made pursuant to this Agreement; provided, however that such audits may not be performed by Theravance more than once per Calendar Year. Such accountants shall be instructed not to reveal to
Theravance the details of its review, except for (i) such information as is required to be disclosed under this Agreement and (ii) such information presented in a summary fashion as is
necessary to report the accountants' conclusions to Theravance, and all such information shall be deemed Confidential Information of the Recording Party; provided, however, that in any event such
information may be presented to Theravance in a summary fashion as is necessary to report the accountants' conclusions. All costs and expenses incurred in connection with performing any such audit
shall be paid by Theravance unless the audit discloses at least a [*] shortfall, in which case the Recording Party will bear the full cost of the audit for such Calendar Year.
Theravance will be entitled to recover any shortfall in payments due to it as determined by such audit, plus interest thereon calculated in accordance with Section 6.8, or alternatively shall
have the right to offset and deduct any such shortfall in payments due to it against payments Theravance is otherwise required to make to the Reporting Party under this Agreement. The documents from
which were calculated the sums due under this Article 6 shall be retained by the relevant Party during the Term. 

 
 

ARTICLE 7
  PROMOTIONAL MATERIALS AND SAMPLES    
    

        7.1    Promotional Materials.    

        7.1.1    Review of Core Promotional Materials.    Subject to applicable Law, in accordance with the direction of the
Joint Project Committee, the Parties will jointly, through consultation and with the assistance of each other, review the core Promotional Materials. The relevant legal or regulatory personnel of each
Party shall have the opportunity to review and comment on all such core Promotional Materials prior to use and such comments shall be considered by the Joint Project Committee in the review of such
core Promotional Materials. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

24

 

        7.1.2    Markings of Promotional Materials.    To the extent required by applicable Law, and further to the extent
reasonably practicable, all Promotional Materials will indicate the contribution of the license from Theravance for the Collaboration Products. Subject to the foregoing, the Theravance Housemark and
the GSK Housemark shall both be given exposure and prominence on all promotional materials, labelling, package inserts or outserts and packaging for the Collaboration Products. 

        7.2    Samples.    Packaging, package inserts and outserts, Sample labels and labeling shall each contain reference to
Theravance and GSK indicating, in the case of Theravance, the contribution of the license from Theravance for the Collaboration Products, if appropriate, and as may be required under applicable FDA
rules and regulations. 

        7.3    Statements Consistent with Labeling.    GSK shall ensure that its sales representatives detail the
Collaboration Products in a fair and balanced manner and consistent with the requirements of the
Federal Food, Drug and Cosmetic Act of the United States, as amended, including, but not limited to, the regulations at 21 C.F.R. (S) 202 in the United States. 

        7.4    Implications of Change in Control in Theravance.    In the event that there is a Change in Control of
Theravance and the references contemplated in Sections 7.1.2 and 7.2 are no longer made to "Theravance,", then other than to the extent required by applicable Law, GSK shall have the right, not to be
unreasonably exercised, to terminate its obligations under Sections 7.1 and 7.2. 

 
 

ARTICLE 8
  REGULATORY MATTERS    
    

        8.1    Governmental Authorities.    GSK shall be solely responsible for communicating with Governmental Authorities
and will keep Theravance informed, through the Joint Project Committee and Joint Steering Committee, of any significant issue or issues arising therefrom. 

        8.2    Filings.    GSK shall also be solely responsible for filing drug approval applications for Collaboration
Products and will use Diligent Efforts in seeking appropriate approvals in those Countries of the Territory for Collaboration Products as GSK reasonably determines and sees fit. Such regulatory
documents for each filing shall be centralized and held at the offices of GSK. Theravance shall provide such reasonable assistance as may be required by GSK where liaison between the Parties is, or
may be, necessary to enable GSK to fulfill its responsibilities hereunder. GSK shall be responsible for maintaining the Approvals obtained under this Section and shall solely own all such Approvals in
the Territory. GSK shall be fully responsible for bearing all costs and expense associated with undertaking and completing said registration activities in the Territory, including but not limited to
the costs of preparing and prosecuting applications for such Approvals and fees payable to regulatory agencies in obtaining and maintaining same. 

        8.3    Exchange of Drug Safety Information.    Subject to the second sentence of this Section 8.3, GSK shall be
responsible for recording, investigating, summarizing, notifying, reporting and reviewing all Adverse Drug Experiences in accordance with Law and shall require that its Affiliates (i) adhere to
all requirements of applicable Laws which relate to the reporting and investigation of Adverse Drug Experiences, and (ii) keep the Joint Project Committee apprised on a regular basis of such
matters arising therefrom. The foregoing shall be subject to any of Theravance's own clinical safety obligations mandated by Law as a result of its ongoing Development activity related to
TD-3327 (as such activity is more specifically referred to in Article 4) and, in acknowledgement of this, it is thereby contemplated that the Parties' respective clinical safety
groups may need to discuss and agree, at the appropriate time after the Effective Date, appropriate safety data exchange procedures related to same. 

        8.4    Recalls or Other Corrective Action.    Each Party shall, as soon as practicable, notify the other Party of any
recall information received by it in sufficient detail to allow the Parties to comply with any 

25

 

and
all applicable Laws. GSK shall promptly notify Theravance of any material actions to be taken by GSK with respect to any recall or market withdrawal or other corrective action related to a
Collaboration Product prior to such action to permit Theravance a reasonable opportunity to consult with GSK with respect thereto. All costs and expenses with respect to a recall, market withdrawal or
other corrective action shall be borne by GSK unless such recall, market withdrawal or other corrective action was due solely to the negligence, willful misconduct or breach of this Agreement by
Theravance. GSK shall have sole responsibility for and shall make all decisions with respect to any recall, market withdrawals or any other corrective action related to the Collaboration Products. 

        8.5    Events Affecting Integrity or Reputation.    During the Term, the Parties shall notify each other immediately
of any circumstances of which they are aware and which could impair the integrity and reputation of the Collaboration Products or if a Party is threatened by the unlawful activity of any Third Party
in relation to the Collaboration Products, which circumstances shall include, by way of illustration, deliberate tampering with or contamination of the Collaboration Products by any Third Party as a
means of extorting payment from the Parties or another Third Party. In any such circumstances, the Parties shall use Diligent Efforts to limit any damage to the Parties and/or to the Collaboration
Products. The Parties shall promptly call a Joint Steering Committee meeting to discuss and resolve such circumstances. 

 
 

ARTICLE 9
  ORDERS; SUPPLY AND RETURNS    
    

        9.1    Orders and Terms of Sale.    Except as otherwise expressly stated in this Agreement, GSK shall have the sole
right to (i) receive, accept and fill orders for the Collaboration Products, (ii) control invoicing, order processing and collection of accounts receivable for the Collaboration Products
sales, (iii) record the Collaboration Products sales in its books of account, and (iv) establish and modify the commercial terms and conditions with respect to the sale and distribution
of the Collaboration Products, including without limitation matters such as the price at which the Collaboration Products will be sold and whether any discounts, rebates or other deductions should be
made, paid or allowed. 

        9.2    Supply of API Compound and Formulated Collaboration Product for Development.    

        9.2.1    Supply of API Compound for Development.    Subject to the terms and conditions of this Agreement, GSK shall
conduct or have conducted any chemical process development required to develop a commercially acceptable process for making API Compound and obtain supply for worldwide requirements of API Compound.
Notwithstanding the foregoing, Theravance may transfer to GSK, at cost, whatever supply it has on hand of TD-3327 API and/or AMI-15471 API and/or intermediate materials for API
manufacture, within specification as of the Effective Date, such cost not to exceed [*]. API Compound requirements for Development activities shall be set forth in the relevant
Development Plan and shall be periodically updated by the Joint Project Committee. 

        9.2.2    Supply of Formulated Collaboration Products for Development.    Subject to the terms and conditions of this
Agreement, GSK shall obtain supply for worldwide requirements of formulated Collaboration Products. Notwithstanding the foregoing, Theravance agrees to transfer to GSK whatever supply it has on hand
of formulated TD-3327, within specification, at cost as of the Effective Date, such cost not to exceed [*]. Formulated Collaboration Product requirements for
Development activities shall be set forth in the relevant Development Plan and shall be periodically updated by the Joint Project Committee. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

26

 

        9.3    Supply of API Compound for Commercial Requirements.    Subject to the terms and conditions of this Agreement,
GSK shall obtain supply of API Compound. A forecast for API Compound requirements for Commercialization of the Collaboration Products shall be prepared and periodically updated by the Joint Project
Committee and coordinated with the applicable Marketing Plans for Collaboration Products. 

        9.4    Supply of Collaboration Products for Commercialization.    Subject to the terms and conditions of this
Agreement, GSK shall obtain supply of the commercial requirements of formulated, packaged and labeled Collaboration Products. Such formulated, packaged and labeled Collaboration Products shall be
manufactured and supplied in accordance with all applicable Laws and current Good Manufacturing Practices. GSK shall be solely responsible for secondary manufacture, packaging and labeling of the
Collaboration Product. 

        9.5    Inventories.    GSK and its Product Suppliers shall maintain an inventory of API Compound and Collaboration
Products in accordance with their normal practices and so as to ensure fulfillment of its respective supply obligations herein. 

 
 

ARTICLE 10
  CONFIDENTIAL INFORMATION    
    

        10.1    Confidential Information.    Each of GSK and Theravance shall keep all Confidential Information received from
the other Party with the same degree of care it maintains the confidentiality of its own Confidential Information. Neither Party shall use such Confidential Information for any purpose other than in
performance of this Agreement or disclose the same to any other Person other than to such of its agents who have a need to know such Confidential Information to implement the terms of this Agreement
or enforce its rights under this Agreement. A Receiving Party shall advise any agent who receives such Confidential Information of the confidential nature thereof and of the obligations contained in
this Agreement relating thereto, and the Receiving Party shall ensure that all such agents comply with such obligations as if they had been a Party hereto. Upon termination of this Agreement, the
Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the Receiving Party's or its agents' possession,
except that the Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall be deemed
to be the property of the Disclosing Party, and shall continue to be subject to the provisions of this Article 10. Notwithstanding anything to the contrary in this Agreement, the Receiving
Party shall have the right to disclose this Agreement or Confidential Information provided hereunder if, in the reasonable opinion of the Receiving Party's legal counsel, such disclosure is necessary
to comply with the terms of this Agreement, or the requirements of any Law. Where possible, the Receiving Party shall notify the Disclosing Party of the Receiving Party's intent to make such
disclosure pursuant to the provision of the preceding sentence sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action the Disclosing
Party may deem to be appropriate to protect the confidentiality of the information. The Receiving Party will cooperate reasonably with the Disclosing Party's efforts to protect the confidentiality of
the information. Each Party will be liable for breach of this Article 10 by any of its Affiliates. 

        10.2    Permitted Disclosure and Use.    Notwithstanding Section 10.1, a Party may disclose Confidential
Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) obtain Marketing Authorization of a Collaboration Product; (b) enforce the
provisions of this Agreement; or (c) comply with Laws. If a Party deems it necessary to disclose Confidential Information of the other Party pursuant to this Section 10.2, such Party
shall give reasonable advance notice of such disclosure to the other Party to permit such other Party sufficient opportunity to object to such disclosure or to take measures to ensure confidential
treatment of such information. The 

27

 

Receiving
Party will cooperate reasonably with the Disclosing Party's efforts to protect the confidentiality of the information. 

        10.3    Publications.    Subject to any Third Party rights existing as of the Effective Date, each Party shall submit
to the Joint Project Committee for review and approval all proposed academic, scientific and medical publications and public presentations relating to a Collaboration Product or any research or
Development activities under this Agreement for review in connection with preservation of Patent Rights, and trade secrets and/or to determine whether Confidential Information should be modified or
deleted from the proposed publication or public presentation. Written copies of such proposed publications and presentations shall be submitted to the Joint Project Committee no later than sixty
(60) days before submission for publication or presentation and the Joint Project Committee shall provide its comments with respect to such publications and presentations within ten
(10) Business Days of its receipt of such written copy. The review period may be extended for an additional sixty (60) days if a representative of the non-publishing Party on
the Joint Project Committee can demonstrate a reasonable need for such extension including, but not limited to, the preparation and filing of patent applications. By mutual agreement of the Parties,
this period may be further extended. The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in
any publications relating to the Collaboration Products or any research or Development activities under this Agreement. 

        10.4    Public Announcements.    Except as may be expressly permitted under Section 10.3 or required by
applicable Laws and subject to the final two sentences of this Section 10.4, neither Party will make any public announcement of any information regarding this Agreement, the Collaboration
Products or any research or Development activities under this Agreement without the prior written approval of the other Party, which approval shall not be withheld unreasonably. Once any statement is
approved for disclosure by the Parties or information is otherwise made public in accordance with the preceding sentence, either Party may make a subsequent public disclosure of the contents of such
statement without further approval of the other Party. Notwithstanding the foregoing, within sixty (60) days following the Effective Date, appropriate representatives of the Parties will meet
and agree upon a process and principles for reaching timely consensus on how the Parties will make public disclosure concerning this Agreement, the Collaboration Products or any research and
Development activities under this Agreement. 

        10.5    Confidentiality of This Agreement.    The terms of this Agreement shall be Confidential Information of each
Party and, as such, shall be subject to the provisions of this Article 10. Either party may disclose the terms of this Agreement if, in the opinion of its counsel, such disclosure is required
by Law. In
such event, the disclosing Party will seek appropriate confidentiality of those portions of the Agreement for which confidential treatment is typically permitted by the relevant Governmental
Authority. 

        10.6    Termination of Prior Confidentiality Agreements.    Except as expressly provided in this Section 10.6,
this Agreement supercedes the Mutual Confidential Disclosure Agreement (the "MCDA") between the Parties dated April 10, 2002. Except as expressly provided in this Section 10.6 and in
Paragraph 8 of the Confidentiality Agreement between the Parties dated October 2, 2002 (the "Patent CDA"), this Agreement supersedes the Patent CDA. Except as set forth in
Paragraph 8 of the Patent CDA, all information disclosed pursuant to the MCDA and the Patent CDA shall be subject to the provisions of this Article 10. 

        10.7    Survival.    The obligations and prohibitions contained in this Article 10 shall survive the expiration
or termination of this Agreement for a period of ten (10) years. 

28

  

 
 

ARTICLE 11
  REPRESENTATIONS AND WARRANTIES; COVENANTS    
    

        11.1    Mutual Representations and Warranties.    Theravance and GSK each represents and warrants to the other as of
the Effective Date that: 

        11.1.1    Such
Party (a) is a company duly organized, validly existing, and in good standing under the Laws of its incorporation; (b) is duly qualified as a
corporation and in good standing under the Laws of each jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification, where the failure to be so
qualified would have a material adverse effect on its financial condition or its ability to perform its obligations hereunder; (c) has the requisite corporate power and authority and the legal
right to conduct its business as now conducted and hereafter contemplated to be conducted; (d) has or will obtain all necessary licenses, permits, consents, or approvals from or by, and has
made or will make all necessary notices to, all Governmental Authorities having jurisdiction over such Party, to the extent required for the ownership and operation of its business, where the failure
to obtain such licenses, permits, consents or approvals, or to make such notices, would have a material adverse effect on its financial condition or its ability to perform its obligations hereunder;
and (e) is in compliance with its charter documents; 

        11.1.2    The
execution, delivery and performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder (a) are
within the corporate power of such Party; (b) have been duly authorized by all necessary or proper corporate action; (c) do not conflict with any provision of the charter documents of
such Party; (d) will not, to the best of such Party's knowledge, violate any law or regulation or any order or decree of any court of governmental instrumentality; (e) will not violate
or conflict with any terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party, or by which such Party or any of its property is bound,
which violation would have a material adverse effect on its financial condition or on its ability to perform its obligations hereunder; 

        11.1.3    This
Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable against such Party
in accordance with its terms, except as such enforceability may be limited by applicable insolvency and other Laws affecting creditors' rights generally, or by the availability of equitable remedies;
and 

        11.1.4    All
of its employees, officers, and consultants have executed agreements or have existing obligations under law requiring assignment to such Party of all Inventions
made by such individuals during the course of and as the result of their association with such Party, and obligating such individuals to maintain as confidential such Party's Confidential Information. 

        11.1.5    Nothing
contained in this Agreement shall give a Party the right to use the Confidential Information received from the other Party in connection with any activity
other than Development and Commercialization of a Pooled Compound or Collaboration Product consistent with this Agreement. 

        11.1.6    As
soon as practicably possible after the Effective Date, the Parties will each deliver to each other a schedule listing (i) in the case of GSK, GSK Patents as
of the date of signature of this Agreement and (ii) in the case of Theravance, Theravance Patents as of the date of signature of this Agreement. 

29

 

        11.2    Additional GSK Representations and Warranties.    GSK further represents, warrants and covenants to Theravance
that: 

        11.2.1    It
has utilized its own scientific, marketing and distribution expertise and experience to analyze and evaluate both the scientific and commercial value of this
collaboration and has solely relied on such analysis and evaluations in deciding to enter into this Agreement; 

        11.2.2    Neither
GSK nor any of its Affiliates is a party to or otherwise bound by any oral or written contract or agreement that will result in any Person obtaining any
interest in, or that would give to any Person any right to assert any claim in or with respect to, any of GSK's rights granted under this Agreement; 

        11.2.3    There
is no claim or demand of any person or entity pertaining to, or any proceeding which is pending or, to the knowledge of GSK, threatened, that challenges the
rights of Theravance in respect of any GSK Know-How or GSK Patents, or that claims that any default exists under any license with respect to any GSK Know-How or GSK Patents to
which GSK is a party, except where such claim, demand or proceeding would not materially and adversely affect the ability of GSK to carry out its obligations under this Agreement; and 

        11.2.4    Having
carried out and completed diligent searches in relation to the GSK Patents, and other than as disclosed to Theravance's counsel by GSK's counsel, GSK is not
aware, nor has been made aware, of any conflict or likely future conflict with the intellectual property rights of any Third Party with respect to GSK Patents. 

        11.3    Additional Theravance Representations and Warranties.    Theravance further represents and warrants to GSK as
of the Effective Date that: 

        11.3.1    Having
carried out and completed diligent searches in relation to the Theravance Patents, and other than as disclosed to GSK's counsel by Theravance's counsel,
Theravance is not aware, nor has been made aware, of any conflict or likely future conflict with the intellectual property rights of any Third Party with respect to Theravance Patents. 

        Theravance
has not received notice from any Third Party of a claim that an issued patent of such Third Party would be infringed by the manufacture, distribution, marketing or sale of the
Collaboration Products under this Agreement; 

        11.3.2    To
Theravance's knowledge, the Theravance Patents are not subject to any pending or any threatened re-examination, opposition, interference or litigation
proceedings; 

        11.3.3    Theravance
has not received notice from any Third Party of a claim asserting the invalidity, misuse, unregisterability or unenforceability of any of the Theravance
Patents, or challenging its right to use or ownership of any of the Theravance Patents or the Theravance Know-How, or making any adverse claim of ownership thereof; 

        11.3.4    Theravance
has not received notice from any Third Party that any trade secrets or other intellectual property rights of such Third Party would be misappropriated by
the development and reduction to practice of the Theravance Patents and Theravance Know-How; and 

        11.3.5    Theravance
has, up to and including the Effective Date, furnished GSK with all material information requested by GSK concerning the quality, toxicity, safety and/or
efficacy concerns that may materially impair the utility and/or safety of the Compound or Collaboration Products. 

        11.4    Covenants.    Each Party hereby covenants and agrees during the Term that it shall carry out its obligations
or activities hereunder in accordance with (i) the terms of this Agreement and (ii) all applicable Laws. 

30

 

        11.5    Disclaimer of Warranty.    Subject to the specific warranties and representations given under
Sections 11.1 through and including 11.3, nothing in this Agreement shall be construed as a warranty or representation by either Party (i) that any Collaboration Product made, used, sold
or otherwise disposed of under this Agreement is or will be free from infringement of patents, copyrights, trademarks, industrial design or other intellectual property rights of any Third Party,
(ii) regarding the effectiveness, value, safety, non-toxicity, patentability, or non-infringement of any patent technology, the Collaboration Products or any information
or results provided by either Party pursuant to this Agreement or (iii) that any Collaboration Product will obtain Marketing Authorization or appropriate pricing approval. Each Party explicitly
accepts all of the same as experimental and for development purposes, and without any express or implied warranty from the other Party. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH
PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 
 

ARTICLE 12
  INDEMNIFICATION    
    

        12.1    Indemnification by GSK.    Subject to Sections 12.4 and 13.2, GSK shall defend, indemnify and hold harmless
Theravance and its Affiliates and each of their officers, directors, shareholders, employees, successors and assigns from and against all Claims of Third Parties, and all associated Losses, to the
extent arising out of (a) GSK's negligence or willful misconduct in performing any of its obligations under this Agreement, (b) a breach by GSK of any of its representations, warranties,
covenants or agreements under this Agreement, or (c) the manufacture, use, handling, storage, marketing, sale, distribution or other disposition of Collaboration Products by GSK, its
Affiliates, agents or sublicensees, except to the extent such losses result from the negligence or willful misconduct of Theravance. 

        12.2    Indemnification by Theravance.    Subject to Sections 12.4 and 13.2, Theravance shall defend, indemnify
and hold harmless GSK and its Affiliates and each of their officers, directors, shareholders, employees, successors and assigns from and against all Claims of Third Parties, and all associated Losses,
to the extent arising out of (a) Theravance's negligence or willful misconduct in performing any of its obligations under this Agreement, or (b) a breach by Theravance of any of its
representations, warranties, covenants or agreements under this Agreement. 

        12.3    Procedure for Indemnification.    

        12.3.1    Notice.    Each Party will notify promptly the other in writing if it becomes aware of a Claim (actual or
potential) by any Third Party (a "Third Party Claim") for which indemnification may be sought by that Party and will give such information with respect thereto as the other Party shall reasonably
request. If any proceeding (including any governmental investigation) is instituted involving any Party for which such Party may seek an indemnity under Section 12.1 or 12.2, as the case may be
(the "Indemnified Party"), the Indemnified Party shall not make any admission or statement concerning such Third Party Claim, but shall promptly notify the other Party (the "Indemnifying Party")
orally and in writing and the Indemnifying Party and Indemnified Party shall meet to discuss how to respond to any Third Party Claims that are the subject matter of such proceeding. The Indemnifying
Party shall not be obligated to indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party or any failure by such Party to notify the Indemnifying Party of
the claim materially prejudices the defense of such claim. 

        12.3.2    Defense of Claim.    If the Indemnifying Party elects to defend or, if local procedural rules or laws do not
permit the same, elects to control the defense of a Third Party Claim, it shall be entitled to do so provided it gives notice to the Indemnified Party of its intention to do so 

31

 

within
forty-five (45) days after the receipt of the written notice from the Indemnified Party of the potentially indemnifiable Third Party Claim (the "Litigation Condition"). The
Indemnifying Party expressly agrees the Indemnifying Party shall be responsible for satisfying and discharging any award made to or settlement reached with the Third Party pursuant to the terms of
this Agreement without prejudice to any provision in this Agreement or right at law which will allow the Indemnifying Party subsequently to recover any amount from the Indemnified Party to the extent
the liability under such settlement or award was attributable to the Indemnified Party. Subject to compliance with the Litigation Condition, the Indemnifying Party shall retain counsel reasonably
acceptable to the Indemnified Party (such acceptance not to be unreasonably withheld, refused, conditioned or delayed) to represent the Indemnified Party and shall pay the reasonable fees and expenses
of such counsel related to such proceeding. In any such proceeding, the Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of the Indemnified Party. The Indemnified Party shall not settle any claim for which it is seeking indemnification without the prior written consent of the Indemnifying Party which consent
shall not be unreasonably withheld, refused, conditioned or delayed. The Indemnified Party shall, if requested by the Indemnifying Party, cooperate in all reasonable respects in the defense of such
claim that is being managed and/or controlled by the Indemnifying Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably
withheld, refused, conditioned or delayed), effect any settlement of any pending or threatened proceeding in which the Indemnified Party is, or based on the same set of facts could have been, a party
and indemnity could have been sought hereunder by the Indemnified Party, unless such settlement includes an unconditional release of the Indemnified Party from all liability on claims that are the
subject matter of such proceeding. If the Litigation Condition is not met, then neither Party shall have the right to control the defense of such Third Party Claim and the Parties shall cooperate in
and be consulted on the material aspects of such defense at each Party's own expense; provided that if the Indemnifying Party does not satisfy the Litigation Condition, the Indemnifying Party may at
any subsequent time during the pendency of the relevant Third Party Claim irrevocably elect, if permitted by local procedural rules or laws, to defend and/or to control the defense of the relevant
Third Party Claim so long as the Indemnifying Party also agrees to pay the reasonable fees and costs incurred by the Indemnified Party in relation to the defense of such Third Party Claim from the
inception of the Third Party Claim until the date the Indemnifying Party assumes the defense or control thereof. 

        12.4    Assumption of Defense.    Notwithstanding anything to the contrary contained herein, an Indemnified Party
shall be entitled to assume the defense of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party pursuant to this Section 12.4, in which
case the Indemnifying Party shall be relieved of liability under Section 12.1 or 12.2, as applicable, solely for such Third Party Claim and related Losses. 

        12.5    Insurance.    During the Term of this Agreement and for a period of [*] after the
termination or expiration of this Agreement, GSK shall obtain and/or maintain at its sole cost and expense, product liability insurance (including any self-insured arrangements) in amounts
which are reasonable and customary in the U.S. pharmaceutical industry for companies of
comparable size and activities. Such product liability insurance or self-insured arrangements shall insure against all liability, including without limitation personal injury, physical
injury, or property damage arising out of the manufacture, sale, distribution, or marketing of the Collaboration Products. GSK shall provide written proof of the existence of such insurance to
Theravance upon request. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

32

 
 
 

ARTICLE 13
  PATENTS    
    

        13.1    Prosecution and Maintenance of Patents.    

        13.1.1    Prosecution and Maintenance of Theravance Patents.    Theravance shall have the exclusive right and the
obligation to (subject to Theravance's election not to file, prosecute, or maintain pursuant to Section 13.1.4) or to cause its licensors to, prepare, file, prosecute in a diligent manner
(including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such
fees and costs required under applicable Laws) and extend all Theravance Patents and related applications. Theravance shall consult with GSK prior to abandoning any Theravance Patents or related
applications that are material to the matters contemplated in this Agreement. Theravance shall regularly advise GSK of the status of all pending applications, including with respect to any hearings or
other proceedings before any Governmental Authority, and, at GSK's request, shall provide GSK with copies of all documentation concerning such applications, including all correspondence to and from
any Governmental Authority. Subject to Section 2.3.3, Theravance shall solicit GSK's advice and review of the nature and text of such patent applications and important prosecution matters
related thereto in reasonably sufficient time prior to filing thereof, and Theravance shall take into account GSK's reasonable comments related thereto; provided, however, Theravance shall have the
final decision authority with respect to any action relating to any Theravance Patent. Within the priority period, Theravance shall agree with GSK regarding the countries outside the United States in
which corresponding applications should be filed ("OUS Filings"). It is presumed that a corresponding Patent
Cooperation Treaty ("PCT") application will be filed unless otherwise agreed by the Parties. Theravance shall effect filing of all such applications within the priority period. 

        Subject
to Section 13.1.4, Theravance shall be responsible for all costs incurred in the United States in connection with procuring Theravance Patents, including applications
preparation, filing fees, prosecution, maintenance and all costs associated with reexamination and interference proceedings in the United States Patent and Trademark Office and United States Courts.
GSK shall be responsible for all out-of-pocket costs and expenses incurred by Theravance after the Effective Date that are associated with procuring corresponding OUS patents,
including without limitation PCT and individual country filing fees, translations, maintenance, annuities, and protest proceedings. For all such OUS patent applications, Theravance will invoice GSK on
a quarterly basis beginning April 1, 2003, setting forth all such expenses incurred. Reimbursement will be made to Theravance in United States Dollars within thirty (30) days of receipt
of the invoice by GSK. GSK will within thirty (30) days following the Effective Date identify the GSK representative that should receive such invoices from Theravance. GSK's obligations
hereunder are in addition to any obligations of GSK under Section 13.1.2(b) 

        13.1.2    Prosecution and Maintenance of Patents Covering Joint Inventions.    

        (a)   For
Patents covering Joint Inventions, the Parties shall agree, without prejudice to ownership, which Party shall have the right to prepare and file a priority
patent application, and prosecute such application(s) and maintain any patents derived therefrom, with the Parties equally sharing the reasonable out-of-pocket costs for the
preparation, filing, prosecution and maintenance of such priority patent application. The Parties will reasonably cooperate to obtain any export licenses that might be required for such activities.
Should the agreed upon Party elect not to prepare and/or file any such priority patent application, it shall (i) provide the other Party with written notice as soon as reasonably possible after
making such election but in any event no later than sixty (60) days before the other Party would be faced with a possible loss of rights, (ii) give the other Party the right, at the
other Party's discretion and sole expense, to prepare and file the 

33

 

priority
application(s), and (iii) offer reasonable assistance in connection with such preparation and filing at no cost to the other Party except for reimbursement of reasonable
out-of-pocket expenses incurred by the agreed upon Party in rendering such assistance. The other Party, at its discretion and cost, shall prosecute such application(s) and
maintain sole ownership of any patents derived therefrom. 

        (b)   Within
nine (9) months after the filing date of a priority application directed to an Invention, the Party filing the priority application shall request that the
other Party identify those non-priority, non-PCT ("foreign") Countries in which the other Party desires that the Party filing the priority application file corresponding patent
applications. Within thirty (30) days after receipt by the other Party of such request from the Party filing the priority application, the other Party shall provide to the Party filing the
priority application a written list of such foreign
countries in which the other Party wishes to effect corresponding foreign patent applications filings. The Parties will then attempt to agree on the particular countries in which such applications
will be filed, provided that in the event agreement is not reached, the application will be filed in the disputed as well as the non-disputed countries (all such filings referred to
hereinafter as "Designated Foreign Filings"). Thereafter, within twelve (12) months after the filing date of the priority application, the Party filing the priority application shall effect all
such Designated Foreign Filings. It is presumed unless otherwise agreed in writing by the Parties, that a corresponding PCT application will be filed designating all PCT member countries. As to each
Designated Foreign Filing and PCT application, GSK shall bear the costs for the filing and prosecutions of such Designated Foreign Filing and PCT application (including entering national phase in all
agreed countries). Should the Party filing the priority application not agree to file or cause to be filed a Designated Foreign Filing, the other Party will have the right to effect such Designated
Foreign Filing in its name. 

        (c)   Should
the filing Party pursuant to Section 13.1.2(a) or 13.1.2(b) no longer wish to prosecute and/or maintain any patent application or patent resulting from
such application, the filing Party shall (i) provide the non-filing Party with written notice of its wish no later than sixty (60) days before the patent or patent
applications would otherwise become abandoned, (ii) give the non-filing Party the right, at the non-filing Party's election and sole expense, to prosecute and/or
maintain such patent or patent application, and (iii) offer reasonable assistance to the non-filing Party in connection with such prosecution and/or maintenance at no cost to the
non-filing Party except for reimbursement of the filing Party's reasonable out-of-pocket expenses incurred by the filing Party in rendering such assistance. 

        (d)   Should
the non-filing Party pursuant to Section 13.1.2(c) not wish to incur its share of preparation, filing, prosecution and/or maintenance costs for
a patent application filed pursuant to Section 13.1.2(a) or 13.1.2(b) or patents derived therefrom, it shall (i) provide the filing Party with written notice of its wish, and
(ii) continue to offer reasonable assistance to the filing Party in connection with such prosecution or maintenance at no cost to the filing Party except for reimbursement of the
non-filing Party's reasonable out-of-pocket expenses incurred by the non-filing Party in rendering such assistance. 

        (e)   The
Parties agree to cooperate in the preparation and prosecution of all patent applications filed under Section 13.1.2(a) and 13.1.2(b), including obtaining and
executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the filing Party concerning the invention disclosed in such patent application,
obtaining execution of such other documents which shall be needed in the filing and prosecution of such patent applications, and, as requested, updating each other regarding the status of such patent
applications. 

34

 

        13.1.3    Prosecution and Maintenance of GSK Patents.    GSK shall have the exclusive right and obligation to (subject
to GSK's election not to file, prosecute or maintain pursuant to Section 13.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by
conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under
applicable Laws) and extend all GSK Patents and related applications. Consistent with Section 2.3.3, GSK will consult with Theravance within the priority period for any patent application that
is material to this Agreement concerning Countries in which corresponding applications will be filed. In the event the Parties can not agree, GSK shall make the final decision. GSK shall consult with
Theravance prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Theravance of the status of all
pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at Theravance's request, shall provide Theravance with copies of documentation
relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 2.3.3, GSK shall solicit Theravance's advice and review of the nature and
text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account Theravance's reasonable
comments relating thereto; provided that GSK shall have the final decision authority with respect to any action relating to a GSK Patent. 

        13.1.4    GSK Step-In Rights.    If Theravance elects not to file, prosecute or maintain the Theravance
Patents or claims encompassed by such Theravance Patents necessary for GSK to exercise its rights hereunder in any Country, Theravance shall give GSK notice thereof within a reasonable period prior to
allowing such Theravance Patents, or such claims encompassed by such Theravance Patents, to lapse or become abandoned or unenforceable, and GSK shall thereafter have the right, at its sole expense, to
prepare, file, prosecute and maintain such Theravance Patents in such Country. 

        13.1.5    Theravance Step-In Rights.    If GSK elects not to file, prosecute or maintain the GSK Patents
or claims encompassed by such GSK Patents necessary for Theravance to exercise its license rights hereunder in any Country, GSK shall give Theravance notice thereof within a reasonable period prior to
allowing such GSK Patents, or such claims encompassed by such GSK Patents, to lapse or become abandoned or unenforceable, and Theravance shall thereafter have the right, at its sole expense, to
prepare, file, prosecute and maintain such GSK Patents in such Country. In the event that GSK elects not to file, prosecute or maintain GSK Patents or claims that would affect the royalty owed
Theravance pursuant to Section 6.3, GSK shall reimburse Theravance for all out-of-pocket expenses incurred by Theravance in connection with Theravance exercising its
Step-In Rights under this Section. 

        13.1.6    Execution of Documents by Agents.    Each of the Parties shall execute or have executed by its appropriate
agents such documents as may be necessary to obtain, perfect or maintain any Patent Rights filed or to be filed pursuant to this Agreement, and shall cooperate with the other Party so far as
reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such Patent Rights. 

        13.1.7    Patent Term Extensions.    The Parties shall cooperate with each other in gaining patent term extension
where applicable to Collaboration Products. The Joint Steering Committee shall determine which patents the Parties shall endeavor to have extended. All filings for such extension will be made by the
Party to whom the patent is assigned after consultation with the other Party. In the event the Joint Steering Committee can not agree, the Party who is assigned the compound patent covering the LABA
in the Collaboration Product will make the decision. 

35

 

        13.2    Patent Infringement.    

        13.2.1    Infringement Claims.    With respect to any and all Claims instituted by Third Parties against Theravance or
GSK or any of their respective Affiliates for patent infringement involving the manufacture, use, license, marketing or sale of a Collaboration Product in the United States during the Term (each, a
"Patent Infringement Claim") as applicable, Theravance and GSK will assist one another and cooperate in the defense and settlement of such Patent Infringement Claims at the other Party's request. 

        13.2.2    Infringement of Theravance Patents.    In the event that Theravance or GSK becomes aware of actual or
threatened infringement of a Theravance Patent during the Term, that Party will promptly notify the other Party in writing (a "Patent Infringement Notice"). Theravance will have the right but not the
obligation to bring an infringement action against any Third Party. If Theravance elects to pursue such infringement action, Theravance shall be solely responsible for the costs and expenses
associated with such action and retain all recoveries. During the Term, in the event that Theravance does not undertake such an infringement action, upon Theravance's written consent, which shall not
be unreasonably withheld, refused, conditioned or delayed, GSK shall be permitted to do so in Theravance's or the relevant Theravance Affiliate's name and on Theravance's or the relevant Theravance
Affiliate's behalf. If Theravance has consented to an infringement action but GSK is not recognized by the applicable court or other relevant body as having the requisite standing to pursue such
action, then GSK may join Theravance as party-plaintiff. If GSK elects to pursue such infringement action, Theravance may be represented in such action by attorneys of its own choice and its own
expense with GSK taking the lead in such action. 

        13.2.3    Infringement of GSK Patents.    In the event that GSK or Theravance becomes aware of actual or threatened
infringement of a GSK Patent during the Term, that Party will promptly notify the other Party in writing. GSK will have the right but not the obligation to bring an infringement action against any
Third Party. If GSK elects to pursue such infringement action, GSK shall be solely responsible for the costs and expenses associated with such action and retain all recoveries. During the Term, in the
event that GSK does not undertake such an infringement action, upon GSK's written consent, which shall not be unreasonably withheld, refused, conditioned or delayed, Theravance shall be permitted to
do so in GSK's or the relevant GSK Affiliate's name and on GSK's or the relevant GSK Affiliate's behalf. If GSK has consented to an infringement action but Theravance is not recognized by the
applicable court or other relevant body as having the requisite standing to pursue such action, then
Theravance may join GSK as a party-plaintiff. If Theravance elects to pursue such infringement action, GSK may be represented in such action by attorneys of its own choice and at its own expense, with
Theravance taking the lead in such action. 

        13.3    Notice of Certification.    GSK and Theravance each shall immediately give notice to the other of any
certification filed under the "U.S. Drug Price Competition and Patent Term Restoration Act of 1984" (or its foreign equivalent) claiming that a GSK Patent or a Theravance Patent is invalid or that
infringement will not arise from the manufacture, use or sale of any Collaboration Product by a Third Party ("Hatch-Waxman Certification"). 

        13.3.1    Notice.    If a Party decides not to bring infringement proceedings against the entity making such a
certification, such Party shall give notice to the other Party of its decision not to bring suit within twenty-one (21) days after receipt of notice of such certification. 

        13.3.2    Option.    Such other Party then may, but is not required to, bring suit against the entity that filed the
certification. 

        13.3.3    Name of Party.    Any suit by Theravance or GSK shall either be in the name of Theravance or in the name of
GSK, (or any Affiliate) or jointly in the name of Theravance and GSK (or any Affiliate), as may be required by law. 

36

 

        13.4    Assistance.    For purposes of this Article 13, the Party not bringing suit shall execute such legal
papers necessary for the prosecution of such suit as may be reasonably requested by the Party bringing suit. The out-of-pocket costs and expenses of the Party bringing suit
shall be reimbursed first out of any damages or other monetary awards recovered in favor of GSK or Theravance. The documented out-of-pocket costs and expenses of the other
Party shall then be reimbursed out of any remaining damages or other monetary awards. The Party initiating and prosecuting the action to completion will retain any remaining damages or other monetary
awards following such reimbursements. 

        13.5    Settlement.    No settlement or consent judgment or other voluntary final disposition of a suit under this
Article may be entered into without the joint written consent of GSK and Theravance (which consent will not be withheld unreasonably). 

ARTICLE 14

TERM AND TERMINATION  

        14.1    Term and Expiration of Term.    Unless otherwise mutually agreed to by the Parties, this Agreement shall
commence on the Effective Date and shall end upon expiration of the Term, unless terminated early as contemplated hereunder. Unless terminated early under this Article 14, the licenses granted
by Theravance to GSK pursuant to Section 2.1 with respect to the Collaboration Products shall be considered fully-paid and shall become non-exclusive upon expiration of
the Term. 

        14.2    Termination for Material Breach.    Either Party may, without prejudice to any other remedies available to it
at law or in equity, terminate this Agreement subject to Section 14.10 in the event that the other Party (as used in this subsection, the "Breaching Party") shall have materially breached or
defaulted in the performance of any of its obligations. The Breaching Party shall, if such breach can be cured, have sixty (60) days after written notice thereof was provided to the Breaching
Party by the non-breaching Party to remedy such default (or, if such default cannot be cured within such 60-day period, the Breaching Party must commence and diligently
continue actions to cure such default during such 60-day period). Any such termination shall become effective at the end of such 60-day period unless the Breaching Party has
cured any such breach or default prior to the expiration of such 60-day period (or, if such default is capable of being cured but cannot be cured within such 60-day period, the
Breaching Party has commenced and diligently continued actions to cure such default provided always that, in such instance, such cure must have occurred within one hundred twenty (120) days
after written notice thereof was provided to the Breaching Party by the non-breaching Party to remedy such default). 

        14.3    GSK Right to Terminate Development of a Collaboration Product.    On a Collaboration
Product-by-Collaboration Product basis, and at any time during Development and prior to First Commercial Sale of the applicable Collaboration Product, GSK shall have the right
to terminate Development of such Collaboration Product (upon the provision of ninety (90) days written notice) for reasons of Technical Failure or Commercial Failure following communication to,
and assessment of such proposed termination by, the Joint Project Committee and Joint Steering Committee (in which case such Collaboration Product shall be referred to as a "Terminated Development
Collaboration Product"). For the avoidance of doubt, a "Terminated Development Collaboration Product" can be any of the following: (i) a Pooled Compound and/or (ii) a Replacement
Compound and/or (iii) a single agent LABA Collaboration Product and/or (iv) a LABA/ICS Combination Product and/or (v) an Other Combination Product. 

37

   
        14.4    GSK Right to Terminate Commercialization of a Collaboration Product Following First Commercial Sale.    On
a
Collaboration Product-by-Collaboration Product basis, and on a Country-by-Country basis, at any time after First Commercial Sale of the applicable
Collaboration Product in such country, GSK shall have the right to terminate Commercialization of such Collaboration Product (upon the provision of one hundred and eighty (180) days written
notice) for reasons of Commercial Failure or Technical Failure and following communication to, and assessment of such proposed termination by, the Joint Project Committee and Joint Steering Committee
(in which case, such Collaboration Product shall be referred to as a "Terminated Commercialized Collaboration Product"). For the avoidance of doubt, a Terminated Commercialized Collaboration Product
can be any of the following: (i) a single agent LABA Collaboration Product and/or (ii) a LABA/ICS Combination Product and/or (iii) an Other Combination Product. 

        14.5    Termination of the Agreement Due to Discontinuation of Development of All Collaboration Products and All Pooled
Compounds.    Any time following the [*] the Effective Date, either Party may terminate this Agreement, subject to Section 14.10, upon
the provision of ninety (90) days written notice if Development of all Collaboration Products and all Pooled Compounds have been discontinued for Technical Failure and/or Commercial Failure.
Notwithstanding the foregoing, in the event that (i) Development of all Collaboration Products and all Pooled Compounds (including any Replacement Compounds) has ceased for at least
[*], (ii) all such termination and/or discontinuance decisions have been validly approved by the Joint Steering Committee, and (iii) both parties have provided
written notice to the other that such party does not intend to contribute any additional Replacement Compounds to the collaboration, then either Party shall be entitled to terminate this Agreement,
subject to Section 14.10, upon the provision of ninety (90) days written notice. 

        14.6    Effects of Termination.    

        14.6.1    Effect of Termination for Material Breach.    

        (a)    Material Breach by Theravance.    In the event this Agreement is terminated by GSK pursuant to
Section 14.2 for material breach by Theravance, all licenses granted by Theravance to GSK under this Agreement shall survive, subject to GSK's continued obligation to pay milestones and
royalties to Theravance hereunder. In such event, GSK shall retain all of its rights to bring an action against Theravance for damages and any other available remedies in law or equity, and shall be
entitled to set-off against any monies payable to Theravance hereunder all amounts GSK reasonably believes constitute its damages incurred by such breach, subject to final judicial
resolution or settlement. Also, Theravance shall, at its sole expense, promptly transfer to GSK copies of all data,
reports, records and materials in its possession or control that relate to the Collaboration Products that contain a GSK Compound and return to GSK, or destroy at GSK's request, all relevant records
and materials in its possession or control containing Confidential Information of GSK (provided that Theravance may keep one copy of such Confidential Information of GSK for archival purposes only in
accordance with Section 10.1). 

        (b)    Material Breach By GSK.    In the event that this Agreement is terminated by Theravance pursuant to
Section 14.2 for material breach by GSK: 

	(i)
	GSK
shall [*] promptly transfer to Theravance copies of all data, reports, records and materials in its possession or control that relate to the
Theravance Compounds and return to Theravance, or destroy at Theravance's request, all relevant records and materials in its possession or control containing Confidential Information of Theravance
(provided that GSK may keep one copy of such Confidential Information of Theravance for archival purposes only in accordance with Section 10.1). 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

38

 

	(ii)
	GSK
shall [*] transfer to Theravance, or shall cause its designee(s) to transfer to Theravance, ownership of all regulatory filings made or
filed for any Collaboration Product that contains a LABA as a single agent (to the extent that any are held in GSK's or such designee(s)'s name), and such transfer to be as permitted by applicable
Laws and regulations; otherwise GSK shall cooperate as necessary to permit Theravance to exercise its rights hereunder.

	(iii)
	Theravance
shall have the non-exclusive right to access, use and cite in any regulatory filing any data relating to formulation of a LABA/ICS Combination
Product or Other Combination Product.

	(iv)
	All
of the provisions of Section [*] shall apply for the benefit of Theravance for any Collaboration Product for which
[*] at the effective date of such termination, subject to the limitations set forth in Section [*].

	(v)
	All
the provisions of Section [*] shall apply for any Collaboration Product that has been Commercialized at the effective date of such
termination.

	(vi)
	All
licenses granted by Theravance to GSK with respect to the applicable Theravance Compounds under this Agreement shall terminate.

	(vii)
	Theravance
shall retain all of its rights to bring an action against GSK for damages and any other available remedies in law or equity, and shall be entitled to
set-off against any monies payable to GSK hereunder all amounts Theravance reasonably believes constitute its damages incurred by such breach, subject to final judicial resolution or
settlement. 

        14.6.2    Effect of Termination by GSK of Certain Terminated Development Collaboration Product(s).    If GSK
terminates a Collaboration Product [*] concerning such Collaboration Product, and Development of all other Collaboration Products and Pooled Compounds have been discontinued
for Technical Failure and/or Commercial Failure, then at the sole election of Theravance, the following shall apply: 

	(a)
	GSK
shall [*] promptly transfer to Theravance copies of all data, reports, records and materials in its possession or control that relate to the Theravance
Compounds and return to Theravance, or destroy at Theravance's request, all relevant records and materials in its possession or control containing Confidential Information of Theravance (provided that
GSK may keep one copy of such Confidential Information of Theravance for archival purposes only in accordance with Section 10.1).

	(b)
	GSK
shall [*] transfer to Theravance, or shall cause its designee(s) to transfer to Theravance, ownership of all regulatory filings made or filed for the
Terminated Development Collaboration Product that contains a LABA as a single agent (to the extent that any are held in GSK's or such designee(s)'s name), such transfer to be as permitted by any Third
Party licenses or other such prior rights and applicable Laws and regulations, otherwise GSK shall cooperate as necessary to permit Theravance to exercise its rights hereunder.

	(c)
	Theravance
shall have the non-exclusive right to access, use and cite in any regulatory filing any data relating to formulation of a LABA/ICS Combination Product or Other
Combination Product.

	(d)
	For
such Terminated Development Collaboration Product (excluding the non-LABA component of a LABA/ICS Combination Product and/or Other Combination Product [*]
GSK shall grant to Theravance the appropriate licenses in the Territory under the GSK Patents, GSK Inventions and GSK Know-How related to the LABA compound, dry powder inhaler formulation,
[*] to enable Theravance to Develop and Commercialize the Terminated Development Collaboration Product in the Field. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

39

 

	(e)
	In
the event of a Change in Control of Theravance prior to termination by GSK under Section 14.3, none of the provisions under this Section 14.6.2 shall survive as they
pertain to any Collaboration Product other than [*]. 

        14.6.3    Effect of Termination by GSK of a Terminated Commercialized Collaboration Product.    The provisions of this
Section 14.6.3 shall apply only where a Terminated Commercialised Collaboration Product is not being or has not been replaced by an alternative
Collaboration Product under this Agreement and provided that, in GSK's reasonable good faith judgment, exercise by Theravance alone or with a Third Party of any of the rights or activities
contemplated by this Section 14.6.3 [*] will not materially damage GSK's continued development, regulatory or commercial use of such GSK Property. 

	(a)
	If
GSK terminates a Collaboration Product after First Commercial Sale of such Collaboration Product in one or more of the Major Market Countries, Theravance shall have the right in
its sole discretion and at its sole expense, for its own benefit or together with a Third Party, to commercialize such Terminated Commercialized Collaboration Product in any of such Major Market
Countries where it has been terminated.

	(b)
	If
GSK terminates Commercialization of a Collaboration Product in all Countries of the Territory following the first commercial sale in any Country of the Territory, Theravance shall
have the right in its sole discretion and at it sole expense, for its own benefit or together with a Third Party, to Commercialise such Terminated Commercialized Collaboration Product in the
Territory.

	(c)
	Subject
to Section 14.6.3(a), GSK shall grant to Theravance the appropriate licenses in the Territory (or in the case of a Country-by-Country termination, in the relevant Countries)
under the GSK Patents, GSK Inventions and GSK Know-How to enable Theravance by itself and/or through one or more Third Party sublicensees, to Commercialize the Terminated Commercialized Collaboration
Product. GSK shall also provide Theravance with all such information and data which GSK, or its sublicensees reasonably have available in such Country, for example access to drug master file, clinical
data and the like, and shall execute such instruments as Theravance reasonably requests, to enable Theravance to obtain the appropriate regulatory approvals to market such Terminated Commercialized
Collaboration Product in such Country and for any other lawful purpose related to Commercialization of such Terminated Commercialized Collaboration Product in such Country.

	(d)
	In
the event Theravance exercises its rights under Section 14.6.3(a) and (b) above, the Parties shall negotiate in good faith a separate commercialization and supply
agreement for such Terminated Commercialized Collaboration Product which shall ensure that, based on commercially reasonable terms (recognizing the Commercialized status of the Terminated
Commercialized Collaboration Product), Theravance has a continuous and uninterrupted supply of such Terminated Commercialized Collaboration Product, for a suitable period of time to enable Theravance
to secure Third Party supply. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

40

 

	(e)
	In
the event of a Change in Control of Theravance, prior to termination by GSK under Section 14.4, none of the provisions under this Section 14.6.3 shall survive as they
pertain to any Collaboration Product other than to a single agent LABA, its [*] formulation, [*]; and the Parties will meet in good faith to explore
other potential commercial options e.g. use of one or more Third Parties for possible continued Commercialisation of such Terminated Commercialised Collaboration Product if it is a LABA/ICS
Combination Product or Other Combination Product.

	(f)
	If
GSK, in the exercise of its reasonable good faith judgment, determines that exercise by Theravance alone or with a Third Party of any of the rights or activities contemplated by
this Section 14.6.3 will materially damage GSK's continued development, regulatory or commercial use of GSK Property, then GSK shall grant to Theravance, for such Terminated Commercialized
Collaboration Product (excluding the non-LABA component of a Combination Product and/or Other Combination Product [*]) the appropriate licenses in the Territory under the GSK
Patents, GSK Inventions and GSK Know-How related to the LABA compound, [*] formulation, [*] as applicable, to enable Theravance to Commercialize a
product containing the LABA Compound in the Field. 

        14.6.4    Effect of Termination of the Agreement Due to Discontinuation of Development Prior to First Commercial Sale of All Collaboration Products and
All Pooled Compounds.    In the event that the Agreement is terminated pursuant to Section 14.5, the following shall occur: 

        (i)    Return of Materials.    GSK shall [*] promptly transfer to Theravance copies of all
data, reports, records and materials in its possession or control that relate to the Theravance Compounds and return to Theravance, or destroy at Theravance's request, all relevant records and
materials in its possession or control containing Confidential Information of Theravance (provided that GSK may keep one copy of such Confidential Information of Theravance for archival purposes only
in accordance with Section 10.1). Theravance shall, at its sole expense, promptly transfer to GSK copies of all data, reports, records and materials in its possession or control that relate to
the GSK Compounds and return to GSK, or destroy at GSK's request, all relevant records and materials in its possession or control containing Confidential Information of GSK (provided that Theravance
may keep one copy of such Confidential Information of GSK for archival purposes only in accordance with Section 10.1). 

        (ii)    Transfer of Regulatory Filings.    GSK shall [*] transfer to Theravance, or shall
cause its designee(s) to transfer to Theravance, ownership of all regulatory filings made or filed for any Terminated Development Collaboration Product (to the extent that any are held in GSK's or
such designee(s)'s name), but only where [*] and such transfer to be as permitted by applicable Laws and regulations. GSK, at its sole discretion, shall also give due
consideration to transferring to Theravance any additional regulatory filings for a Terminated Development Collaboration Product which contains a [*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

41

 

        (iii)    License Rights.    All licenses granted by Theravance to GSK with respect to the Collaboration Products under
this Agreement shall terminate. 

        (iv)    Stock Return.    GSK shall return to Theravance all available formulated and API stocks that contain a
Theravance Compound and which are then held by GSK or cause such API stocks to be provided to Theravance if held by a vendor or other Third Party on behalf of GSK. 

        (v)    Limitations on Further Development by GSK.    GSK shall not be permitted to continue or re-initiate
clinical Development of any GSK Compound that is both a Terminated Collaboration Product and a LABA in the Field for a period of [*] after the date of such termination. 

        14.7    License Rights.    Except as otherwise provided herein in, all licenses granted hereunder relating to
Terminated Collaboration Products shall terminate. Also the Parties accept that nothing provided for in this Article 14 or elsewhere in this Agreement, grants any licenses (whether exclusive,
semi-exclusive or otherwise) from GSK to Theravance for any (i) GSK Compound (ii) GSK Invention (ii) GSK Know How and (iv) GSK Patents, except for those rights
essential and specific to enable Theravance to exercise those rights and carry out those activities contemplated under Section 14.6 above. 

        14.8    Milestone Payments.    Neither Party shall be obligated to make a Development Milestone payment under
Section 6.2 which is triggered by an event occurring after the effective date of termination of this Agreement with respect to a Collaboration Product. 

        14.9    Subsequent Royalties.    If after termination of this Agreement either Party subsequently Develops and
Commercializes any [*] for the treatment / prophylaxis of respiratory diseases which (i) was [*] or (ii) was a
[*], it will pay to the other Party a royalty on Net Sales of any such products at the rate of [*] for a single-agent product and
[*] for the first combination product for a period of [*] from the date of launch on a Country-by-Country basis; provided,
however, that this royalty shall not apply to any compound or product (including new product line extensions and/or
re-formulation work) where the original compound or product is, as of the date of signature of this Agreement, already Commercialized. 

        14.10    Accrued Rights; Surviving Obligations.    Termination, relinquishment or expiration of this Agreement for any
reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or
expiration shall not relieve any Party from obligations which are expressly or by implication intended to survive termination, relinquishment or expiration of this Agreement, including without
limitation Article 10, and shall not affect or prejudice any provision of this Agreement which is expressly or by implication provided to come into effect on, or continue in effect after, such
termination, relinquishment or expiration. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

42

 
ARTICLE 15

LIMITATIONS RELATING TO THERAVANCE EQUITY SECURITIES  

        15.1    Purchases of Equity Securities.    So long as this Agreement remains in effect and for a period of
[*] thereafter, except as permitted by Section 15.2, or as otherwise agreed in writing by Theravance, GSK and its Affiliates will not (and will not assist or encourage
others to) directly or indirectly in any manner: 

        15.1.1    acquire,
or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, gift or otherwise, any direct or indirect beneficial ownership
(within the meaning of Rule l3d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) or interest in any securities or direct or indirect rights, warrants or
options to acquire, or securities convertible into or exchangeable for, any securities of Theravance; 

        15.1.2    make,
or in any way participate in, directly or indirectly, alone or in concert with others, any "solicitation" of "proxies" to vote (as such terms are used in the
proxy rules of the Securities and Exchange Commission (the "SEC") promulgated pursuant to Section 14 of the Exchange Act);
provided, however, that the prohibition in this Section 15.1.2 shall not apply to solicitations exempted from the proxy solicitation rules by Rule 14a-2 under the Exchange
Act as such Rule 14a-2 is in effect as of the date hereof; 

        15.1.3    form,
join or in any way participate in a "group" within the meaning of Section 13(d)(3) of the Exchange Act with respect to any voting securities of
Theravance; 

        15.1.4    acquire
or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, exchange or otherwise, (i) any of the assets, tangible or
intangible, of Theravance or (ii) direct or indirect rights, warrants or options to acquire any assets of Theravance, except for such assets as are then being offered for sale by Theravance; 

        15.1.5    enter
into any arrangement or understanding with others to do any of the actions restricted or prohibited under Sections 15.1.1, 15.1.2, 15.1.3, or 15.1.4. 

        15.1.6    otherwise
act in concert with others, to seek to offer to Theravance or any of its stockholders any business combination, restructuring, recapitalization or similar
transaction to or with Theravance or otherwise seek in concert with others, to control, change or influence the management, board of directors or policies of Theravance or nominate any person as a
director of Theravance who is not nominated by the then incumbent directors, or propose any matter to be voted upon by the stockholders of Theravance. 

        15.2    Exceptions for Purchasing Securities of Theravance.    Nothing herein shall prevent GSK or its Affiliates (or
in the case of Section 15.2.4, their employees) from: 

        15.2.1    purchasing
the Series E Preferred Stock of Theravance on the Effective Date as contemplated herein. 

        15.2.2    purchasing
additional equity securities of Theravance after the Effective Date if after such purchase GSK and its Affiliates would own in the aggregate no greater
percent of the total voting power of all voting securities of Theravance then outstanding than GSK together with its Affiliates owned immediately after purchase of the Series E Preferred Stock
on the Effective Date. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

43

 

        15.2.3    acquiring
securities of Theravance issued in connection with stock splits or recapitalizations or on exercise of pre-emptive rights afforded to Theravance
stockholders generally. 

        15.2.4    purchasing
securities of Theravance pursuant to (i) a pension plan established for the benefit of GSK's employees, (ii) any employee benefit plan of
GSK, (iii) any stock portfolios not controlled by GSK or any of its Affiliates that invest in Theravance among other companies, or (iv) following an initial public offering of Theravance
common stock, for the account of a GSK employee in such employee's personal capacity. 

        15.2.5    acquiring
securities of another biotechnology or pharmaceutical company that beneficially owns any of Theravance's securities. 

        15.2.6    acquiring
equity securities of Theravance without any limitation following initiation by a third party of an unsolicited tender offer to purchase
[*] or more of any class or service of Theravance's publicly traded voting securities (a "Hostile Tender Offer"); provided that the exception provided by this
Section 15.2.6 shall be limited to the classes or series of Theravance's securities that are the subject of the Hostile Tender Offer; provided, further, that, in the event that either
(a) such Hostile Tender Offer is terminated or expires without the purchase of at least [*] of any class or series of Theravance's publicly traded voting securities by
such third party, or (b) the Theravance Board of Directors subsequently recommends that such offer be accepted, then following the date of such termination, expiration or recommendation the
acquisitions by GSK and/or its Affiliates under this Section 15.2.6 prior to the events described in clauses (a) and (b) above shall not be considered a breach by GSK of the
provisions of Section 15.2 as long as GSK, at its option, either: 

          (i)  divests
(or cause to be divested) in one or more open-market transactions such number of shares of Theravance's securities acquired by it and its Affiliates
pursuant to this Section 15.2.6 such that after such divestiture GSK and its Affiliates would own in the aggregate no greater percent of the total voting power of all voting securities of
Theravance then outstanding than GSK together with its Affiliates owned immediately prior to the commencement of such Hostile Tender Offer, any such divestiture to be completed as expeditiously as
possible consistent with applicable securities laws and regulations and in a manner intended to shield GSK and its Affiliates from liability for recovery of short swing profits under Section 16
of the Exchange Act and the rules promulgated thereunder; or 

         (ii)  enters
into a voting agreement, proxy or similar arrangement pursuant to which (A) all Theravance voting securities acquired pursuant to this
Section 15.2.6 are voted on all matters to be voted on by
holders of Theravance voting securities, including, but not limited to, in favor of any transaction involving a proposed Change in Control (as defined below) of Theravance in the same proportion as
the outstanding Theravance voting securities not held by GSK or any GSK Affiliate are voted, (B) no Theravance voting securities beneficially owned by GSK and/or any Affiliate abstain from such
a vote, and (C) no dissenter or appraisal or similar rights are exercised with respect to any vote relating to a Change in Control of Theravance. 

        15.3    Voting.    Until the date of an initial public offering of Theravance common stock, GSK shall ensure that all
outstanding Theravance voting securities beneficially owned by GSK and/or any GSK Affiliate are voted for management's nominees to the Board of Directors of Theravance to the extent not inconsistent
with Section 2.8 of the Investors' Rights Agreement. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

44

 

        15.4    Theravance Voting Securities Transfer Restrictions.    

        15.4.1    So
long as this Agreement remains in effect and for a period of one (1) year thereafter, neither GSK nor any of its Affiliates shall dispose of beneficial
ownership of Theravance voting securities except (i) pursuant to a bona fide public offering registered under the Securities Act of either Theravance voting securities or securities
exchangeable or exercisable for Theravance voting securities (in which the securities are broadly distributed and GSK does not select the purchasers); or (ii) pursuant to Rule 144 under
the Securities Act (provided that if Rule 144(k) is available, such transfer nevertheless is within the volume limits and manner of sale requirements applicable to non-144(k)
transfers under Rule 144); or (iii) in transactions that to the knowledge of GSK do not, directly or indirectly, result in any person or group owning or having the right to acquire or
intent to acquire beneficial ownership of Theravance voting securities with aggregate voting power of five percent or more of the aggregate voting power of all outstanding Theravance voting
securities. 

        15.4.2    Notwithstanding
the foregoing, the restrictions on disposition under Section 15.4.1 shall not apply if, as a result of such disposition, (A) no filing
by any Person (including, but not limited to GSK or any of its Affiliates) shall be required under any Law (including but not limited to the Exchange Act) that would identify GSK or any of its
Affiliates as the seller of the securities, and (B) neither GSK nor any of its Affiliates (or any transferee thereof) would be required by Law (including without limitation the disclosure
requirements of the Securities Act of 1933, as amended (the "Securities Act"), and the Exchange Act) to make any public announcement of the transfer or disposition. 

        15.4.3    So
long as this Agreement remains in effect and for a period of one (1) year thereafter, neither GSK nor any of its Affiliates may make any public disclosure
of any holdings of or disposition of beneficial ownership of Theravance voting securities unless such disclosure is approved in advance in writing by Theravance, such approval not to be unreasonably
withheld or delayed. Notwithstanding the foregoing, no consent of Theravance shall be required for any filing that GSK or any of its Affiliates is required to make under applicable Law in any
jurisdiction, including without limitation any Form 144 under the Securities Act, any Form 4 under the Exchange Act, or any Schedule 13D or 13G or any amendments thereto under the
Exchange Act; provided that, prior to making any such filings, GSK shall use reasonable efforts to (i) to provide Theravance notice and a copy of such proposed filings and (ii) consult
with Theravance on the content of such filings. 

        15.5    Termination of Purchase Restrictions.    The limitations on purchase of equity securities set forth in
Section 15.1 shall terminate immediately upon a transaction or series of related transactions following a Change in Control of Theravance. 

ARTICLE 16

MISCELLANEOUS  

        16.1    Relationship of the Parties.    Each Party shall bear its own costs incurred in the performance of its
obligations hereunder without charge or expense to the other except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of
the other Party's employees or for any employee benefits of such employee. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement for
any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without said Party's approval. For all purposes, and notwithstanding any other
provision of this Agreement to the contrary, GSK's legal relationship under this Agreement to Theravance shall be that of independent contractor. This Agreement is not a partnership agreement and
nothing in this 

45

 

Agreement
shall be construed to establish a relationship of co-partners or joint venturers between the Parties. 

        16.2    Registration and Filing of This Agreement.    To the extent, if any, that either Party concludes in good faith
that it or the other Party is required to file or register this Agreement or a notification thereof with any Governmental Authority, including without limitation the U.S. Securities and Exchange
Commission, the Competition Directorate of the Commission of the European Communities or the U.S. Federal Trade Commission, in accordance with Law, such Party shall inform the other Party thereof.
Should both Parties jointly agree that either of them is required to submit or obtain any such
filing, registration or notification, they shall cooperate, each at its own expense, in such filing, registration or notification and shall execute all documents reasonably required in connection
therewith. In such filing, registration or notification, the Parties shall request confidential treatment of sensitive provisions of this Agreement, to the extent permitted by Law. The Parties shall
promptly inform each other as to the activities or inquiries of any such Governmental Authority relating to this Agreement, and shall reasonably cooperate to respond to any request for further
information there from on a timely basis. 

        16.3    Force Majeure.    The occurrence of an event which materially interferes with the ability of a Party to
perform its obligations or duties hereunder which is not within the reasonable control of the Party affected or any of its Affiliates, not due to malfeasance by such Party or its Affiliates, and which
could not with the exercise of due diligence have been avoided (each, a "Force Majeure Event"), including, but not limited to, an injunction, order or action by a Governmental Authority, fire,
accident, labor difficulty, strike, riot, civil commotion, act of God, inability to obtain raw materials, delay or errors by shipping companies or change in law, shall not excuse such Party from the
performance of its obligations or duties under this Agreement, but shall merely suspend such performance during the continuation of the Force Majeure. The Party prevented from performing its
obligations or duties because of a Force Majeure Event shall promptly notify the other Party of the occurrence and particulars of such Force Majeure and shall provide the other Party, from time to
time, with its best estimate of the duration of such Force Majeure Event and with notice of the termination thereof. The Party so affected shall use Diligent Efforts to avoid or remove such causes of
nonperformance as soon as is reasonably practicable. Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. The Party subject to
the Force Majeure Event shall not be liable to the other Party for any direct, indirect, consequential, incidental, special, punitive, exemplary or other damages arising out of or relating to the
suspension or termination of any of its obligations or duties under this Agreement by reason of the occurrence of a Force Majeure Event, provided such Party complies in all material respects with its
obligations under this Section 16.3. 

        16.4    Governing Law.    This Agreement shall be construed, and the respective rights of the Parties determined,
according to the substantive law of the State of Delaware notwithstanding the provisions governing conflict of laws under such Delaware law to the contrary, except matters of intellectual property law
which shall be determined in accordance with the intellectual property laws relevant to the intellectual property in question. 

        16.5    Attorneys' Fees and Related Costs.    In the event that any legal proceeding is brought to enforce or
interpret any of the provisions of this Agreement, the prevailing party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses of litigation whether or not the action or
proceeding proceeds to final judgment. 

        16.6    Assignment.    This Agreement may not be assigned by either Party without the prior written consent of the
other Party; provided, however that either Party may assign this Agreement, in whole or in part, to any of its Affiliates if such Party guarantees the performance of this Agreement by such Affiliate;
and provided further that either Party may assign this Agreement to a successor to all or substantially all of the assets of such Party whether by merger, sale of stock, sale of assets or other
similar transaction. This Agreement shall be binding upon, and subject to the terms of the foregoing sentence, inure to the benefit of the Parties hereto, their permitted successors, legal
representatives and assigns. 

46

  

        16.7    Notices.    All demands, notices, consents, approvals, reports, requests and other communications hereunder
must be in writing and will be deemed to have been duly given only if delivered personally, by facsimile with confirmation of receipt, by mail (first class, postage prepaid), or by overnight delivery
using a globally-recognized carrier, to the Parties at the following addresses: 

	Theravance:	 	Theravance, Inc.

901 Gateway Boulevard

South San Francisco, CA 94080

Facsimile: 650-827-8683

Attn: Senior Vice President, Commercial Development
	

GSK:	
 	

Glaxo Group Limited

Glaxo Wellcome House

Berkeley Avenue

Greenford

Middlesex UB6 0NN

United Kingdom

Attn: Company Secretary

Facsimile: 011 44 208-047-6912
	

With a copy to:	
 	

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Attn: Corporate Law

Facsimile: 011 44 208-047-6912
	

and with a copy to:	
 	

Brentford

Middlesex

TW8 9GS

United Kingdom

Attn: Vice President, Worldwide Business Development

Facsimile: 011 44 208-990-8142

or
to such other address as the addressee shall have last furnished in writing in accord with this provision to the addressor. All notices shall be deemed effective upon receipt by the addressee. 

        16.8    Severability.    In the event of the invalidity of any provisions of this Agreement or if this Agreement
contains any gaps, the Parties agree that such invalidity or gap shall not affect the validity of the remaining provisions of this Agreement. The Parties will replace an invalid provision or fill any
gap with valid provisions which most closely approximate the purpose and economic effect of the invalid provision or, in case of a gap, the Parties' presumed intentions. In the event that the terms
and conditions of this Agreement are materially altered as a result of the preceding sentences, the Parties shall renegotiate the terms and conditions of this Agreement in order to resolve any
inequities. Nothing in this Agreement shall be interpreted so as to require either Party to violate any applicable laws, rules or regulations. 

        16.9    Headings.    The headings used in this Agreement have been inserted for convenience of reference only and do
not define or limit the provisions hereof. 

        16.10    Waiver.    Any term or condition of this Agreement may be waived at any time by the Party that is entitled to
the benefit thereof, but no such waiver shall be effective unless set forth in a written 

47

 

instrument
duly executed by or on behalf of the Party waiving such term or condition. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed
to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. Except as expressly set forth in this Agreement, all rights and remedies available
to a Party, whether under this Agreement or afforded by law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. 

        16.11    Entire Agreement.    This Agreement (including the exhibits and schedules hereto) constitutes the entire
agreement between the Parties hereto with respect to the within subject matter and supersedes all previous agreements and understandings between the Parties, whether written or oral. This Agreement
may be altered, amended or changed only by a writing making specific reference to this Agreement and signed by duly authorized representatives of Theravance and GSK. 

        16.12    No License.    Nothing in this Agreement shall be deemed to constitute the grant of any license or other
right in either Party, to or in respect of any Collaboration Product, patent, trademark, Confidential Information, trade secret or other data or any other intellectual property of the other Party,
except as expressly set forth herein. 

        16.13    Third Party Beneficiaries.    None of the provisions of this Agreement shall be for the benefit of or
enforceable by any Third Party, including without limitation any creditor of either Party hereto. No such Third Party shall obtain any right under any provision of this Agreement or shall by reasons
of any such provision make any Claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto. 

        16.14    Counterparts.    This Agreement may be executed in any two counterparts, each of which, when executed, shall
be deemed to be an original and both of which together shall constitute one and the same document. 

        16.15    Single Closing Condition.    The obligation of each Party to consummate the transaction contemplated hereby
is subject to the satisfaction of the following condition (the "Closing Condition"): All filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and any other similar
competition or merger control laws that are necessary in any jurisdiction with respect to the transaction contemplated hereby shall have been made and any required waiting period under such laws shall
have expired or been terminated and any Governmental Authority that has power under or authority to enforce such laws shall have, if applicable, approved, cleared or decided neither to initiate
proceedings or otherwise intervene in respect of the transaction contemplated hereby nor to refer the transaction to any other competent Governmental Authority. Each Party shall use good faith efforts
to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other party in doing, all things necessary, proper or advisable to consummate and make
effective the transaction contemplated by this Agreement, including, but not limited to satisfaction of the Closing Condition and each Party shall keep the other Party reasonably apprised of the
status of matters relating to the completion of same. In connection with the foregoing, the Parties hereby agree to negotiate in good faith to make as soon as practicable any modification or amendment
to this Agreement or any agreement related hereto that is required by the United States Federal Trade Commission, Department of Justice or equivalent Governmental Authority, provided that no Party
shall be required to agree to any modification or amendment that, in the reasonable opinion of such Party's external legal or financial counsel, would be adverse to such Party. This Agreement may be
terminated by either Party upon written notice any time after June 1, 2003 if the transactions contemplated by this Agreement shall not have been consummated by June 1, 2003 due to
failure to satisfy the Closing Condition; provided, however, that the terminating Party shall not have breached in any material respect its obligations under this Agreement in any manner that shall
have been the proximate cause of, or resulted in, the failure to satisfy the Closing Condition or otherwise to consummate the transactions contemplated by this Agreement by such date. 

48

 

        IN
WITNESS WHEREOF, Theravance and GSK, by their duly authorized officers, have executed this Agreement on November 14, 2002. 

	THERAVANCE, INC.	 	GLAXO GROUP LIMITED
	

By:	
 	

/s/  RICK E WINNINGHAM      
 Rick E Winningham

Chief Executive Officer	
 	

By:	
 	

/s/  JEAN-PIERRE GARNIER      
 Jean-Pierre Garnier

Chief Executive Officer

49

 
 
 

Schedule 1.19    
    
    Criteria for Theravance New Compounds and Replacement Compounds    
    

	1.
	[*],
patentable.

	2.
	Potency
[*].

	3.
	[*]
activity [*].

	4.
	Selectivity
[*].

	5.
	Selectivity
at [*].

	6.
	No
significant inhibition of [*].

	7.
	Duration
of agonist activity [*].

	8.
	Stable
compound, [*].

	9.
	Oral
bioavailability [*].

	10.
	No
significant generation [*].

	11.
	Irritation
[*]. 

[*]=CERTAIN
INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

50

 
 
 

Schedule 6.1.2    
    
    Preferred Stock Purchase Agreement    
    

51

 
 

THERAVANCE, INC.    
    
    SERIES E PREFERRED    
    
    STOCK PURCHASE AGREEMENT    
    
    December 19, 2002    
    

 
 
 

TABLE OF CONTENTS    
    

	 
	 	Page

	1. Purchase and Sale or Stock	 	1
	 	1.1 Sale and Issuance of Series E Preferred Stock	 	1
	 	1.2 Closing	 	1
	

2. Representations and Warranties of the Company	
 	

1
	 	2.1 Organization, Good Standing and Qualification	 	1
	 	2.2 Capitalization and Voting Rights	 	2
	 	2.3 Subsidiaries	 	2
	 	2.4 Authorization	 	3
	 	2.5 Valid issuance of Preferred and Common Stock	 	3
	 	2.6 Governmental Consents	 	3
	 	2.7 Offering	 	3
	 	2.8 Litigation	 	3
	 	2.9 Patents and Trademarks	 	4
	 	2.10 Compliance with Other Instruments	 	4
	 	2.11 Agreements; Action	 	5
	 	2.12 Related Party Transactions	 	5
	 	2.13 Permits	 	6
	 	2.14 Disclosure	 	6
	 	2.15 Corporate Documents	 	6
	 	2.16 Title to Property and Assets	 	6
	 	2.17 Tax Returns, Payments and Elections	 	6
	 	2.18 Environmental Law	 	6
	 	2.19 Proprietary Information and Employment Agreements	 	6
	 	2.20 Financial Statements	 	6
	 	2.21 Changes	 	7
	 	2.22 Registration Rights	 	8
	 	2.23 Real Property Holding Corporation	 	8
	 	2.24 Labor Agreements	 	8
	 	2.25 Insurance	 	8
	

3. Representations and Warranties of the Investor	
 	

8
	 	3.1 Authorization	 	8
	 	3.2 Purchase Entirely for Own Account	 	8
	 	3.3 Disclosure of Information	 	8
	 	3.4 Investment Experience	 	8
	 	3.5 Accredited Investor	 	9
	 	3.6 Restricted Securities	 	9
	 	3.7 Further Limitations on Disposition	 	9
	 	3.8 Legends	 	9
	

4. Conditions of Investor's Obligations at Closing	
 	

10
	 	4.1 Representations and Warranties	 	10
	 	4.2 Performance	 	10
	 	4.3 Compliance Certificate	 	10
	 	4.4 Qualifications	 	10
	 	4.5 Proceedings and Documents	 	10
	 	4.6 Opinion of Company Counsel	 	10
	 	4.7 Investors' Rights Agreement	 	10
	 	 	 

i

 

	 	4.8 Filing of the Restated Certificate	 	10
	 	4.9 HSR Act	 	10
	

5. Conditions of the Company's Obligations at Closing	
 	

10
	 	5.1 Representations and Warranties	 	10
	 	5.2 Qualifications	 	10
	 	5.3 Investors' Rights Agreement	 	11
	 	5.4 HSR Act	 	11
	

6. Miscellaneous	
 	

11
	 	6.1 Survival of Warranties	 	11
	 	6.2 Successors and Assigns	 	11
	 	6.3 Governing Law	 	11
	 	6.4 Counterparts	 	11
	 	6.5 Titles and Subtitles	 	11
	 	6.6 Notices	 	11
	 	6.7 Finder's Fee	 	11
	 	6.8 Expenses	 	12
	 	6.9 Amendments and Waivers	 	12
	 	6.10 Severability	 	12
	 	6.11 Confidentiality	 	12
	 	6.12 Publicity	 	12
	 	6.13 Entire Agreement	 	13
	 	6.14 Waiver of Conflicts	 	13

	

SCHEDULE A	
 	

Schedule of Exceptions	
 	

 
	

EXHIBIT A	
 	

Restated Certificate of Incorporation	
 	

 
	EXHIBIT B	 	Amended and Restated Investors' Rights Agreement	 	 
	EXHIBIT C	 	Opinion of Counsel for the Company	 	 

ii

 
 

THERAVANCE, INC.    
    
    SERIES E PREFERRED STOCK PURCHASE AGREEMENT    
    

        THIS STOCK PURCHASE AGREEMENT is made as of the 19th day of December, 2002, by and among Theravance, Inc., a Delaware corporation (the "Company"), and
Glaxo Group Limited, a limited liability company organized under the laws of England and Wales (the "Investor"). 

        THE
PARTIES HEREBY AGREE AS FOLLOWS: 

        1.    Purchase and Sale of Stock.    

        1.1    Sale and Issuance of Series E Preferred Stock.    

        (a)   The
Company shall adopt and file with the Secretary of State Delaware on or before the Closing (as defined below) the Restated Certificate of Incorporation in the form
attached hereto as Exhibit A (the "Restated Certificate"). 

        (b)   On
or prior to the Closing (as defined below), the Company shall have authorized (i) the sale and issuance pursuant to this Agreement of up to an aggregate of
4,000,000 shares at a price of $10.00 per share of its Series E Preferred Stock and (ii) the issuance of the same number of shares of its Common Stock to be issued upon conversion of the
Series E Preferred Stock (the "Conversion Shares"). The Series E Preferred Stock and the Conversion Shares shall have the rights, preferences, privileges and restrictions set forth in
the Restated Certificate. 

        (c)   Subject
to the terms and conditions of this Agreement, the Investor agrees, severally and not jointly, to purchase at the Closing and the Company agrees to sell and
issue to the Investor at the Closing, 4,000,000 shares of the Company's Series E Preferred Stock for an aggregate purchase price of $40,000,000. 

        1.2    Closing.    The purchase and sale of the Series E Preferred Stock shall take place at the offices of
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, 610 Lincoln Street, Waltham, MA 02451, at 10:00 A.M., on the date all conditions to closing set forth in Sections 4 and 5
have been satisfied or effectively waived, or at such other time and place as the Company and Investor mutually agree upon orally or in writing (which time and place are designated as the "Closing").
At the Closing the Company shall deliver to the Investor a certificate representing the Series E Preferred Stock that the Investor is purchasing against payment of the purchase price therefor
by check or wire transfer, or any combination thereof. 

        2.    Representations and Warranties of the Company.    The Company hereby represents and warrants to the Investor
that, except as set forth on a Schedule of Exceptions (the "Schedule of Exceptions") furnished to the Investor, which exceptions shall be deemed to be representations and warranties as if made
hereunder: 

        2.1    Organization, Good Standing and Qualification.    The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to (i) execute, deliver and perform its obligations under this Agreement and the
Amended and Restated Investors' Rights Agreement dated of even date herewith, by and among the Company and the Investors, the form of which is attached hereto as  Exhibit B (the "Investors' Rights
Agreement"), (ii) to issue and sell the Series E Preferred Stock hereunder, (iii) to issue
the Conversion Shares in accordance with the Restated Certificate, (iv) to perform its obligations under the Restated Certificate, and (v) to carry on its business as now conducted and
as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on
its business or properties. 

 

        2.2    Capitalization and Voting Rights.    The authorized capital of the Company will consist immediately prior to
the Closing, of: 

        (a)    Preferred Stock.    50,000,000 shares of Preferred Stock (the "Preferred Stock"), of which (i) 5,020,000
shares have been designated Series A Preferred Stock (the "Series A Preferred Stock"), 4,988,000 of which are outstanding; (ii) 5,100,000 shares have been designated
Series B Preferred Stock (the "Series B Preferred Stock"), 5,074,000 of which are outstanding; (iii) 18,823,000 shares have been designated Series C Preferred Stock (the
"Series C Preferred Stock"), 18,745,166 of which are outstanding; (iv) 1,666,666 shares have been designated Series D Preferred Stock (the "Series D Preferred Stock"),
1,666,666 of which are outstanding (which are initially convertible into 2,777,777 shares of Common Stock); (v) 13,888,889 shares have been designated Series D-1 Preferred
Stock (the
"Series D-1 Preferred Stock"), 13,169,905 of which are outstanding; and (vi) 4,000,000 shares have been designated Series E Preferred Stock (the "Series E
Preferred Stock"), none of which will be outstanding prior to the Closing, and up to all of which may be sold pursuant to this Agreement. The rights, privileges and preferences of the Preferred Stock
will be as stated in the Company's Restated Certificate. 

        (b)    Common Stock.    120,000,000 shares of common stock, par value $0.01 ("Common Stock"), of which 11,158,392
shares are issued and outstanding. 

        (c)   The
outstanding shares of Common Stock and Preferred Stock are all duly and validly authorized and issued, fully paid and nonassessable, and were issued in accordance
with the registration or qualification provisions of the Securities Act of 1933, as amended (the "Act") and any relevant state securities laws, or pursuant to valid exemptions therefrom. 

        (d)   Except
for (A) the conversion privileges of the Preferred Stock, (B) the rights provided in Section 2.5 of the Investors' Rights Agreement,
(C) currently outstanding warrants to purchase 4,000 shares of Series A Preferred Stock, (D) currently outstanding warrants to purchase 4,000 shares of Series B Preferred
Stock, (E) currently outstanding warrants to purchase 45,000 shares of Series C Preferred Stock, (F) a currently outstanding warrant to purchase 48,611 shares of
Series D-1 Preferred Stock, and (G) currently outstanding options to purchase 7,187,436 shares of Common Stock granted to employees, directors, board members, consultants and
service providers, there are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the Company of any shares of
its capital stock. In addition to the aforementioned options, the Company has reserved an additional 969,493 shares of its Common Stock for issuance upon exercise of options to be granted in the
future under the Company's 1997 Stock Plan. Except for the provisions of the Restated Certificate, the Investors' Rights Agreement and of that certain Amended and Restated Stockholders' Voting
Agreement dated as of January 25, 1999 by and among the Company and the other parties listed therein, the Company is not a party or subject to any agreement or understanding, and, to the best
of the Company's knowledge, there is no agreement or understanding between any persons and/or entities, which affects or relates to the voting or giving of written consents with respect to any
security or by a director of the Company. No stock plan, stock purchase, stock option or other agreement or understanding between the Company and any holder of any equity securities or rights to
purchase equity securities provides for acceleration or other changes in the vesting provisions of such agreement or understanding as the result of any merger, consolidated sale of stock or assets,
change in control or any other similar transaction(s) by the Company. 

        2.3    Subsidiaries.    The Company does not presently own or control, directly or indirectly, any interest in any
other corporation, association or other business entity, other than Theravance East, Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company. The Company is not a
participant in any joint venture, partnership, or similar arrangement. 

2

 

        2.4    Authorization.    All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement and the Investors' Rights Agreement (collectively, the "Transaction Documents"), the performance of all obligations of the
Company hereunder and thereunder, and the authorization, issuance (or reservation for issuance), sale and delivery of the Series E Preferred Stock being sold hereunder and the Common Stock
issuable upon conversion of the Series E Preferred Stock has been taken or will be taken prior to the Closing, and the Transaction Documents constitute valid and legally binding obligations of
the Company, enforceable in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application
affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, and
(iii) to the extent the indemnification provisions contained in the Investors' Rights Agreement may be limited by applicable federal or state securities laws. 

        2.5    Valid Issuance of Preferred and Common Stock.    The Series E Preferred Stock that is being purchased by
the Investor hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid, and
nonassessable, and will be free of restrictions on transfer other than restrictions on transfer under the Transaction Documents and under applicable state and federal securities laws. The Common Stock
issuable upon conversion of the Series E Preferred Stock purchased under this Agreement has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the
Restated Certificate, will be duly and validly issued, fully paid, and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under the Transaction Documents
and under applicable state and federal securities laws. The Series E Preferred Stock that is being purchased by the Investor hereunder, and the Common Stock issuable upon conversion of such
Series E Preferred Stock is not subject to preemptive rights or rights of first refusal that have not been waived or complied with. The outstanding Series A, Series B,
Series C, Series D and Series D-1 Preferred Stock was duly and validly issued, fully paid, and is nonassessable. The Common Stock issuable upon conversion of the
outstanding Series A, Series B, Series C, Series D and Series D-1 Preferred Stock has been duly and validly reserved for issuance and, upon issuance in
accordance with the terms of the Restated Certificate, will be duly and validly issued, fully paid, and nonassessable and will be free of restrictions on transfer other than restrictions on transfer
under the documents executed in connection with the sale of the Series A, Series B, Series C, Series D and Series D-1 Preferred Stock and under
applicable state and federal securities laws. The outstanding Series A, Series B, Series C, Series D and Series D-1 Preferred Stock and the Common Stock
issuable upon conversion of such Preferred Stock is not subject to preemptive rights or rights of first refusal that have not been waived or complied with. 

        2.6    Governmental Consents.    No consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated
by this Agreement, except (i) a filing under the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), (ii) the filing of the Restated Certificate with the
Secretary of State of Delaware; and (iii) certain post-closing filings as may be required pursuant to federal securities laws and under the "Blue Sky" laws of the various states. 

        2.7    Offering.    Subject in part to the truth and accuracy of the Investor's representations set forth in
Section 3 of this Agreement, the offer, sale and issuance of the Series E Preferred Stock and the Conversion Shares as contemplated by this Agreement are exempt from the registration
requirements of any applicable state and federal securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such
exemption. 

        2.8    Litigation.    There is no action, suit, proceeding or investigation pending or, to the Company's knowledge,
currently threatened against the Company that questions the validity of the Transaction 

3

 

Documents,
or the right of the Company to enter into such agreements, or to consummate the transactions contemplated hereby or thereby, or if determined adversely, might result, either individually or
in the aggregate, in (i) any material adverse changes in the assets or business of the Company, financially or otherwise or (ii) any change in the current equity ownership of the
Company, nor is the Company aware that there is any basis for the foregoing. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate. 

        2.9    Patents and Trademarks.    The Company owns, or has rights to use pursuant to a valid license, all patents,
trademarks, service marks, trade names, copyrights, trade secrets, information, proprietary rights and processes necessary for its business as now conducted. There are no outstanding options, licenses
or agreements of any kind relating to the foregoing proprietary rights, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other person or entity other than such licenses or agreements
arising from the purchase of "off the shelf" or standard products. The use, modification, licensing, sublicensing, sale, or any other exercise of rights involving such intellectual property does not
infringe any copyright, trade secret, trademark, service mark, trade name, firm name, logo, trade dress, mask work, moral right, other intellectual property right, right of privacy or right in
personal data, or to the knowledge of the Company, any patent, of any person. No claims (i) challenging the validity, effectiveness, or ownership by the Company of any of the Company's
intellectual property, or (ii) to the effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale or any other exercise of rights in any product,
work, technology, service or process as used, provided or offered at any time, or as proposed for use, reproduction, modification, distribution, licensing, sublicensing, sale or any other exercise of
rights, by the Company infringes or will infringe on any intellectual property or other proprietary or personal right of any person have been asserted or, to the knowledge of the Company,
(A) are threatened by any person nor (B) are there any valid grounds for any bona fide claim of any such kind. To the knowledge of the Company, there is no unauthorized use, infringement
or misappropriation of any of the Company's intellectual property by any third party, employee or former employee. The Company's employees are not obligated under any contract (including licenses,
covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of his or her best
efforts to promote the interests of the Company or that would conflict with the Company's business as proposed to be conducted. Neither the execution nor delivery of the Transaction Documents, nor the
carrying on of the Company's business by the employees of the Company, nor the conduct of the Company's business as proposed, will, to the best of the Company's knowledge, conflict
with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such employees is now obligated. The
Company does not believe it is or will be necessary to utilize any inventions of any of its employees made prior to their employment by the Company unless such inventions are properly assigned to the
Company. 

        2.10    Compliance with Other Instruments.    The Company is not in violation or default in any material respect of
any provision of its Restated Certificate or Bylaws, or in any material respect of any instrument, judgment, order, writ, decree or contract to which it is a party or by which it is bound, or, to the
best of its knowledge, of any provision of any statute, rule or regulation applicable to the Company. The execution, delivery and performance of the Transaction Documents, and the consummation of the
transactions contemplated hereby and thereby will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default
under any such provision, instrument, judgment, order, writ, decree or contract or an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company or the
suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, 

4

 

authorization,
or approval applicable to the Company, its business or operations or any of its assets or properties. 

        2.11    Agreements; Action.    

        (a)   Except
for agreements explicitly contemplated by the Transaction Documents, there are no agreements, understandings or proposed transactions between the Company and any
of its officers, directors, affiliates, or any affiliate thereof. 

        (b)   There
are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or decrees to which the Company is a party or by which
it is bound that may involve (i) provisions restricting or affecting the development, manufacture or distribution of the Company's products or services; (ii) obligations (contingent or
otherwise) of, or payments to, the Company in excess of $100,000 (other than obligations of, or payments to, the Company arising from agreements entered into in the ordinary course of business); or
(iii) indemnification by the Company with respect to infringements of proprietary rights (other than indemnification obligations arising from agreements entered into in the ordinary course of
business). 

        (c)   The
Company has not (i) declared or paid any dividends or authorized or made any distribution upon or with respect to any class or series of its capital stock,
(ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $1,000,000 or in the aggregate in excess of $5,000,000, (iii) made any loans or
advances to any person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in
the ordinary course of business. 

        (d)   For
the purposes of subsection (c) above, all indebtedness and liabilities involving the same person or entity (including persons or entities the Company has
reason to believe are affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection. 

        (e)   The
Company is not a party to and is not bound by any contract, agreement or instrument, or subject to any restriction under its Restated Certificate or Bylaws that
adversely affects its business as now conducted or as proposed to be conducted, its properties or its financial condition. 

        (f)    The
Company has not engaged in the past three (3) months in any discussion (i) with any representative of any corporation or corporations regarding the
consolidation or merger of the Company with or into any such corporation or corporations, (ii) with any corporation, partnership, association or other business entity or any individual
regarding the sale, conveyance or disposition of all or substantially all of the assets of the Company or a transaction or series of related transactions in which more than fifty percent (50%) of the
voting power of the Company is disposed of, or (iii) regarding any other form of acquisition, liquidation, dissolution or winding up of the Company. 

        2.12    Related-Party Transactions.    No employee, officer, or director of the Company or member of his or her
immediate family is indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. To the Company's knowledge, none of such persons has
any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation that
competes with the Company, except that employees, officers, or directors of the Company and members of their immediate families may own stock in publicly traded companies that may compete with the
Company. No member of the immediate family of any officer or director of the Company is directly or indirectly interested in any material contract with the Company. 

5

 

        2.13    Permits.    The Company has all franchises, permits, licenses, and any similar authority necessary for the
conduct of its business as now being conducted by it, the lack of which could materially and adversely affect the business, properties, prospects, or financial condition of the Company, and the
Company believes it can obtain, without undue burden or expense, any similar authority for the conduct of its business as planned to be conducted. The Company is not in default in any material respect
under any of such franchises, permits, licenses, or other similar authority. 

        2.14    Disclosure.    The Company has provided the Investor with all information requested by the Investor in
connection with their decision to purchase the Shares, including all information the Company believes is reasonably necessary to make such investment decision. To the Company's knowledge, neither this
Agreement, the Investors' Rights Agreement, nor any other statements or certificates made or
delivered in connection herewith or therewith contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading. 

        2.15    Corporate Documents.    Except for amendments necessary to satisfy representations and warranties or
conditions contained herein (the form of which amendments has been approved by the Investor), the Restated Certificate and Bylaws of the Company are in the form previously provided to the Investor. 

        2.16    Title to Property and Assets.    The Company owns its property and assets free and clear of all mortgages,
liens, loans and encumbrances, except such encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company's ownership or use of such property or assets
and has good and marketable title to such property. With respect to the property and assets it leases, the Company is in compliance with such leases and holds a valid leasehold interest free of any
liens, claims or encumbrances. 

        2.17    Tax Returns, Payments and Elections.    The Company has timely filed all tax returns and reports as required
by law. These returns and reports are true and correct in all material respects. The Company has paid all taxes and assessments due, except those contested by it in good faith, if any. The Company has
not been advised (a) that any of its federal, state or local returns are being audited as of the date hereof, or (b) of any deficiency in assessment or proposed judgment to its federal,
state or other taxes. The Company has no knowledge of any liability of any tax to be imposed upon its properties or assets as of the date of this Agreement that isn't adequately provided for. 

        2.18    Environmental Law.    To the Company's knowledge, the Company is not in violation of and has no liability or
potential liability under any applicable statute, law, or regulation relating to the environment, and to the best of its knowledge, no material expenditures are or will be required in order to comply
with any such existing statute, law, or regulation. 

        2.19    Proprietary Information and Employment Agreements.    Each current and former employee, officer and consultant
of the Company has executed a standard Proprietary Information and Inventions Agreement. The Company is not aware that any of its employees, officers or consultants are in violation thereof, and the
Company will use its best efforts to prevent any such violation. The Company has not entered into any employment agreements. 

        2.20    Financial Statements.    The Company has made available to the Investor its audited financial statements as of
and for the twelve-month period ended December 31, 2001, and its unaudited financial statements for the six-month period ending September 30, 2002 (the "Financial
Statements"). The Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods indicated and with each other
except that the unaudited Financial Statements may not contain all footnotes required by generally accepted accounting principles. The Financial Statements fairly present the financial condition and
operating results of the Company as of the dates, and for the periods, indicated therein, subject in the case of the 

6

 

unaudited
Financial Statements to normal year-end audit adjustments. Except as set forth in the Financial Statements, the Company has no material liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business subsequent to the date of the Financial Statements and (ii) obligations under contracts and commitments incurred in
the ordinary course of business and not required under generally accepted accounting principles to be reflected in the Financial Statements, which, in both cases, individually or in the aggregate, are
not material to the financial condition or operating results of the Company. Except as disclosed in the Financial Statements, the Company is not a guarantor or indemnitor of any indebtedness of any
other person, firm or corporation. The Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with generally accepted accounting
principles. 

        2.21    Changes.    Since September 30, 2002 there has not been: 

        (a)   any
change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial Statement, except changes in the
ordinary course of business that have not been, in the aggregate, materially adverse; 

        (b)   any
damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting the assets, properties, financial condition, operating results,
prospects or business of the Company (as such business is presently conducted and as it is proposed to be conducted); 

        (c)   any
waiver by the Company of a valuable right or of a material debt owed to it; 

        (d)   any
satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and that is not
material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted and as it is proposed to be conducted); 

        (e)   any
material change or amendment to a material contract or arrangement by which the Company or any of its assets or properties is bound or subject; 

        (f)    any
material change in any compensation arrangement or agreement with any employee; 

        (g)   any
sale, assignment or transfer of any patents, trademarks, copyrights, trade secrets or other intangible assets; 

        (h)   any
resignation or termination of employment of any key employee or officer of the Company; and the Company, to the best of its knowledge, does not know of the impending
resignation or termination of employment of any such employee or officer; 

        (i)    receipt
of notice that there has been a loss of, or material order cancellation by, any major customer of the Company; 

        (j)    any
mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or assets, except liens for
taxes not yet due or payable; 

        (k)   any
loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel
advances and other advances made in the ordinary course of its business; 

        (l)    any
declaration, setting aside or payment or other distribution in respect of any of the Company's capital stock, or any direct or indirect redemption, purchase or other
acquisition of any of such stock by the Company; 

        (m)  to
the best of the Company's knowledge, any other event or condition of any character that might materially and adversely affect the assets, properties, financial
condition, operating 

7

 

results
or business of the Company (as such business is presently conducted and as it is proposed to be conducted); or 

        (n)   any
agreement or commitment by the Company to do any of the things described in this Section 2.21. 

        2.22    Registration Rights.    Except as required pursuant to the Investors' Rights Agreement, the Company is not
presently under any obligation, and has not granted, any rights to register any of the Company's presently outstanding securities or any of its securities that may hereafter be issued. 

        2.23    Real Property Holding Corporation.    The Company is not a real property holding corporation within the
meaning of Code Section 897(c)(2) and any regulations promulgated thereunder. 

        2.24    Labor Agreements.    The Company is not bound by or subject to (and none of its assets or properties is bound
by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Company's knowledge, has sought to
represent any of the employees, representatives or agents of the Company. There is no strike or other labor dispute involving the Company pending, or to the Company's knowledge, threatened, that could
have a material adverse effect on its business or properties, nor is the Company aware of any labor organization activity involving its employees. 

        2.25    Insurance.    The Company maintains in full force and effect such types and amounts of insurance issued by
insurers of recognized responsibility insuring the Company with respect to its business and properties, in such amounts and against such losses and risks which are usual and customary in the Company's
business as to amount and scope. 

        3.    Representations and Warranties of the Investor.    The Investor hereby represents and warrants that: 

        3.1    Authorization.    The Investor has full power and authority to enter into the Transaction Documents, and each
such Agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief, or other equitable remedies, and (iii) to the extent the indemnification provisions contained in the Investors' Rights Agreement may be limited by applicable federal or state securities
laws. 

        3.2    Purchase Entirely for Own Account.    This Agreement is made with the Investor in reliance upon the Investor's
representation to the Company, which by the Investor's execution of this Agreement the Investor hereby confirms, that the Series E Preferred Stock to be received by the Investor and the Common
Stock issuable upon conversion thereof (collectively, the "Securities") will be acquired for investment for the Investor's own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of applicable securities
laws. By
executing this Agreement, the Investor further represents that the Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations
to such person or to any third person, with respect to any of the Securities. 

        3.3    Disclosure of Information.    The Investor further represents that it has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of the Series E Preferred Stock and the business, properties, prospects and financial condition of the
Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investor to rely thereon. 

        3.4    Investment Experience.    The Investor is an investor in securities of companies in the development stage and
acknowledges that it is able to fend for itself, can bear the economic risk of its 

8

 

investment,
and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Series E Preferred Stock. The
Investor also represents that it has not been organized for the purpose of acquiring the Series E Preferred Stock. 

        3.5    Accredited Investor.    The Investor is an "accredited investor" within the meaning of SEC Rule 501 of
Regulation D, as presently in effect. 

        3.6    Restricted Securities.    The Investor understands that the Securities it is purchasing are characterized as
"restricted securities" under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations such securities may be resold without registration under the Act, only in certain limited circumstances. In this connection, the Investor represents that it is familiar with SEC
Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 

        3.7    Further Limitations on Disposition.    Without in any way limiting the representations set forth above, the
Investor further agrees not to make any disposition of all or any portion of the Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this
Section 3 and the Investors' Rights Agreement provided and to the extent this Section and such agreements are then applicable, and: 

        (a)   There
is then in effect a Registration Statement under the Act covering such proposed disposition and such disposition is made in accordance with such Registration
Statement; or 

        (b)   (i) The
Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, including, but not limited to, the name of the transferee, and (ii) if reasonably requested by the Company, the Investor shall have furnished the Company
with an opinion of counsel, reasonably satisfactory to the Company that such disposition will not require registration of such shares under the Act. It is agreed that the Company will not require
opinions of counsel for transactions made pursuant to Rule 144 except in unusual circumstances. 

        (c)   Notwithstanding
the provisions of Section 3.2 or Paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be
necessary for a transfer by the Investor (i) that is a partnership to a partner of such partnership or a retired partner of such partnership who retires after the date hereof, or to the estate
of any such partner or retired partner or the transfer by gift, will or intestate succession of any partner to his or her spouse or to the siblings, lineal descendants or ancestors of such partner or
his or her spouse, or (ii) to any entity that is not a natural person and is controlled by, controls or is under common control with the Investor, if the transferee agrees in writing to be
subject to the terms hereof to the same extent as if he or she were an original Investor hereunder. 

        (d)   In
addition, Investor agrees that, without the Company's written consent, in no event shall any transfer of Securities by the Investor made prior to the initial public
offering of the Company's Common Stock pursuant to an effective registration statement under the Act be effective if the transferee is a direct competitor with the primary business of the Company (as
determined in the sole discretion of the Company's Board of Directors). The Company agrees that it shall not unreasonably withhold consent for any transfer by Investor to a member or affiliate of
Investor or an affiliate of GlaxoSmithKline PLC. 

        3.8    Legends.    It is understood that the certificates evidencing the Securities may bear one or all of the
following legends: 

        (a)   "These
securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or hypothecated in the absence
of a registration statement in effect with respect to the securities under such Act or an opinion of counsel 

9

 

satisfactory
to the Company that such registration is not required or unless sold pursuant to Rule 144 of such Act." 

        (b)   Any
legend required by the laws of any state. 

        4.    Conditions of Investor's Obligations at Closing.    The obligations of the Investor under subsection 1.1(c) of
this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against the Investor if it does not consent
thereto: 

        4.1    Representations and Warranties.    The representations and warranties of the Company contained in
Section 2 shall have been true on and as of the date of this Agreement. 

        4.2    Performance.    The Company shall have performed and complied with all agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 

        4.3    Compliance Certificate.    The Chief Executive Officer of the Company shall deliver to each Investor at the
Closing a certificate stating that the conditions specified in Sections 4.1 and 4.2 have been fulfilled. 

        4.4    Qualifications.    All authorizations, approvals, or permits, if any, of any governmental authority or
regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective
as of the Closing. 

        4.5    Proceedings and Documents.    All corporate and other proceedings in connection with the transactions
contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to the Investor, and they shall have received all such counterpart original and
certified or other copies of such documents as they may reasonably request. 

        4.6    Opinion of Company Counsel.    The Investor shall have received from Gunderson Dettmer Stough Villeneuve
Franklin & Hachigian, LLP, counsel for the Company, an opinion, dated as of the Closing, in the form attached hereto as Exhibit C. 

        4.7    Investors' Rights Agreement.    The Company and the Investor shall have entered into the Investors' Rights
Agreement. 

        4.8    Filing of the Restated Certificate.    The Restated Certificate shall have been filed with the Secretary of
State of Delaware, and shall not have been amended or modified since the date of filing. 

        4.9    HSR Act.    The waiting period applicable to the consummation of the transactions contemplated hereby and by
that certain Collaboration Agreement between the Company and the Investor under the
HSR Act shall have expired or been terminated and no action by the Department of Justice or Federal Trade Commission challenging or seeking to enjoin the consummation of such transactions shall have
been instituted and be pending. 

        5.    Conditions of the Company's Obligations at Closing.    The obligations of the Company to the Investor under this
Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by the Investor: 

        5.1    Representations and Warranties.    The representations and warranties of the Investor contained in
Section 3 shall be true on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing. 

        5.2    Qualifications.    All authorizations, approvals, or permits, if any, of any governmental authority or
regulatory body of the United States or of any state that are required in connection with 

10

 

the
lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective as of the Closing. 

        5.3    Investors' Rights Agreement.    The Company and the Investor shall have entered into the Investors' Rights
Agreement. 

        5.4    HSR Act.    The waiting period applicable to the consummation of the transactions contemplated hereby and by
that certain Collaboration Agreement between the Company and the Investor under the HSR Act shall have expired or been terminated and no action by the Department of Justice or Federal Trade Commission
challenging or seeking to enjoin the consummation of such transactions shall have been instituted and be pending. 

        6.    Miscellaneous.    

        6.1    Survival of Warranties.    The warranties, representations and covenants of the Company and the Investor
contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter
thereof made by or on behalf of the Investor or the Company. 

        6.2    Successors and Assigns.    Except as otherwise provided herein, the terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Securities). Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. 

        6.3    Governing Law.    This Agreement shall be governed by and construed under the laws of the State of California
as applied to agreements among California residents entered into and to be performed entirely within California. 

        6.4    Counterparts.    This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 

        6.5    Titles and Subtitles.    The titles and subtitles used in this Agreement are used for convenience only and are
not to be considered in construing or interpreting this Agreement. 

        6.6    Notices.    All notices required or permitted hereunder shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, if not, then
on the next business day or (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
Notwithstanding the foregoing or any provision to the contrary in the Investors' Rights Agreement or the Restated Certificate, the Company agrees that when any notice is given to the Investor, whether
under this Agreement, the Investors' Rights Agreement or the Restated Certificate, such notice shall not be deemed to be effectively given until a copy of such notice is transmitted to the Investor
via facsimile. All notices and certificates will be addressed to the Investor at the address set forth on the signature page hereto or at such other address as the Company or the Investor may
designate by ten (10) days advance written notice to the other parties hereto. 

        6.7    Finder's Fee.    The Investor agrees to indemnify and to hold harmless the Company from any liability for any
commission or compensation in the nature of a finders' fee (and the costs and expenses of defending against such liability or asserted liability) for which such Investor or any of its officers,
partners, employees, or representatives is responsible. 

        The
Company agrees to indemnify and hold harmless the Investor from any liability for any commission or compensation in the nature of a finders' fee (and the costs and expenses of
defending 

11

 

against
such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

        6.8    Expenses.    Irrespective of whether the Closing is effected, each party shall bear their own costs and
expenses incurred with respect to the negotiation, execution, delivery and performance of this Agreement. If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the Investors' Rights Agreement or the Restated Certificate, the prevailing party shall be entitled to reasonable attorney's fees, costs and necessary disbursements in addition to any other
relief to which such party may be entitled. 

        6.9    Amendments and Waivers.    Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor. Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities
are convertible), each future holder of all such securities, and the Company. 

        6.10    Severability.    If one or more provisions of this Agreement are held to be unenforceable under applicable
law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its
terms. 

        6.11    Confidentiality.    Any confidential information obtained by the Investor pursuant to this Agreement which is
labeled or otherwise identified as confidential or proprietary shall be treated as confidential and shall not be disclosed to a third party without the prior written consent of the Company and shall
not be used by the Investor for any purpose other than monitoring the Investor's investment in the Company, except that the Investor may disclose such information (i) to its attorneys,
accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to its affiliates, officers,
directors, shareholders, members and/or partners in the ordinary course of business or pursuant to disclosure obligation to affiliates, shareholders, members and/or partners; provided that such
information is provided to such persons and entities with notice that such information is confidential and should be treated as such, (iii) to any prospective purchaser of the Investor's shares
of the Company, provided (in the case of disclosure in clause (iii)) the recipient agrees to keep such information confidential and to use such information solely for evaluation of such
proposed purchase, or (iv) as may otherwise be required by law. Notwithstanding the foregoing, such information shall not be deemed confidential for the purpose of enforcement of this Agreement
and said information shall not be deemed confidential after it becomes publicly known through no fault of the recipient. The provisions of this Section 6.11 shall be in addition to, and not in
substitution for, the provisions of any separate confidentiality agreement executed by the
parties hereto; provided that if there is any conflict between the provisions of this Section 6.11 and the more restrictive provisions of such separate confidentiality agreement, the provisions
of such separate confidentiality agreement shall prevail. 

        6.12    Publicity.    No party or any affiliate of a party shall make, or cause to be made, any publicity, news
release or other such general public announcement or make any other disclosure to any third party in respect of this Agreement or the transactions contemplated hereby (including, without limitation,
disclosure of Investor's ownership interest in the Company) without the prior written consent of the other parties; provided however, that the foregoing
provision is not intended to limit communications deemed reasonably necessary or appropriate by a party or its affiliates to its employees, stockholders, partners, directors, officers, potential
investors, accountants and legal counsel who are under an obligation to preserve the confidentiality of the foregoing. Notwithstanding the foregoing provision, the parties and their respective
affiliates shall not be prohibited from making any disclosure or release that is required by law, court order, or applicable regulation, or is considered 

12

 

necessary
by legal counsel to fulfill an obligation under securities laws or the rules of a national stock exchange. 

        6.13    Entire Agreement.    This Agreement and the documents referred to herein constitute the entire agreement among
the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 

        6.14    Waiver of Conflicts.    Each party to this Agreement acknowledges that Gunderson Dettmer Stough Villeneuve
Franklin & Hachigian, LLP ("Gunderson Dettmer"), counsel for the Company, has in the past and may continue to perform legal services for certain of the Investors in the purchase of the
Company's Series A, Series B, Series C, Series D, Series D-1 and Series E Preferred Stock and other matters. Accordingly, each party to this
Agreement hereby (1) acknowledges that they have had an opportunity to ask for information relevant to this disclosure; (2) acknowledges that Gunderson Dettmer represented the Company in
the transaction contemplated by this Agreement and has not represented any individual Investor or any individual stockholder or employee of the Company in connection with such transaction; and
(3) gives its informed consent to Gunderson Dettmer's representation of certain of the Investors in such unrelated matters and to Gunderson Dettmer's representation of the Company in connection
with this Agreement and the transactions contemplated hereby. 

        IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 

	 	 	THERAVANCE, INC.
	 	 	 	 	 
	 	 	 	 	 
	 	 	By:	 	/s/  RICK E WINNINGHAM      
 Rick E Winningham

President and Chief Executive Officer

13

QuickLinks

COLLABORATION AGREEMENT by and between THERAVANCE, INC. and GLAXO GROUP LIMITED

COLLABORATION AGREEMENT

ARTICLE 1 DEFINITIONS

ARTICLE 2 RIGHTS AND OBLIGATIONS

ARTICLE 3 GOVERNANCE OF DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS

ARTICLE 4 DEVELOPMENT OF PRODUCTS

ARTICLE 5 COMMERCIALIZATION

ARTICLE 6 FINANCIAL PROVISIONS

ARTICLE 7 PROMOTIONAL MATERIALS AND SAMPLES

ARTICLE 8 REGULATORY MATTERS

ARTICLE 9 ORDERS; SUPPLY AND RETURNS

ARTICLE 10 CONFIDENTIAL INFORMATION

ARTICLE 11 REPRESENTATIONS AND WARRANTIES; COVENANTS

ARTICLE 12 INDEMNIFICATION

ARTICLE 13 PATENTS

Schedule 1.19 Criteria for Theravance New Compounds and Replacement Compounds

Schedule 6.1.2 Preferred Stock Purchase Agreement

THERAVANCE, INC. SERIES E PREFERRED STOCK PURCHASE AGREEMENT December 19, 2002

TABLE OF CONTENTS

THERAVANCE, INC. SERIES E PREFERRED STOCK PURCHASE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]